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Uveal melanoma (UM) is the most common primary intraocular malignancy occurring in 
adults, with a propensity for liver metastases, which occur in ~50% of patients. Despite 
successful treatment of the primary tumour, there is currently no effective systemic 
therapy to treat metastatic disease. UM patient management is dependent upon accurate 
stratification into high or low risk of metastatic progression. Prognostication of UM patients 
currently involves the integration of clinical, histological, and genetic features of the 
tumour obtained by multiplex ligation-dependant probe amplification (MLPA) or 
microsatellite analysis (MSA), in order to obtain a refined predicted metastatic risk. The 
aims of this thesis were to examine prognostication performed in Liverpool and improve 
the way patients are stratified according to metastatic risk. In chapter 2 the genetic 
characteristics of the rarest form of UM, iris melanoma (IM) was examined. Molecular 
analysis was performed on archival IM samples collected over a twenty year period and 
demonstrated that a low-metastatic genotype was most commonly observed; this 
correlates with the improved survival of this UM subtype in comparison to ciliary body and 
choroidal melanomas. Chromosomal aberrations often seen in posterior UM are also seen 
in IM, in both treatment-naïve and irradiated tumours. MSA is a common method of 
genotyping for small UM with low DNA yields, i.e. fine-needle aspirate biopsy samples 
(FNAB). In chapter 3, I demonstrated that MSA can accurately determine chromosome 3 
copy number in FNAB samples. I found no demonstrable differences in the quality or clarity 
of the genotypes generated in both treatment-naïve and irradiated UM. By examining 
metastasis-free survival in these samples, I established that there was no evidence that 
surgical intervention causes iatrogenic dissemination. Loss of 3q was identified as an 
indicator of poor prognosis and allelic imbalance as an indicator of good prognosis. In 
chapter 4, in the largest study to date, I demonstrated that loss of nuclear BAP1 protein 
expression (nBAP1) was a significant independent prognostic parameter associated with 
metastatic risk and reduced survival, with a stronger association with poor outcome than 
monosomy 3 (M3). Additionally I identified two subgroups within M3 UM whereby M3 
nBAP1+ cases were associated with a prolonged survival in comparison to nBAP1- UM. To 
address the clinical need to integrate copy number analysis of chromosomes 1, 3, 6 and 8 
and gene mutation status of GNAQ, GNA11, BAP1, SF3B1, EIF1AX, CYSTLR2, PLCB4, TTC28, 
KTN1, TP53BP1, and CSMD1 in chapter 5, I designed, compared and validated targeted 
next-generation sequencing (NGS) panels for UM.  I demonstrated the superiority of hybrid 
capture as an enrichment method, and was able to successfully analyse copy number and 
single nucleotide variants in both fresh and formalin fixed tissue. Mutations in BAP1 were 
found to be the most important prognostic factor in terms of survival, and gains of 1q were 
associated with an increased incidence of metastatic death. I identified novel mutations in 
PLCB4, TTC28, CSMD1, KTN1 and TP53BP1 that require further evaluation. In chapter 6 I 
investigated protein expression levels of a recently identified molecule RasGRP3 in 
GNAQ/GNA11 mutant UM cell lines and primary tumours and compared this with BRAF 
mutant conjunctival melanoma specimens. I demonstrated that RasGRP3 was significantly 
and selectively overexpressed in response to GNAQ/11 mutations. This demonstrates that 
activation of the MAP-kinase pathway occurs through a different mechanism to that 
occurring in conjunctival melanoma. In conclusion, I have examined in detail ways of 
enhancing our current practice for prognostication in UM. There is a need for BAP1 
mutations and nBAP1 negativity to be implemented into routine prognostication. This may 
be achievable by replacing current MLPA and MSA testing with the targeted UM NGS panel. 
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1.1 Incidence and Aetiology 
 
Uveal melanoma (UM) is the most common primary intraocular cancer, affecting 6 
individuals per million per year in the United Kingdom (1). Caucasian populations are at an 
increased risk of developing UM in comparison to other ethnicities, especially those 
individuals with fair skin and blue/grey eyes (2). The aetiology of UM is unknown however, 
there are known associations with UM.  These include: ocular melanocytosis (increased 
population of melanocytes within the uvea and episclera), oculodermal melanocytosis 
(naevus of Ota, which also involves the periocular skin and meninges), simple and dysplastic 
cutaneous naevi and cutaneous melanomas, and neurofibromatosis type 1 (3) (4). Rare 
reports of families with an excess of UM cases have been published. UM is part of the 
autosomal dominantly inherited ‘BAP1 (BRCA1-associated protein-1) familial cancer 
syndrome’ (5). Affected patients, who have germline mutations in BAP1 develop 
mesotheliomas and unusual benign atypical melanocytic skin tumours as well as UM. 
It is assumed that UM arises from a malignant transformation of neural crest-derived 
melanocytes, cells that produce melanin via a process called melanogenesis, located in the 
uvea (6). Around 90% of UM arise in the choroid, the vascular layer responsible for limiting 
uncontrolled reflection in the eye, located between the retina and sclera (Figure 1.1) (7). An 
additional 3-4% of UM arise in the iris, the coloured part of the eye that controls dilation of 
the pupil, and the remainder of UM occur in the ciliary body, a ring-shaped structure 







Figure 1.1 Anatomy of the human eye: 1) sclera 2) choroid 3) retina 4) macula 5) fovea 6) 
optic nerve 7) posterior chamber 8) cornea 9) anterior chamber 10) lens 11) pupil 12) iris 
13) ciliary body. (Image sourced from Harper Collins) 
 
1.2 Clinical Diagnosis 
UM are normally diagnosed when patients are referred to ophthalmologists in specialised 
ocular oncology centres by their family doctor or optometrists after presenting with 
symptoms or incidental findings (8).  Patients who present with a variety of symptoms, such 
as photopsia, floaters, blurred vision, and visual field loss, are more likely to have been 
referred by their General Practitioner (9). However, up to 30% of patients will report no 
symptoms at all, and these patients are more likely to be referred by optometrists after 
routine eye examinations (10). In order to make a diagnosis of UM, patients undergo a 
clinical examination with slit-lamp microscopy and indirect ophthalmoscopy coupled with 
ultrasonography, optical coherence tomography, auto-fluorescence and fluorescein 
angiography (figure 1.2) (9). In 1995, a pneumonic with five traits were proposed as an aid 
to diagnose melanoma: Thickness >2 mm, presence of sub-retinal Fluid, Symptoms i.e. 
photopsia or floaters, Orange pigment, and Margin near the optic disc (TFSOM) (11). In 
2009 a multivariate analysis was performed on 2514 cases of choroidal naevi that revealed 
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an additional 2 risk factors associated with melanoma growth: ultrasonographic 
Hollowness, and absence of a Halo (TFSOM-HH)  (12). 
 
 
Figure 1.2 Fundoscopy (Optos) image showing an inferior choroidal and ciliary body 
melanoma with an extensive exudative retinal detachment (Courtesy of the Liverpool 




1.3 Clinical Management of Primary UM 
Once the diagnosis has been made, the clinical management of the primary UM is highly 
dependent upon the size and location of the tumour. Other factors that are taken into 
consideration before choosing a course of treatment are patient choice/motivation, 
secondary illnesses (e.g. diabetes and glaucoma), and the visual acuity of the unaffected 
healthy eye (13).  
 
1.3.1 Plaque Radiotherapy 
Ruthenium brachytherapy for primary UM was first implemented in the 1960’s by Peter 
Lommatzsch (14). To date, plaque radiotherapy continues to be considered a highly 
effective modality of treatment in institutions across the world.  Although institutes vary in 
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their approach, iodine-125 and ruthenium-106 are the most frequently used radiation 
sources (15). Plaque radiotherapy is seen as an eye-sparing treatment, since the radioactive 
implant is sutured onto the outer sclera adjacent to the tumour, and is then removed after 
the appropriate amount of radiation has been emitted (figure 1.3) (16). This approach 
allows high doses of radiation to be delivered to the tumour without damaging the other 
structures in the eye enabling some visual acuity to be retained where possible.  It is for 
these reasons that the Collaborative Ocular Melanoma Study (COMS) championed the use 
of plaque radiotherapy in the treatment of medium-sized choroidal melanomas (17). 
Plaque radiotherapy is most effective when used to treat small-to-medium sized tumours 
where the tumour thickness is ≤7mm (18). However, complications do arise from this 
treatment (particularly if larger UM are treated), such as radiation retinopathy (19), 
vitreous haemorrhage (20), radiation cataract (21), neovascular glaucoma (22), radiation 
maculopathy (23), radiation optic neuropathy and iris rubeosis due to ‘toxic tumour 
syndrome’ (24). Despite this, plaque radiotherapy remains a useful treatment in preserving 
the cosmetic appearance of the eye. 
 
 







1.3.2 Proton Beam Radiotherapy 
Proton beam radiotherapy (PBR) was first implemented in the treatment of UM in 1991 at 
the Centre de Protontherapie d'Orsay in Paris (25). It is a process that involves the surgical 
insertion of metallic tantalum markers around the periphery of the tumour, which are then 
used to direct proton radiation to the tumour (figure 1.4) (26). As with plaque radiotherapy, 
PBR is considered an eye-preserving treatment as the precise nature of the radiation 
delivery minimises damage to surrounding structures (27). However, in contrast to plaque 
radiotherapy, PBR can be used to treat tumours that are larger and closer to the optic disc 
and the fovea (28), taking advantage of the Bragg peak. The Bragg peak is a phenomenon 
whereby protons enter a patient’s body, gradually increasing the absorbed dose of 
radiation as depth increases, rising to a peak when the proton ultimately stops. A dose of 
radiation typically between 53 to 70Gy is delivered over several visits (29). PBR is usually 
administered with safety margins of between 2.0 – 4.0mm of the tumour depending upon 
the tumour location and other considerations such as protection of the optic nerve and 
fovea and counteracting diffuse spread (30). The cumulative risk of local treatment failure is 
low (1-6%) and is correlated with tumours that have a large basal diameter and tumour 
height (30). Unfortunately, a proportion of eyes treated by PBR will go on to be enucleated 
either due to tumour recurrence or other factors i.e. painful blind-eye and neovascular 
glaucoma (31). However, the overall 5- year survival rate for those treated with PBR is 
around 80% with a 5-year metastasis free survival of 80.6% due to the typical tumour and 
genetic characteristics of smaller tumours. (32). As with plaque radiotherapy, PBR is also 
associated with some complications, such as radiation maculopathy (33), papillopathy (34), 
neovascular glaucoma (35), cataract (36), vitreous haemorrhage (37), intraocular 
inflammation (38) as well as dry eye and mydriasis. The latter can be overcome if the PBR is 
administered through closed eyelids (39). These complications increase the likelihood of 
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vision loss in the treated eye; despite this PBR remains a good treatment for conserving the 




Figure 1.4 Proton beam radiotherapy in UM; tantalum markers are sutured to the tumour 
site and these are used to enable radiation to be delivered in this region, minimising 
damage to surrounding structures (Original image).  
 
 
1.3.3 Trans-scleral Local Resection 
The technique, first pioneered in Glasgow in 1973 by Wallace S Foulds, is a surgical 
procedure that is considered an eye and vision-preserving treatment (40). The tumour is 
localised preoperatively using the aforementioned clinical examination techniques. The 
surgery involves a lamellar scleral dissection that exposes the choroid; an incision is then 
made into surrounding healthy choroid and inner scleral lamella around the tumour, which 
is then stripped from the retina and removed (41). Following tumour removal, the outer 
scleral flap is closed over the surgical coloboma, and a 20mm ruthenium plaque is sutured 
to the outer sclera surface, and a dose of 100 – 200 Gy is administered to the resected area 
(42). Ideal tumours for trans-scleral local resection surgery are 5-15 mm in thickness. Local 
resection may be performed post-therapy: e.g. larger sized tumours associated with ‘toxic 
tumour syndrome’ (i.e. the release of cytotoxic substances causing secondary retinal 
detachment and neovascular glaucoma) after PBR (43) (44). In ~80% of cases, the surgery 
results in a cosmetically acceptable eye with approximately 66% of patients maintaining 
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useful vision (45). The metastatic death rate after local resection is reduced from 92% to 
30% at 15 years with the presence of more than 3 risk factors, such as epithelioid cells, 
largest basal diameter and lack of adjunctive radiotherapy (46). Several studies have shown 
that in comparison with plaque radiotherapy, trans-scleral local resection preserves visual 
function and results in decreased incidence of optic neuropathy and secondary glaucoma 
(47) (48). One of the complications associated with trans-scleral local resection is 
incomplete tumour removal that can result in tumour recurrence months to years after 
treatment (49).  This, in addition to retinal detachment, are the most common causes of 
enucleation and visual loss after trans-scleral local resection (50). Tumour recurrences can 
be counteracted by the addition of a plaque over the area of the local resection following 
completion of the surgery. 
 
1.3.4 Endoresection 
Endoresection is a surgical procedure that was initially developed to treat juxtapapillary 
choroidal melanomas that traditionally would have been enucleated (51). The procedure - 
also referred to as ‘internal eye wall resection’ or ‘retinochoroidectomy’ - involves cutting 
the tumour into miniscule fragments with a vitreous cutter during a pars plana vitrectomy 
(figure 1.5) (52) (53). Endoresection is reserved for thick, posterior UM near the macula or 
optic disc, where PBR would cause visual loss and are too thick for plaque radiotherapy 
(54). Like trans-scleral local resection, endoresection is a useful surgical technique to 
remove post radiotherapy toxic tumours (55).  A recent study showed that only 3% of the 
cohort treated using endoresection over 20 years experienced local recurrence of the 
tumour (56). Additionally, as long as the UM have not extended into the fovea, useful vision 
can be retained using this procedure (57). Similar to trans-scleral local resection, 
endoresection also has associated risks of early and late postoperative complications. There 
is a belief amongst some ophthalmologists that during the surgical procedure there could 
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be a dissemination of tumour cells (58). However, a study by García-Arumí et al. examining 
the long-term outcomes of endoresection patients demonstrated a local recurrence rate at 
3 and 5 years was 5.8%., with more patients experiencing retinal detachment, scleral bed 
bleeding, ocular hypertension, epiretinal proliferation, subretinal fibrosis, radiation 
retinopathy and subretinal neovascularisation (59). Therefore, endoresection remains a 
useful (albeit controversial) technique in preserving the cosmetic appearance of the eye 
and vision. 
 
Figure 1.5 Endoresection of a choroidal melanoma; a) a hole is made in the retina directly 
above the tumour b) using a vitreous cutter the tumour is dissected into tiny fragments; c) 
a laser is passed into the eye to burn away any remaining tumour and edges of the retina 
are welded into place; d) silicon oil is inserted into the eye to keep the retina in place and to 





Enucleation is a surgical procedure that involves removing the entire globe and replacing it 
with an implant or prosthesis to which the eye muscles can be sutured resulting in an 
acceptable cosmetic result. Patients are treated using this modality if the tumour is too 
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advanced at initial presentation or is located on the ciliary body (60). Similarly if the tumour 
has caused severe ocular complications, such as total retinal detachment or neovascular 
glaucoma, enucleation may be performed to remove a painful blind eye (61). Some patients 
opt to have the eye removed regardless of whether it can be treated using conservative 
therapies, such as plaque radiotherapy or PBR (62). Secondary enucleation is also 
sometimes performed due to complications of conservative eye-saving therapy or to 
tumour recurrence (63). Enucleation had previously been thought to be responsible for 
disseminating tumour cells and increasing the incidence of metastatic melanoma-related 
mortality (the Zimmerman hypothesis) (64). Additionally, enucleation was thought to be a 
superior treatment of UM in comparison to eye conserving radiotherapy treatments (65). 
However, these hypotheses were later disproved as COMS reported no statistically 
significant difference in survival between patients treated by enucleation alone and pre-
enucleation radiotherapy (66).  
 
1.3.6   Fine-needle Aspirate Biopsies 
 
Diagnostic fine-needle aspirate biopsies (FNAB) for masses of indeterminate origin were 
first described by Jakobiec et al. in ophthalmic oncology centres (67). There are two main 
techniques utilised for sampling UM; tumours located anteriorly to the equator are 
sampled using a technique called trans-scleral biopsy whereby a scleral flap is created in 
order to insert the needle and biopsy,  tumours located posteriorly to the equator and 
therefore inaccessible via the sclera, are sampled using a technique referred to as a trans-
retinal biopsy, where a needle is inserted through the pars plana and used to sample the 
tumour. In 2002, Naus et al. of successfully examined the viability of using FNAB for 
prognostic testing (68). The safety of the procedure has been examined by a number of 
studies, confirming it is perfectly innocuous and effective at confirming chromosome 3 
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statuses (69) (70) (71). An assessment of the surgical technique has shown that common 
complications such as transient localised bleeding, vitreous haemorrhage and retinal 
perforation have decreased over time (72). 
 
1.4 Management of Metastases 
Due to the lack of lymphatics located in the eye, UM spreads haematogenously (73). 
Lymphatic spread is only possible where anterior scleral infiltration of the primary tumour 
occurs, allowing tumour access to the conjunctival lymphatics (74). The most common site 
of metastatic spread is to the liver, although UM cells can also spread to the lungs, bones 
and skin (75). Despite successful treatment of the primary tumour, up to 50% of UM 
patients will die of metastatic disease with 90% of those developing hepatic metastases 
(76).  
 
The COMS study examining the development of metastatic disease discovered that 
metastatic spread of the primary tumour occurred in 25% of patients at 5 years and 34% of 
patients by 10 years (77). The development of liver metastases is associated with a 
particularly poor prognosis, and in the absence of treatment, life expectancy is reduced to 
less than 6 months (78). Currently, the most effective way to treat patients with established 
liver metastases is by surgical resection, which is highly dependent upon the size and 
location of the tumours (79). Advanced miliary disease is often missed by conventional 
imaging (e.g. ultrasound or magnetic resonance imaging (MRI)), and the number of liver 
metastases detected preoperatively is a strong prognostic indicator (80). Patient survival is 
strongly associated with the quality of the liver resection, with more patients being alive 
after two years when the tumour could be completely resected (R0) compared to 
incomplete resection (R1) (81). In addition, patients who are treated by liver resection have 
a more favourable survival in comparison to patients who are not treated (82). There are 
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several other treatment options available once liver metastases have been detected, such 
as isolated liver perfusion (83), chemoembolisation (84), immunoembolisation (85) and 
hepatic intra-arterial chemotherapy (86). Patients who are not suitable candidates for liver 
resection are limited to the treatment options they can receive. There are currently no 
immunotherapy or chemotherapy agents that are effective in treating metastatic UM (87). 
The systemic chemotherapy agents that are used to treat metastatic UM patients have little 
effect on overall survival in comparison to localised treatment (88). Some of the drugs used 
more recently to treat metastatic disease (e.g. tyrosine kinase inhibitors, angiogenesis 
inhibitors and mitogen-activated protein kinase (MEK) inhibitors) have demonstrated a 
limited effect to improve survival; however, on-going clinical trials will ultimately determine 
what role they will have in patient treatment (89). 
 
1.5 Metastatic Risk Factors  
Risk of metastatic spread of UM is associated with a number of factors including clinical, 
histological and genetic which I will describe in more detail below. 
 
1.5.1 Chromosomal Copy Number 
1.5.1.1 Monosomy 3 
The most widely reported gross chromosomal abnormality in UM is complete or partial loss 
of chromosome 3, or monosomy 3. This was initially reported by Prescher et al. in 1990 
after an examination of UM using conventional karyotyping showed 43% of the cohort had 
monosomy 3 (90). A subsequent study showed that chromosome 3 loss was strongly 
associated with UM patients who have a poor prognosis (91).  Since the study in 1996, 
several other groups have confirmed the prognostic significance of monosomy 3, and it is 
now widely regarded as one of the most useful prognostic parameters when considering 




1.5.1.2   Chromosome 8 
Abnormalities in chromosome 8 also have been established in UM, presenting as a gain of 
8q or isochromosome 8q  (95).  Abnormalities in 8q have been reported in genetic studies 
of UM (96) and are often associated with monosomy 3 UM, and therefore with a poor 
patient prognosis (93) (92). The region of 8q, which was found to be most commonly 
amplified during a comparative genomic hybridisation study, was 8q24-->qter, an area that 
encompasses the c-myc oncogene (97). Gain of 8q, especially c-myc is thought to occur 
later in the genetic progression of UM, and generally follows chromosome 3 loss (98). 
 
1.5.1.3   Chromosome 6 
The development of UM is thought to be associated with oncogenes located on 6p and 
tumour suppressor genes on 6q of prognostic relevance, although they have not yet been 
identified (99) (68). Aberrations in chromosome 6, frequently found in cutaneous 
melanomas, have also been linked to UM (100, 101). Gains in 6p have been associated with 
a more favourable prognosis (93), whereas losses in 6q have been reported to worsen 
survival in UM (102). A study by Lake et al. 2013 examined 58 UM samples by array SNP and 
identified frequent amplifications of the CNKSR3 gene located on 6q25.2, associated with 
increased protein expression and improved patient survival (103). 
 
1.5.1.4 Chromosome 1 
Rearrangements in chromosome 1 are a common occurrence in cutaneous melanomas and 
most frequently affect the p (short) arm (104) (105). Partial deletions and regions where 
heterozygosity is lost on 1p in cutaneous melanoma indicate the possible location(s) for 
tumour suppressor genes (106). Abnormalities in 1p are also routinely found in UM (107). 
The prognostic significance of 1p loss, particularly 1p36 has, been shown to impact disease-
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free survival (102). This occurs in metastasising tumours concurrent with monosomy 3 
suggesting a role in the promotion of tumourigenesis and tumour cell dissemination (108). 
The frequencies of 1q amplifications have been described to occur in as many as 24% of 
UM, however the prognostic significance is not yet fully understood (1).  
 
1.5.2 Mutations in UM 
1.5.2.1 GNAQ and GNA11 
GNAQ and GNA11 are heterotrimeric proteins, which function as Gq alpha subunits; 
activating phospholipase C and involved in the transduction and modulation of several 
cellular signalling pathways. Located on 9q21.2 and 19p13.3 respectively, studies have 
shown that mutations in exons 4 (R183) and 5 (Q209) of the GTPases GNAQ and GNA11 are 
exclusive to UM and uveal nevi (figure 1.6) (109). These mutations occur in 84% of UM, and 
are mutually exclusive of each other (110). GNAQ and GNA11 mutations are thought to be 
an early event in UM development (111). Mutations of R183 and Q209 inhibit the GTPase 
function of the gene, which results in an inability to hydrolyse GTP to GDP leaving the 
protein in a constitutively active state (112). There is little evidence to suggest whether 
GNAQ or GNA11 mutations negatively influence patient survival (113). However, mutations 
in GNAQ and GNA11 lead to downstream oncogenic signalling, due to their integral 
involvement in the mitogen activated protein kinase (MAPK) pathway (114).  A recent study 
examined the effects of MAPK/ERK Kinase (MEK) and protein kinase C (PKC) inhibitors on 
GNAQ and GNA11 mutant cell lines and found a significant reduction in proliferation and 
induction of apoptosis (115). Sanger sequencing of GNAQ and GNA11 has proven to be an 





Figure 1.6 Mutations in GNAQ and GNA11 in UM; A) an adenosine to thymine transition 
resulting in a substitution to leucine (GNA11 c.626 A>T Q209L) and B) an adenosine to 




1.5.2.2   SF3B1 
SF3B1 is a protein coding gene that encodes subunit 1 of the splicing factor 3b protein 
complex, which contributes to the splicing of pre-mRNAs located on 2q33.1. Mutations in 
this gene are frequently found in breast cancer, myelodysplastic syndrome and advanced 
chronic lymphocytic leukaemia (118). Recently, whole exome sequencing was used to 
examine novel SF3B1 mutations in UM and found these occurred frequently in UM with D3 
(119). A recent study demonstrated that SF3B1 mutations occurred in a mutually exclusive 
fashion to BAP1 mutations, suggesting that there are two distinct pathways of tumour 
progression (120). SF3B1 mutations are thought to affect sister chromatid cohesion and 
mitotic segregation through compromised splicing of sororin; an essential protein involved 
in the stable binding of cohesion to chromatin and enabling sister chromatin cohesion in 
interphase pre-mRNA (121). Recurrent mutations in this gene in codon 625 have also been 
associated with differential alternative splicing of coding and noncoding genes (122). SF3B1 
mutations were initially thought to have a protective function as they occurred almost 
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exclusively in disomy 3 UM with good prognostic features  (119) (120). However, recent 
data has shown that disomy 3 UM with SF3B1 mutations have a 7-fold increased risk of 
metastatic disease occurring at a longer follow up time when compared to disomy 3 
tumours without mutations in SF3B1 (123).  
 
1.5.2.3   EIF1AX 
EIF1AX encodes an essential eukaryotic translation initiation factor found on Xp22.12, 
which is required for ribosome dissociation and stabilising the binding of Met-tRNA to 40S 
ribosomal subunits. EIF1AX mutations in UM are a relatively recent finding, occurring across 
hotspots on exons 1 and 2 (119). Mutations in EIF1AX are associated with a more 
favourable prognosis as they have only been shown to occur in disomy 3 cases, and are 
mutually exclusive of BAP1 and SF3B1 mutations (110). Several studies have shown that 
mutations in EIF1AX play a protective role to prevent metastasis even when taking into 
consideration other risk factors (119, 124). Moreover, a recent study was able to establish 
that mutations in EIF1AX are also associated with clinical and histopathological features 
typically associated with a good prognosis (125). 
 
1.5.2.4   BAP1 
BAP1, or “BRCA associated protein 1”, is a deubiquitinating enzyme found on the short arm 
of chromosome 3. Somatic BAP1 mutations are associated with cancers, such as clear cell 
renal carcinoma, mesothelioma and non-small cell lung cancer, in addition to being strongly 
associated with metastasis in UM and other cancers (126). BAP1 is involved in numerous 
cellular processes, such as DNA damage response, regulation of transcription, cell cycle and 
cell growth (127) (128). There is also evidence that germline mutations in BAP1 increase 
susceptibility to UM, cutaneous melanoma, mesothelioma and other cancers (5) (3). Recent 
studies have shown that BAP1 mutations are found more frequently in monosomy 3 UM 
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and are associated with metastatic progression (129) (130). Mutations in BAP1 frequently 
lead to a loss of nuclear BAP1 protein expression which is associated with reduced survival 
time irrespective of chromosome 3 status (131). Both are factors which make BAP1 
mutations extremely important indicators of prognosis. 
 
1.5.2.5   Other mutations 
In addition to the aforementioned mutations, other less frequently occurring mutations 
have also been documented that may contribute to metastatic progression of UM. A 
recurrent mutation of the G-Coupled protein receptor CYSLTR2 (13q14.2) was identified in 
4/9 UM samples where GNAQ/GNA11 mutations were absent (132). Similarly, a gain-of-
function mutation was detected in PLCB4 (20p12.3) in 1/54 UM, a downstream target of 
GNAQ/GNA11 in a mutually exclusive fashion (133). A recent study by Royer-Bertrand et al. 
identified an additional five mutations in more than one of the 33 UM sampled examined in 
their study; KTN1, DLK2, CSMD1, TTC28 and TP53BP1, however the impact of these 
mutations has yet to be established (134). Additionally, mutations in the splicing factor 
SRSF2 resulting in a change-of-function have also been identified in two separate studies in 
the same region that has been reported to disrupt splicing in myelodysplastic syndrome 
(135) (136) (137). A mutation in FBXW7 in metastases was identified by Luscan et al. and 
this was also observed by Martin et al. however its involvement in tumourigenesis remains 
unknown (138) (119). 
 
1.5.3 Clinical Risk Factors 
1.5.3.1   Tumour Size 
Tumour size is an important prognostic parameter, which is typically associated with a poor 
clinical outcome in UM patients. Widely used as a predictor of metastatic disease, tumour 
size is made up of the largest basal tumour diameter and tumour height, which is 
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established during the initial examination by the ophthalmologist using ultrasonography. 
Patients who have tumours larger than 16mm at initial presentation usually undergo liver 
function tests and liver ultrasonography as these features are associated with an increased 
risk of metastatic disease (139). It is hypothesised that large UM have existed longer, and 
hence may be composed of aggressive cells that grow rapidly, which are both factors that 
predispose to metastatic disease (140). Multivariate analysis has shown that the frequency 
of monosomy 3 and disease specific mortality increases about two-fold when the largest 
tumour diameter >18mm (141). An American Joint Committee on Cancer (AJCC) 
commissioned study to develop a tumour, node, metastasis (TNM) staging for UM utilising 
baseline and survival data of 7369 patients which demonstrated a strong correlation 
between reduced survival and tumour size (PMID: 23258307).  
 
1.5.3.2   Ciliary body involvement  
Ciliary body involvement occurs in approximately 10% of all UM. Due to their location and 
delayed onset of visual changes, ciliary body melanomas tend to grow to a larger size 
before they are detected, remaining hidden behind the iris diaphragm (142). Various 
studies have shown an association with ciliary body involvement and increased mortality, 
making ciliary body involvement an important prognostic parameter to consider when 
predicting metastases (143).   
 
1.5.3.3   Extraocular extension  
Extraocular extension from a primary UM occurs in ~13% of patients (144). Up to two thirds 
of patients with extraocular extension will eventually die of metastatic disease (145). There 
are different routes by which UM can spread extraocularly; vortex veins, optic nerve, ciliary 
arteries, scleral perforation and aqueous drainage channels (Figure 1.7). The route of 
extraocular spread is highly dependent on the intraocular tumour location, (139). 
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Extraocular spread has been shown to be significantly associated with large basal diameter, 
presence of closed loops, epithelioid cell morphology and monosomy 3 UM, which are all 
features of aggressive tumours (146). 
 
 
Figure 1.7 Haematoxylin and Eosin stained sections depicting extraocular growth of UM 
cells; a) the cornea, b) an area of extraocular growth of melanoma cells outside of the 
sclera c) the iris, d) the ciliary body and e) a choroidal melanoma. 
 
1.5.3.4   Age and gender  
Studies have shown that there is no gender difference in the incidence of UM, with males 
and females affected equally. An in-depth analysis of UM revealed that men had a tendency 
to have posteriorly located tumours that were larger than the tumours in females (147) and 
which had a higher disease-specific mortality (148). UM diagnosed in females were more 
likely to be in the ciliary body or iris (147). Age at diagnosis is also another important factor 
to consider when determining a patient’s long term prognosis. Studies have shown that 
older patients have significantly worse survival rates compared to their younger 
counterparts (149). Univariate analysis has shown that patients <60 years old have a better 
survival rate (150). 
 
1.5.4 Histopathological Risk Factors 
1.5.4.1   Cytomorphology  
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Cytological classification of UM is a significant predictor of disease-free survival. Cell types 
were first categorised by Callendar in 1931 (151) into 6 histologic types; spindle A, spindle 
B, epithelioid, mixed, fascicular and necrotic. Spindle A cells are cigar-shaped with finely 
dispersed chromatin whereas spindle B cells have plumper nuclei with more distinct 
nucleoli and are generally more oval in shape. Epithelioid cells are named as such because 
they are epithelial-like, with an abundant cytoplasm, round nuclei and prominent nucleoli. 
This then formed the basis for subsequent modifications made by McLean et al. who 
simplified the classification by subdividing mixed-cell types into percentage and size of 
epithelioid content, and classifying spindle-cell types as mixed-cell if they containing small 
or rare epithelioid cells (Figure 1.8) (152). The fascicular and necrotic cell types were also 
removed from the classification system, and most spindle A cell specimens are now 
classified as spindle cell naevi (153).  
 
 
Figure 1.8 Cytomorphology of UM: A) Epithelioid cells distinguishable by their round nuclei 
and abundant cytoplasm B) Spindle cells with a long cigar-like shape nucleus. (Courtesy of 
Prof. S.E. Coupland) 
 
 
1.5.4.2   Mitotic count 
Mitotic count is defined as the number of tumour cells undergoing mitosis and is a useful 
prognostic tool in numerous cancer types.  The mitotic count is determined by examining 
haematoxylin and eosin (H&E) stained sections of UM and counting the number of mitoses 
per 40 high-power field (40x objective) (154). Observable mitotic figures are classified using 
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the criteria established by Van Diest et al. in 1992; absence of nuclear membrane, presence 
of condensed chromosomes which are either clotted, arranged in planes or in separate 
clots (Figure 1.9) (155). Another approach to measuring mitotic activity has involved 
immunohistochemical analysis using an antibody that detects the mitotic marker, phospho-
histone H3 (Figure 1.9) (156). A method commonly used to assess the mitotic count is 
examining tumour sections following immunohistochemical detection of Ki67 positive cells, 
a well-known marker of cellular proliferation (157). A study examining mitosis in 918 UM 
patients by examining H&E stained sections established that a high mitotic count (>4/40) 
was an independent predictive factor for metastatic death regardless of chromosome 3 
status (158). A high mitotic count is symptomatic of aggressive, fast-growing tumours and is 
a useful predictor of metastatic disease 
 
Figure 1.9 A phospho-histone H3-stained UM tumour section showing proliferating tumour 
cells (Courtesy of Prof. S.E. Coupland). 
 
1.5.4.3   Closed connective tissue loops  
In 1992 it was suggested that metastatic potential and tumour progression were linked to 
the arrangement of the microvasculature or connective tissue patterns within UM (159). 
Several vascular patterns were identified using Periodic acid-Schiff (PAS) positive staining; 
straight channels, parallel straight channels, cross-linked channels, incomplete closed loops, 
and complete closed loops (Figure 1.10) (160). These patterns were later organised into two 
distinct hierarchical groups: tumours with parallel and straight channels, and tumours with 
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networks of complete and incomplete loops branched or unbranched, with the latter being 
associated with a more aggressive tumour phenotype (161). Statistical analysis has shown 
that the incidence of closed connective tissue loops are associated with ciliary body 
tumours, epithelioid cell types, and large tumour size (162). It is not clear whether these 
‘loops’ represent blood vessels or only connective tissue; however, formation of 
microvascular channels in UM has been described in vitro, and  has been termed 
‘vasculogenic mimicry’, which is a de novo event lacking the presence of endothelial cells 
(163) (164). 
 
Figure 1.10 A Periodic acid-Schiff stained UM section under green light, showing the PAS+ 
closed connective tissue loops. (Courtesy of Prof. S.E. Coupland) 
 
1.5.4.4   Lymphocytes  
Cancer-related inflammation has recently been defined as the seventh hallmark of cancer, 
which includes the presence of inflammatory mediators such as chemokines and cytokines 
in addition to inflammatory cells such as macrophages and lymphocytes (165). Tumour-
infiltrating lymphocytes (TILs) can be found in around 5–12% of all UM (166). Studies have 
shown that the immune response in UM is enhanced by the high levels of HLA (Human 
Leukocyte Antigen)-DR on the surface of T-helper cells (167). In tumours such as cutaneous 
melanoma, the increased presence of TILs is associated with a good prognosis (168). 
However, in UM the presence of TILs has been shown to be associated with an adverse 
prognostic outcome (169) (170). A recent study demonstrated a clear association between 
monosomy 3 and the presence of CD8+ and CD4+ lymphocytes (171). 
23 
 
1.5.4.5   Macrophages 
Macrophages originate from a specific type of white blood cells called monocytes that are 
responsible for destroying intra-cellular material such as microbes, foreign substances and 
cancer cells in a process known as phagocytosis. However, tumour-associated macrophages 
(TAMs) contribute directly to growth and progression of tumour cells in a number of ways. 
TAMs are a source of growth factors, promote angiogenic factors, matrix proteases and 
suppress the adaptive immunity as well as inhibiting apoptosis resulting in increased cell 
proliferation (172). A study examining 139 macrophage-infiltrated enucleated eyes showed 
a positive correlation between the numbers of CD68+ TAMs and the presence of epithelioid 
cells, heavy pigmentation and high microvascular density, as well as an association with 
increased melanoma-specific mortality (173). The presence of macrophages in UM has 
been also proposed to correlate to monosomy 3 (174). 
 
1.6 Prognostication Methods 
1.6.1 Fluorescence in situ Hybridisation 
Fluorescence in situ Hybridisation (FISH) is a molecular cytogenetic technique that employs 
the use of fluorescently-labelled probes that bind to sequences of DNA for the detection 
and localisation of specific genes on chromosomes (175). FISH is considered a useful tool in 
establishing copy number changes and chromosomal rearrangements in cancers, and 
developmental disorders (176, 177), and is still widely used today to determine 
chromosome 3 status of UM (178) (Figure 1.11). However, many ocular oncology treatment 
centres are no longer using FISH in routine analysis of UMs. This is partly due to the fact 
that the centromeric probes used to identify loss of chromosome 3 are unable to identify 
partial losses of either 3p or 3q, (179). Furthermore, FISH is unable to detect isodisomy 3, 
which is associated with an unfavourable prognosis (180). There are numerous issues 
performing FISH for FFPE tissues such as lengthy pre-treatment regimens and labour 
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intensive procedures. Other techniques are now available that provide more detailed 






Figure 1.11 A fluorescence in situ hybridisation (FISH) image of UM cells: A) a monosomy 3 
UM cell; the red dots are centromeric chromosome 3 probes only one centromere is 
present in each cell B) a monosomy 3 UM cell with amplification of the c-myc region; the 
red probe corresponds to the centromeric region of chromosome 8 and the green probe 
corresponds to the c-myc gene of which there are three copies. (Courtesy of Prof. B. 
Damato) 
 
1.6.2 Multiplex Ligation-dependent Probe Amplification 
Multiplex Ligation-dependent Probe Amplification (MLPA) is a commercially-available and 
widely used assay to detect ploidy, mutations, single nucleotide polymorphisms (SNPs) and 
DNA methylation.  It is a unique technique whereby multiple targets are amplified using a 
single primer pair, hybridised and ligated into a complete probe resulting in uniquely sized 
amplicons, which facilitate separation via capillary electrophoresis (182). The use of MLPA 
for copy number analysis in UM is undertaken using a specific kit, SALSA P027, designed by 
the manufacturers MRC Holland (MRC Holland, The Netherlands). The kit contains 50 
probes that hybridise to gene loci on chromosomes 1p, 3, 6 and 8 (183). MLPA was 
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established as a useful tool for predicting metastatic death in UM by Damato et al. 2009 
(184). A study of 452 choroidal melanomas supported the use of MLPA for routine clinical 
prognostication with combined chromosome 3 loss and 8q gain having a worse prognosis 
that monosomy 3 alone, especially when considered together with the clinical and 
histologic risk factors (76). A recent larger study encompassing a cluster analysis of 602 
MLPA results and clinical outcome, identified three prognostic groups: group 1 (normal 
chromosomes 3 and 8q), group 2 (either 3 or 8q abnormal), and group 3 (3 and 8q 
abnormal).(185). Although suitable for both fresh and FFPE material, MLPA has been shown 
to perform better on fresh/snap-frozen tumour material (186). In addition, tumour 
heterogeneity has also been demonstrated to be a limitation of MLPA, as not all sampling 
methods are representative of the whole tumour which can yield equivocal results (187). 
Heterogeneous populations of tumour cells can contribute to differences in molecular 
profiling; this has led to concerns that a single tumour biopsy may not be representative of 




Figure 1.12 MLPA ‘Piano’ scores highlighting the different results seen in UM patients: all 
probes that fall in between the red lines are considered within the ‘normal range. A) MLPA 
results showing losses across the loci chr3 (monosomy 3) and polysomy 8q; B) MLPA results 
showing normal copy numbers for chromosomes 3 and 8. 
 
 
1.6.3 Microsatellite Analysis 
Microsatellite analysis (MSA) is a valuable diagnostic tool used routinely in clinical practice 
to determine aneuploidy in pre-natal tissues (188). MSA is also used as a prognostic tool to 
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establish chromosome 3 status in UM (189). Microsatellites are generally found in the non-
coding regions of the genome and are small repeating regions of 1-6 base pairs. MSA is a 
relatively easy and rapid test to perform whereby the region containing the microsatellite is 
amplified by multiplex-PCR. Fragment analysis of the fluorescently tagged probes is then 
employed to establish an allelic ratio; a comparison of tumour material and matched blood 
sample from each patient. The genotype of a locus is determined from the value of the 
allelic ratio, where loss of heterozygosity (LOH) is >2.5, no loss of heterozygosity (NLOH) 
<1.4 and allelic imbalance between 1.4 and 2.5 (190). MSA only requires tiny amounts of 
DNA >5ng/µl making this a suitable technique to employ on smaller samples such as fine-
needle aspiration biopsies (70). A large study of 374 UM samples by Thomas et al. 2012 
demonstrated the prognostic value of establishing chromosome 3 status using MSA, with 
LOH and allelic imbalance being associated with metastatic death (190). MSA is also a 
useful technique in establishing tumours with acquired homozygosity, or isodisomy, where 
conventional methods of testing such as karyotyping have shown a normal disomy 3 result 
(180).  
 
1.6.4 Gene Expression Profiling 
Gene expression profiling (GEP) is a technique that simultaneously measures mRNA 
expression of multiple genes. GEP was employed by Tschentscher et al. 2003, who 
established an association between different levels of gene expression and chromosome 3 
status in UM (191). The relationship between gene expression and survival was later also 
explored by Onken et al. 2004 leading to a classification of UM as low-grade/class 1 or high-
grade/class 2. The data identified 12 signature genes that could distinguish between low 
and high metastatic risk UM and has led to the development of a commercial test in which 
the 12 signature genes and 3 housekeeping genes form the Decision DxUM panel marketed 
by Castle Biosciences in the USA for prognostication of UM patients (192). The GEP 
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classification system for UM was later revised to take into account low-risk/class 1 patients 
who developed metastases. This led to the creation of class 1a and 1b tumours, with the 
latter indicating an intermediate risk of metastasis (193). Recent studies have shown 
‘Preferentially Expressed Antigen In Melanoma’ or PRAME to be an independent prognostic 
biomarker in UM, which is hypomethylated and activated in both class 1 and 2 tumours and 
associated with an increased metastatic risk (194, 195). Although an effective method of 
classifying tumours as high or low risk, these results are not used in conjunction with other 
well published clinical and histopathological prognostic features, reducing the accuracy of 
the prognostication. Moreover, recent data suggests that GEP cannot distinguish between 
primary UM and secondary metastases from other primary tumours (196). 
 
1.6.5 The Liverpool Uveal Melanoma Prognostication Online (LUMPO) Tool 
‘Liverpool Uveal Melanoma Prognostication Online’ or LUMPO is a freely available 
multivariate analysis tool used to create a personalised prognostic curve for UM patients 
(www.ocularmelanomaonline.org) (Figure 1.13). The patient’s own clinical, 
histopathological and genetic results are compared with a healthy age- and gender-
matched individual using a clinically validated mathematical algorithm (197). This is 
particularly important because the survival prognosis of choroidal melanoma correlates 
with clinical stage in addition to histologic grade, genetic type, and other competing causes 
of death. LUMPO allows each patient prognostication to be personalised, sparing them 
from unnecessary screening tests that cause anxiety. This allows screening to be focused to 
high-risk UM patients allowing any metastatic spread to be detected earlier. The Liverpool 
Ocular Oncology Centre (LOOC) was the first centre to provide this personalised service to 
patients and a recent google analysis of the tool showing 3836 hits from 2204 users in 717 
cities around the world. An updated version of this software is currently online which also 
28 
 
incorporates chromosome 8q status. This is in the process of being externally validated by 
the ocular oncology group (OOG). 
 
Figure 1.13 LUMPO – Version I: A personalised survival curve that is indicative of a high risk 
of developing metastatic UM. This patient is a 65 year old man with an epithelioid celled, 
monosomy 3 ciliochoroidal melanoma. They have an 80% greater chance to have died of 
metastatic disease when compared to age and gender matched population. The normal 
population is depicted using the black line at the top of the graph where the patients are 




1.7 Advances in Prognostication 
Next-generations (NGS) studies of UM have contributed to the identification of recurrent 
mutations in UM in BAP1, SF3B1, EIF1AX, CYSLTR2 and PLCB4 (129) (119) (132) (133). Larger 
whole exome studies like those carried out by Royer-Bertrand et al. and Robertson et al. 
that integrated copy number and mutation data enabled the identification of four distinct 
molecular subgroups in terms of survival (134) (135). This has facilitated the development 
of targeted NGS panels that have the potential to be used to aid prognostication in the 
clinic (198). 
1.8 Scope of Thesis 
This review of the published literature makes it abundantly clear that there are numerous 
prognostic factors to consider when determining the metastatic risk of patients with UM. 
Most recently, mutations identified in BAP1, SF3B1 and EIF1AX have been shown to 
contribute to the metastatic risk stratification of patients with this disease. In an era of 
‘personalised medicine’ it is becoming increasingly important to look at the specific genes 
and proteins that contribute to cancer growth, survival and spread in order to provide more 
accurate diagnoses and targeted therapies. The clinical use of next generation sequencing 
(NGS) has increased over the last 5 years enabling medical professionals to create large 
targeted sequencing panels for hereditary cancers, neurodegenerative disorders and other 
diseases. NGS has many advantages over traditional Sanger sequencing, primarily the ability 
to fully sequence a range of mutations on a multitude of genes, at a comparatively low cost. 
This thesis examines our current methods of prognostication for UM patients and aims to 
investigate how these can be improved/enhanced. In Chapter 2 the similarities and 
differences between the rare subtype of uveal melanoma; iris melanoma and the more 
commonly diagnosed choroidal melanoma by analysing genetic data alongside clinical and 
histopathological features of the tumours. The efficacy of MSA in correctly predicting 
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patient outcome based on their chromosome 3 status and the effect that radiotherapy has 
on obtaining a clear genetic result was investigated in Chapter 3. We also examined the 
relationship between nBAP1 protein expression and survival in Chapter 4 by undertaking a 
statistical analysis to establish the relationships between nBAP1 expression, chromosome 3 
data and survival. In Chapter 5, I describe a bespoke NGS panel that we designed on the 
basis of TCGA data, which mapped out in detail the most common mutations in UM. This 
new NGS panel for UM includes both the most common mutations in UM as well as the 
significant copy number variations. This panel was tested on both fresh and formalin-fixed 
paraffin embedded (FFPE) tumour material, with the view of ultimately introducing into 
medical care. Chapter 6 focussed on understanding the role of a protein recently identified 
in uveal melanoma, RasGRP3, by examining protein expression in primary UM samples by 
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2.1   Introduction 
The iris is a thin, circular, multi-layered structure consisting of the iris pigment epithelium 
and the pigmented outer stroma. There are two muscles within the iris: the sphincter that 
constricts the iris pupil, and the dilator that dilates it. The iris is responsible for controlling 
the amount of light that reaches the retina by controlling the diameter and size of the pupil. 
The pigmented outer stroma, with its scattered melanocytes, is the structure within the iris 
responsible for defining the range of eye colours present in humans: blue, hazel, green or 
brown.  
Iris melanomas (IM) are the rarest of all UMs, consisting of only 5% of all cases, and are 
thought to arise from neoplastically-transformed iris melanocytes (199) (Figure 2.1). 
Primary treatment of IM varies depending on the behaviour and size of the tumour: small 
lesions where there is not any documented growth can be observed and treatment 
delayed. Different treatment options are available when the lesion is more aggressive, and 
include PBR, brachytherapy, local resection or iridocyclectomy and enucleation, if there is 
involvement of the angle or diffuse iris involvement. IM are considered less aggressive than 
choroidal and ciliary body melanomas, primarily because they are detected earlier as they 
are externally visible due to their physical location. In addition, IM are thought to be privy 
to host immune responses within the aqueous that suppress the metastatic potential of the 
tumours in comparison to other UM (200). Moreover, IM are more likely to be comprised of 
spindle cells, which are associated with a more favourable prognosis (201). Metastatic 
spread in IM is reported in 0.5% of cases at 3 years and 7% at 10 years with an overall 5-
year mortality of 2-3% (202). There are several risk factors for the metastatic spread of IM: 
increased patient age, ciliary body involvement, angle involvement, raised intraocular 
pressure, extrascleral extension, size (>3mm diameter, 1mm thickness), diffuse growth 
pattern, rapid growth, indistinct edges, hyphaema, pigment dispersion, ectropion uveae, 
prominent vascularity and pupillary ‘peaking’ or ‘splinting’ (203). The chromosomal 
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alterations in posterior UM are well-documented in the literature, and there is a clear 
correlation between genetics and metastatic death; however, due to the rarity of IM there 
have been limited studies on their genetic alterations.  
 
The aim of chapter 2 was to determine whether the genetic changes associated with 
posterior UM are also detected in IM.  This was achieved by: 1) undertaking MLPA/MSA 
analysis of IM; and 2) analysing the genetic data together with the clinical and 




Figure 2.1 Clinical and histological examples of IM. A) An iris melanoma that extends from 
8-9 o’clock (courtesy of Prof. B Damato); B) An IM section at x10 magnification; the iris 
pigment epithelium is on the posterior surface, the anterior stroma and iris leaf show 
atypical melanocytes C) An IM section of the lesion in B at x40 magnification showing the 
atypical melanocytes in greater detail; D) Melan-A immunohistochemical staining of the 




2.2   Materials and Methods 
A retrospective database review of all IM patients attending the LOOC between January 
1993 and March 2015 was performed. Clinical, histopathological, genetic and follow-up 
information for the identified IM cases was recorded. All samples had been examined and 
classified by an Ophthalmic Pathologist according to the modified Callender’s classification 
of UM. Cases were excluded in which iris involvement was judged to be secondary to 
invasion from a posterior UM based on the clinical history of the patients. All patients had 
undergone full pre-operative ophthalmic and systemic examinations including slit-lamp 
examination, gonioscopy, ocular coherence tomography (OCT) and echographic 
measurements of the tumour using a water-bath filled ultrasound probe with 2% 
hypromellose (EyeCubed Ultrasound, Ellex Ltd.). 
 
2.2.1   DNA extraction from fresh UM 
FNAB were centrifuged at 1500RPM for 2 mins. Tissue lysis and protein digestion was 
carried out using 180µl Buffer ATL (Qiagen GmbH, Hilden) and 40µl of Proteinase K 
(20mg/µl) (Qiagen GmbH, Hilden). Samples were incubated at 56°C 350RPM on a 
Thermomixer comfort (Eppendorf). An additional 20µl of Proteinase K was added after 4 
hours and the samples were incubated overnight. Genomic DNA was isolated using DNeasy 
Blood and Tissue spin columns (Qiagen GmbH, Hilden), purifying the DNA with two AW1 
buffer washes to remove contaminants and enzyme inhibitors followed by a further wash in 
AW2 buffer. DNA was re-suspended in 35µl TE buffer (10mM Tris-HCl pH 8.0, 0.1mM EDTA) 
(Life Technologies ltd. Carlsbad).  
 
2.2.2   DNA extraction from FFPE tumour samples 
After H&E-stained sections were examined and the tumour area identified, 5-10 20µm thick 
sections were microdissected from 6 iridocyclectomy and 6 enucleation samples using a 
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scalpel and each placed in a sterile 1.5ml Eppendorf tube. Tissue lysis and protein digestion 
was carried out using 180µl Buffer ATL (Qiagen GmbH, Hilden) and 40µl of Proteinase K 
(20mg/µl) (Qiagen GmbH, Hilden). Samples were incubated at 56°C 350RPM on a 
Thermomixer comfort (Eppendorf) overnight. On day 2, an additional 10µl of Proteinase K 
was added at three separate intervals and the samples were incubated overnight. On day 3, 
FFPE lysis underwent an additional incubation at 70°C to destroy crosslinks with histones. 
Genomic DNA was isolated using DNeasy Blood and Tissue spin columns (Qiagen GmbH, 
Hilden), purifying the DNA with two AW1 buffer washes to remove contaminants and 
enzyme inhibitors and one AW2 wash. DNA was re-suspended in 35µl TE buffer (10mM Tris-
HCl pH 8.0, 0.1mM EDTA) (Life Technologies ltd. Carlsbad). 
 
2.2.3   DNA extraction from patient matched whole blood 
200µl of matched whole blood was digested in 20µl of proteinase K (20mg/µl) (Qiagen 
GmbH, Hilden) and 200µl AL buffer (Qiagen GmbH, Hilden). Samples were incubated at 
56°C 350RPM on a Thermomixer comfort (Eppendorf) for 10 minutes. Genomic DNA was 
isolated using DNeasy Blood and Tissue spin columns (Qiagen GmbH, Hilden). The DNA was 
then purified by washing with AW1 and AW2 buffers. DNA was re-suspended in 35µl TE 
buffer (10mM Tris-HCl pH 8.0, 0.1mM EDTA) (Life Technologies ltd. Carlsbad).  
 
2.2.4   DNA Quantification 
DNA concentration was quantified by fluorometry (Invitrogen Qubit fluorometer and 
broad-range DNA quantification assay; Life Technologies, Carlsbad, CA; Glasgow, UK). The 
fluorometer was calibrated using two DNA standards; standard 1 which has a concentration 
of 0ng/µl and standard 2 which has a concentration of 100ng/µl. The Qubit working 
solution was prepared by diluting the dsDNA BR Reagent 1:200 in Qubit dsDNA BR Buffer. 
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1µl of sample DNA was then mixed with 199µl of the Qubit working solution and incubated 
at RT for 2 minutes. DNA concentration was subsequently measured. 
 
2.2.5   Multiplex Ligation-Dependant Probe Amplification (MLPA) 
Copy number variations in chromosomes 1, 3, 6 and 8 were identified using the SALSA 
MLPA UM P027 kit (MRC-Holland, Amsterdam, The Netherlands). 100ng of tumour DNA 
extracted from IM samples in addition to DNA from 6 normal choroid samples for FFPE 
tumour material and 6 fresh blood samples for fresh tumour material, was diluted in 5µl 
(20ng/µl) of TE buffer (10 mM Tris-HCl (pH 8.0) 0.1 mM EDTA, Life Technologies, Scotland) 
and transferred into 0.2ml thin walled 8-strip tubes (Thermo Scientific). Negative and 
positive controls were included in each run; negative control used was TE buffer and 
positive controls consisted of previously tested samples of known outcome.  All PCR steps 
were carried out using a G-Storm GS1 Thermal Cycler (GRI- Genetic Research 
Instrumentation Ltd, Essex). Samples were denatured at 98°C for 5 minutes and allowed to 
cool to 25°C. A hybridisation mixture, consisting of 1.5µl of SALSA Probemix and 1.5µl of 
MLPA buffer, was added to the denatured DNA. The samples were then heated at 95°C for 
1 min and the probes were hybridised overnight at 60°C for 16-18 hours. 32µl of a ligation 
mixture consisting of 3µl of Ligase-65 Buffer A, 3µl Ligase-65 Buffer B, 1µl of Ligase-65 
enzyme and 25µl nuclease free water was added to the samples and incubated at 54°C for 
15 mins (for ligation of adjacent probes), 98°C for 5 mins (for heat inactivation of Ligase-65 
enzyme) and allowed to cool to 20°C. 10µl of PCR mix consisting of 6.5 µl nuclease free 
water, 2 µl SALSA PCR primer mix, 1µl of 22% BSA (Sigma) and 0.5 µl SALSA Polymerase was 
added to samples. The samples were then subjected to 35 cycles of 30 seconds 95°C; 30 




2.2.6   MLPA fragment analysis using capillary electrophoresis 
1µl of MLPA PCR products was mixed with 0.5µl GeneScan 500 LIZ size standard (Applied 
Biosystems, Foster City, California) and 8.5µl HiDi Formamide (Applied Biosystems, Foster 
City, California) in a semi-skirted 96-well plate (Starlabs Ltd, United Kingdom). Samples 
were denatured at 95°C for 3 minutes and placed on ice to cool for 5 minutes. The IM 
samples were separated and analysed on a 3500 Genetic Analyser (Applied Biosystems) 8 
capillary sequencer and GeneMapper software (Applied Biosystems) in the molecular 
pathology department of the Royal Liverpool University Hospital, Liverpool.  Fluorescence 
intensity was depicted by varying peak heights for each of the 50 probes included in the 
SALSA MLPA UM PO27 kit (Figure 3.1). Analysis of MLPA data was performed using a 
MatLab adapted version of a spreadsheet (Excel; Microsoft, Redmond, WA) designed by the 
National Genetics Reference Laboratory (NGRL), Manchester, UK 
(http:/www.ngrl.org.uk/Manchester/).  MLPA data was considered reliable if 6 or more 
control probes were within the normal range. As previously described by Lake et al. (2012) 
dosage quotients were categorised as; ≤0.65 deletion, 0.65 – 0.84 borderline loss, 0.85 – 
1.14 normal, 1.15 – 1.35 borderline amplification and ≥1.35 amplification. 75% of the 
probes needed to be in agreement in order to definitively classify chromosomal ‘loss’ or 
‘gain’ and anything under 75% is considered an unclassified result (186). 
 
2.2.7   Microsatellite analysis 
IM samples yielding <100 ng DNA were analysed for chromosome 3 aberrations by MSA. 
5ng of IM tumour DNA with matched blood DNA from the same patient was transferred 
into 0.2ml thin walled 8-strip tubes (Thermo Scientific). Two separate multiplex PCR 
reactions containing primer pairs that flank 8 microsatellites on chromosome 3 (4 on 3p 
and 4 on 3q) have previously been optimised for MSA testing (Table 2.1) (190). 24µl of 
master mix consisting of; 8.9µl nuclease free water (Qiagen, GmbH, Hilden Germany), 12µl 
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2x Qiagen Multiplex PCR mix (Qiagen, GmbH, Hilden Germany), 0.5µl 22% BSA (Sigma) and 
2.1µl primers (Eurofins, Germany) was added to the samples. The samples were transferred 
to a G-Storm GS1 Thermal Cycler (GRI- Genetic Research Instrumentation Ltd, Essex) and 
after an initial activation step at 95°C for 15 minutes they are subjected to 35 cycles of; 
94°C for 30 seconds, 56°C for 90 seconds and 72°C for 60 seconds with a final extension for 
30 minutes at 60°C, allowing the samples to cool at 10°C. PCR products were then analysed 
using the ABI 3500 Genetic Analyser (Applied Biosystems) and the fragment analysis 
completed using GeneMapper (Applied Biosystems). The electropherograms generated 
show the peaks of the marker and the “peak area” obtained from the test (tumour) and 
reference (whole blood) samples of the same patient. A marker is classed as “informative” 
when the two allelic peaks are present in the reference sample (i.e. blood) and can be 
compared to the corresponding test sample (i.e. tumour). If two allelic peaks are not 
present in the reference blood sample, the marker is classified as “non-informative” (NI) 
and an allelic ratio (AR) cannot be calculated for that particular microsatellite. From the 
data generated by the informative markers, the following classifications are given: Loss of 
heterozygosity (LOH) - Data shows LOH for a particular marker when AR > 2.5. No Loss of 
heterozygosity (NLOH) - Data shows NLOH for a particular marker when the AR = 1 – 1.3.  
Allelic Imbalance (AI) Data shows AI when the AR = 1.4 - 2.5.  
Based on the MSA data generated the IM were classified as follows:  M3 when two or more 
microsatellites on chromosome arm 3p and two or more microsatellites on chromosome 
arm 3q show LOH the case is classified as being at high risk of developing metastatic 
disease; D3 when two or more microsatellites on chromosome arm 3p and two or more 
microsatellites on chromosome arm 3q show NLOH; and the remaining markers do not 
display LOH the case is classified as being at low risk of developing metastatic disease or AI. 




Table 2.1 Primer Sequences for microsatellites covering chromosome 3 








Name Primer sequence Multiplex 
primer 
group 
Tm cM Arm 
D3S3050 For_TGGTGGTATGCATTTGTCAG 
Rev_ATTCCCTGACTTCAAGTGCA 
2 55.3 °C 10.31 p (26-
24.2) 




1 58.1 °C 29.62 p (25.3) 200-230bp Dinucleotide FAM/ 
blue 
D3S1300 For_ GAATAAACCTGAGAATCATCCCT 
Rev_ CATGACGTTCCTTTGTAGTGTTT 






























2.3   Results 
2.3.1   Patients 
A retrospective database review was carried out by Mrs. Yamini Krishna of all IM patients 
attending LOOC between January 1993 and March 2015. Of these I identified 26 cases 
where DNA could be obtained to perform molecular analysis. 
 
2.3.2   Molecular Genetic Analysis 
DNA was available from 26 patients: 22 samples were obtained after primary treatment of 
the tumour (12 were biopsies taken on the last day of PBR) and 4 samples were secondary 
procedures due to tumour recurrence (enucleations or iridocyclectomies). Eight of the IM 
had secondary ciliary body involvement where the primary tumour had been iridal in origin. 
Genetic analysis of IM was performed by MLPA in 20 cases and MSA in 6 cases. D3 was 
reported in 15/26 (58%) of the cases and M3 in 4/26 (15% cases).  3/26 (12%) cases yielded 
an unclassifiable chromosome 3p result but both cases had a normal 3q. 4/26 (15%) cases 
showed loss of chromosome 3p only. MLPA was performed on 18/26 (69%) cases; polysomy 
8q was present in only 1 case and gain of 6p was found in 4 cases (Table 2.2). Of the 
patients who died from metastatic IM one patient was M3 with a loss of 6p, the other had 
D3 with a gain of 6p, loss of 6q, loss of 8p and gain of 8q.    
 
2.3.3   Histopathological Analysis 
14/26 (54%) of the IM examined genetically had spindle cell morphology; 10/26 (38%) were 
of mixed cell type; and 2/26 (8%) were of epithelioid morphology. The mean follow-up time 
of the IM patients from our cohort was 99.9 months (median 88.5 months; range 6 - 247). 
At the end of the study 19/26 (73%) patients were alive with no evidence of metastatic 
spread and 6/26 (23%) patients had died; 2 from metastatic IM and 4 from other causes 
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including sepsis, metastatic rectal carcinoma and an upper gastrointestinal haemorrhage. 






Table 2.2 Clinical, genetic and histopathological data for the 26 iris melanoma cases examined. *Sample on which genetic testing was performed; †Biopsy 
taken prior to PBR; ‡Chromosome 3 data determined by MSA; –, Not performed/not applicable; AI, angle involvement; CBI, ciliary body involvement; F, 
female; G, gain; IM, iris melanomas; L, loss; LBD, largest basal diameter; M, male; MSA, microsatellite analysis; N, normal; NMD, no mutation detected; PBR, 
proton beam radiotherapy; U, unclassifiable; UH, ultrasound height














Cell Type Chromosome Data Death; 
Cause Chr1p Chr3p Chr3q Chr6p Chr6q Chr8p Chr8q 
1 F 32 IM Iris excisional 
biopsy* 
– 217 2.3 2.2 Spindle N U N N N N N No 
2 M 33 IM; CBI Iridocyclectomy* – 205 1.5 1.1 Mixed N L N N N N N No 
3 M 55 IM Iridocyclectomy* – 142 7.5 1.1 Mixed N N N N N N N Yes: Other 
4 M 58 IM PBR+biopsy* – 88 6.5 2.9 Spindle N L L G N N N No 
5 M 48 IM PBR Iridocyclectomy* 176 3.3 1.8 Mixed N N N N N N N No 
6 M 51 IM; CBI PBR Enucleation* 111 2.9 1.3 Mixed N L L N N L N No 
7 M 57 IM PBR+biopsy*† – 90 4.2 1.3 Spindle N N N N N N N No 
8 M 53 IM PBR+biopsy* – 6 5.4 3.1 Mixed N N N N N N N No 
9 M 79 IM; CBI Enucleation* – 79 7.2 3.3 Mixed N L L L N N N Yes; MM 
10 M 57 IM; CBI; 
AI 
PBR Enucleation* 66 6.7 5.0 Mixed N N N G L L G Yes; MM 
11 F 52 IM Iridocyclectomy* – 247 1.2 1.1 Spindle N U N G N N N Yes; Other 
12 F 84 IM; CBI; 
AI 
Enucleation* – 94 12.3 3.6 Mixed N L L N N N N Yes; Other 
13 M 25 IM; CBI Iridocyclectomy* – 72 1.9 1.6 Spindle – N‡ N‡ – – – – No 
14 M 64 IM; AI PBR Enucleation* 89 4.5 0.7 Epithelioid N L N N N N N No 
15 M 35 IM PBR+biopsy* – 57 2.3 0.5 Spindle – N‡ N‡ – – – – No 
16 M 61 IM PBR+biopsy* – 56 4.3 1.8 Spindle – N‡ N‡ – – – – No 
17 F 44 IM PBR+biopsy* – 55 2.4 1.0 Spindle – N‡ N‡ – – – – No 
18 M 73 IM PBR+biopsy* – 8 8.7 1.2 Spindle N N N N N N N Yes; Other 
19 M 60 IM PBR+biopsy* – 109 8.6 3.3 Spindle N N N G N N N No 
20 F 61 IM; CBI Iridocyclectomy* – 94 4.6 2.0 Spindle N N N N N N N No 
21 M 47 IM; CBI; 
EOE 
Enucleation* – 90 2.6 1.1 Mixed N N N N N N N No 
22 M 54 IM PBR+biopsy* – 178 4.4 1.1 Epithelioid – N‡ N‡ – – – – No 
23 F 62 IM PBR+biopsy* – 88 6.5 1.2 Mixed N L N N N N N No 
24 M 22 IM PBR+biopsy* – 64 3.3 2.0 Spindle – N‡ N‡ – – – – No 
25 F 64 IM PBR+biopsy* – 62 4.7 1.6 Spindle N U N N N N N No 
26 M 43 IM PBR+biopsy* – 53 3.7 1.1 Spindle N L N N N N N No 
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2.4   Discussion 
At the close of study in February 2018 this was the largest study carried out on IM (204). The 
genetics of IM has been investigated in other studies by different methodologies: e.g. 
karyotyping, MSA and FISH. This study was the first of its kind to examine the molecular 
genetics using MLPA. The incidence of chromosome 3 loss and polysomy 8q in IM in this study 
was not consistent with the previously reported cases in the literature, possibly reflecting the 
varying genetic techniques used to examine these tumours. This is discussed below. 
The first reported case of cytogenetic analysis of IM was by White et al. (1995) where they 
utilised conventional karyotyping to examine a single case of IM (205). They reported 
aneuploidies on chromosomes; X, 2 7, 15 and 18 in addition to rearrangements of 4q, 8q, 12p 
and several marker chromosomes. This is in contrast to the well-documented copy number 
changes in chromosomes 1, 3, 6 and 8 expected in posterior UM. An analysis of 20 IM cases 
using the molecular cytogenetic technique FISH (206) reported 6/20 (30%) cases with 
complete loss of chromosome 3, 3/20 (15%) showed partial loss of chromosome 3 and 9/18 
(50%) cases had polysomy 8q. This differed to our present study where polysomy 8q was 
present in only one sample. In this study by Mensink et al. 4/20 patients developed metastatic 
disease and 3 of these patients had died at the close of study. All of these patients had 
complete loss of chromosome 3 and polysomy 8q with presence of epithelioid cells.  
Shields et al. (2011) analysed 17 treatment naïve IM using MSA, reporting D3 in 5/17 (29%) 
cases, M3 in 5/17 (29%) cases, and partial loss of chromosome 3 in 7/17 (41%) cases, again 
different to the 15% cases with partial loss of chromosome 3 found in this study (207). None of 
the cases that were found to have a normal chromosome 3 copy number had a 
mixed/epithelioid cytomorphology, whereas in my study 6/17 (35%) of disomy 3 tumours 
contained epithelioid cells. Furthermore, in contrast to the data from Mensink et al. and the 
data obtained in my study, Shields et al. did not report any patients developing a local 
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recurrence or metastatic disease. This may be due to the relatively short follow up for the 
cases included in the Shields study; 16 months as compared with 247 months in my study. 
In the present study, two patients died from metastatic IM. One of the patients who died from 
metastatic UM had a normal chromosome 3 with gain of 6p and polysomy 8q. One explanation 
for this is that the normal chromosome 3 result could be due to a rare phenomenon known as 
acquired homozygosity or isodisomy (180). Isodisomy occurs when one copy of chromosome 3 
is lost and subsequently duplicated. This may then result in chromosome 3 with two copies of 
the mutated tumour suppressor gene BAP1. However, this case also had other hallmarks of a 
‘high risk’ UM, in particular it had a large tumour diameter (LBD), both ciliary body and angle 
involvement, in addition to the presence of epithelioid cells. Taken together, these factors can 
also contribute to the development of metastatic disease. The other patient’s tumour showed 
loss of chromosome 3 and loss of 6p in addition to other high risk features such as ciliary body 
involvement and presence of epithelioid cells. 
 In the present study the follow-up time available for patients who had monosomy 3 ranged 
from 79 – 111 months, a longer follow up period would have perhaps seen more deaths from 
metastatic disease. Nevertheless the frequency of monosomy 3 (15%) and polysomy 8q (6%) 
detected in this study is inconsistent with that reported for posterior UM (216). Two recent 
next generation sequencing studies of IM have shed further light on the mutations present in 
melanomas arising at this location. Scholz et al. 2017 identified frequent mutations in EIF1AX 
which fits with the prevalence of D3 that occurs in IM (208). In contrast, the study by Van 
Poppelen et al. 2018 identified BAP1 mutations in 43% of their cohort, in addition to 2 
mutations in SF3B1. A possible explanation for this could be the IM selected for their study had 
not originated from the iris (209). 
 
In this chapter, I have demonstrated that the same chromosomal aberrations observed in 
posterior UM are also seen in IM, in both treatment naïve and irradiated IM, with a low-
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metastatic risk genotype most commonly observed. Further follow-up and assessment of more 





















































3.1 Introduction  
 
Non-coding regions of the genome contain small tandem nucleotide repeats known as 
microsatellites. Microsatellites or ‘Short Tandem Repeats’ are small repeating regions of 
between 1 to 6 base pairs and the numbers of these repeats can be highly variable. As the 
majority of microsatellites occur in non-coding regions of the genome they do not produce 
proteins, enabling the unimpeded accumulation of mutations, facilitating variation. This 
variability enables microsatellites to be utilised as markers for a range of genetic tests such as 
aneuploidy screening, paternity testing and DNA fingerprinting. Individuals typically have two 
alleles for all microsatellites as they are inherited from each parent and these maternal and 
paternal alleles are often different lengths. As microsatellites are inherited they are 
heterozygous, and when one pair of alleles is mutated or deleted, this is defined as loss of 
heterozygosity (LOH). LOH occurs frequently in tumour cells, arising from multiple genetic 
events, such as faulty repair of DNA breaks and errors during mitosis i.e. non-disjunction.  LOH 
can impact the genome in numerous ways, e.g. loss of gene expression, haploinsufficiency and 
unmasking recessive tumour suppressor genes. Microsatellite analysis (MSA) is a polymerase 
chain reaction (PCR)-based technique that amplifies microsatellites of interest using unique 
fluorescently-tagged sequences flanking these regions as primers. These loci are amplified on 
nuclear DNA extracted from a tissue sample and a matched whole blood DNA sample. This can 
then be easily analysed using fragment analysis by capillary electrophoresis. Human 
chromosome 3 consists of 210 Mb of DNA (~7% of the human genome), with one study 
identifying at least one hundred and six microsatellite repeat-containing loci on this 
chromosome (210). MSA of UM was first performed by Tschentscher et al. to examine the 
feasibility of identifying tumours with M3 in comparison to other methods such as karyotyping 
and array CGH (211). In this study, fluorescently-tagged primers pairs were obtained from 
Research Genetics (Research Genetics, Huntsville, USA) corresponding to 7 sites on 
chromosome 2; 3 on 3p and 4 on 3q, preferring loci with a tetra-repeat structure to enable 
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quantitative evaluation of the signals. In a similar study, Shields et al., evaluated 10 
polymorphic microsatellite markers on chromosome 3 selected from the Applied Biosystems 
Inc. (ABI; http://www.appliedbiosystems.com/) human genome mapping kit, v2.5 (212). In 
their 2012 study, Thomas et al. assessed 8 loci using primers purchased from Eurogentec 
(Seraing, Belgium). Each study utilised forward primers linked to distinct fluorescent labels in 
order to enable single-lane analysis of markers from one chromosome. To correct for the 
difference in amplification efficiency of different marker alleles, the ratio of allele peak areas 
(allele ratio (AR)) in the tumour was normalised against the peak ratio obtained in the 
corresponding DNA from blood (190). Once determined the genotype of the loci can be 
classified depending on the AR calculated. At Liverpool AR are classified as follows: AR≥2.5, 
loss of heterozygosity (LOH); AR 2.49 - 1.4, allelic imbalance (AI) or AR≤1.39, no loss of 
heterozygosity (NLOH). At the Liverpool Ocular Oncology Centre (LOOC), MSA is used to detect 
LOH of chromosome 3. Due to the relatively low amount of input DNA required for the PCR-
based test, this is usually reserved for smaller UM samples, especially those obtained from 
fine-needle aspirate biopsies (FNAB) often after radiotherapy has been administered, where 
there is <100ng of DNA available for genetic analysis. Additionally, MSA of chromosome 3 can 
be used when other techniques for example, MLPA, fail to provide a result for chromosome 3 
or ‘acquired homozygosity’ or isodisomy is suspected (180). The use of FNAB for 
prognostication is controversial. Those reluctant to use the procedure argue that it increases 
the risk of disseminating tumour cells, precipitating metastasis (213-215). There are some 
cases in the literature that show local recurrence and extraocular extension can occur 
following intraocular biopsy (215-217). An ex vivo study performed by Glasgow et al (1988) 
demonstrated iatrogenic dissemination of tumour cells following transvitreal biopsy, however, 
in general this is a rare complication (218). At the LOOC, FNAB are routinely used in clinical 





The aim of chapter 3 was to: (1) examine survival of patients with UM where the chromosome 
3 status was determined by MSA (2) assess the effect, if any, that radiotherapy has on 
obtaining chromosome 3 classification (3) establish whether taking a FNAB before the 


























3.2   Methods 
3.2.1   DNA extraction from fresh UM 
DNA extracted from 284 fresh UM samples were performed using the methods described in 
chapter 2.2.1. 
3.2.2   DNA extraction from patient matched whole blood 
DNA extracted from 284 blood samples were performed using the methods described in 
chapter 2.2.3. 
3.2.3   DNA Quantification 
DNA quantification performed using the methods described in chapter 2.2.4. 
3.2.4   Microsatellite Analysis 
Microsatellite Analysis was performed using the methods described in chapter 2.2.7. 
 
Based on the MSA data generated the UM were classified as follows:  M3 when two or more 
microsatellites on chromosome arm 3p and two or more microsatellites on chromosome arm 
3q show LOH the case is classified as being at high risk of developing metastatic disease; D3 
when two or more microsatellites on chromosome arm 3p and two or more microsatellites on 
chromosome arm 3q show NLOH; and the remaining markers do not display LOH the case is 
classified as being at low risk of developing metastatic disease or AI.  
 
3.2.5   Statistical Analysis 
Metastasis-free survival (months) was calculated from the date of first diagnosis until death, or 
study closure on 15th May 2018. Kaplain Meier survival and Fisher’s exact statistical analysis 
carried out using SPSS Statistics v.24 
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3.3   Results 
3.3.1   Clinical and Histopathological features of the examined UM 
Chromosome 3 status as determined by MSA was examined in 284 patients treated at the 
LOOC between January 2011 and December 2015 (Table 3.2). The study consisted of 134 males 
and 150 females with a mean age of 58.6 years at primary management (median age 61; range 
14 – 92 years). The mean follow-up period was 37.6 months (median follow-up 37 months; 
range 0– 133 months). At study closure, 240/284 (85%) patients were alive, 34/284 (12%) 
patients had developed or died from metastatic disease and 12/284 (4%) patients died from 
other causes. The 284 samples consisted of: 249 biopsies, 27 enucleations, 3 local resections, 2 
endoresections and 3 iridocyclectomies. The primary treatment for the 284 samples was: 85 
PBR, 158 ruthenium plaque, 26 enucleations, 6 diagnostic biopsies and subsequent genetic 
analysis, 4 local resections, 3 iridocyclectomies, 1 endoresection and 1 photodynamic therapy.  
The tumours had a median LBD of 11.05mm (range, 1.82 – 20.80mm) and a median UH of 
3.1mm (range, 0.9 – 18.5mm). 93/259 (36%) tumour samples contained epithelioid cells and 
171/264 (65%) were spindle cell tumours, cytomorphology was not available for 20 cases due 
to low cellularity. 38/284 (13%) of tumours involved the ciliary body and 5/284 (2%) of 
tumours had extraocular extension. 21/38 (55%) surgical resection samples contained PAS+ 
loops and 6/40 (15%) had necrosis. Of the 240 UM that received radiotherapy, 131 (55%) were 
biopsied before and 109 (45%) after administration of radiotherapy (Table 3.1). 
 
Table 3.1 Patients receiving biopsy pre and post RXT 
 
 
Primary Treatment Biopsy taken Total 
Before RXT After RXT 
Proton Beam RXT 22 61 83 
Ruthenium Plaque RXT 109 48 157 
Total 131 109 240 
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Table 3.2 Tumour demographics  
 All Tumours (n=284) M3 (n=78) D3 (n=174) Partial loss of 3q (n=8) AI (n=17) Unclassifiable (n=7) 
Median age at PM (years) 61 (14 – 92) 62 (14 -90) 57 (16 – 92) 62 (45 – 81) 59 (44 – 82) 61 (46-71) 
Female 150 (53%) 44 (57%) 89 (51%) 6 (75%) 11 (65%) 3 (43%) 
Male 134 (47%) 34 (43%) 85 (49%) 2 (25%) 6 (35%) 4 (57%) 
  
Median LBD (mm) 11.05 (1.82 – 20.80) 13.2 (4.4 – 20.80) 10.45 (1.82 – 19.4) 8.65 (5.5 – 13.7) 9.8 (5.8 – 17.4) 10.5 (7.7 – 14.8) 
Median UH (mm) 3.1 (0.90 – 18.50) 4.1 (0.9 - 18.5) 2.65 (0.9 – 11.7) 2.2 (1.1 – 10.1) 2.4 (0.9 – 9.8) 3.3 (1 – 5.4) 
  
AJCC Stage (n=284) (n=78) (n=174) (n=8) (n=17) (n=7) 
1 133 (47%) 21 (27%) 92 (53%) 7 (88%) 9 (53%) 4 (57%) 
2 99 (35%) 34 (44%) 56 (32%) - 6 (35%) 3 (43%) 
3 41 (14%) 16 (20%) 22 (13%) 1 (12%) 2 (12%) - 
4 11 (4%) 7 (9%) 3 (2%) - - - 
       
Cell Type (n=259) (n=78) (n=156) (n=6) (n=13) (n=7) 
Epithelioid 93 (36%) 52 (67%) 34 (22%) 1 (2%) 3 (23%) 3 (43%) 
Spindle 166 (64%) 26 (33%) 122 (78%) 5 (8%) 10 (77%) 4 (57%) 
  
Ciliary Body Involvement (n=284) (n=78) (n=174) (n=8) (n=17) (n=7) 
Yes 38 (13%) 18 (23%) 16 (10%) 3 (4%) 1 (6%) - 
No 246 (87%) 60 (77%) 158 (90%) 5 (6%) 16 (94%) 7 (100%) 
  
Extraocular Extension (n=283) (n=77) (n=174) (n=8) (n=17) (n=7) 
Yes 5 (2%) 3 (4%) 2 (1%) - - - 
No 278 (98%) 74 (96%) 172 (99%) 8 (100%) 17 (100%) 7 (100%) 
  
Biopsy taken Pre/Post RXT (n=240) (n=65) (n=147) (n=6) (n=15) (n=7) 
Pre 131 (56%) 39 (60%) 79 (54%) 3 (50%) 7 (47%) - 
Post 109 (45%) 26 (40%) 68 (46%) 3 (50%) 8 (53%) 7 (100%) 
       
Survival (n=284) (n=78) (n=174) (n=8) (n=17) (n=7) 
Months 56.9 (5.7 – 111.7) 46.35 (6.1 – 86.9) 58.85 (11.1 – 111.7) 47.6 (5.7 – 80.6) 62.1 (30.8 – 82.6) 50.0 (48.3 – 73.3) 
  
Status (n=284) (n=78) (n=174) (n=8) (n=17) (n=7) 
Alive 240 (85%) 46 (59%) 163 (94%) 6 (75%) 17 (100%) 7 (100%) 
Metastatic 33 (12%) 27 (35%) 5 (3%) 2 (25%) - - 
Death other causes 11 (3%) 5 (6%) 6 (3%) - - - 
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3.3.2   Genetic features of examined UM 
As described in the materials and methods, MSA results were classified into 5 groups; 
78/284 (28%) tumours were M3, 174/284 (61%) tumours were D3, 8/284 (3%) tumours had 
a partial loss of chromosome 3 (all loss of 3q), 17/284 (6%) tumours were AI and 7/284 (3%) 
tumours were unclassifiable. Of the 34 patients who developed metastatic disease 27 had 
M3 UM, 2 had loss of 3q and 5 were D3 (Table 3.3).  
 
Table 3.3 Chromosome 3 status and outcome for 284 cases of UM analysed by MSA  
 
Status Chromosome 3 
Unclassifiable Loss Disomy Loss 3q Allelic 
Imbalance 
Total 
Alive 7 46 163 6 16 238 
Metastasis 0 27 5 2 0 34 
Other 0 5 6 0 1 12 
Total 7 78 174 8 17 284 
 
Of the 17 UM patients classified as AI, 5 were treated with PBR and had biopsies taken after 
radiotherapy was administered, 10 were treated with ruthenium plaque, 5 of whom had 
biopsies taken after radiotherapy, 1 patient was treated by enucleation and the remaining 
by local resection. The AI cohort consisted of 6 males and 11 females with a median age at 
primary management of 50 years (rang 44 – 82 years). The tumours had a median LBD of 
9.8mm (range, 5.8 – 17.4mm) and a median UH of 2.4mm (range, 0.9 – 9.8mm). 16/17 
(94%) had no ciliary body involvement and no cases demonstrated extraocular growth.  
10/17 (59%) cases had a spindle cell morphology, 3/17 (18%) contained epithelioid cells and 
for 4/17 (23%) cytomorphology could not be assessed. At the close of the study in May 
2018, all AI patients were all alive and well with no evidence of metastatic disease.  
 
The 240 cases treated by radiotherapy revealed little difference in the frequency of M3/D3 
results (Table 3.4). When comparing the success rate of the genetic testing in these samples 
we classified successful samples as those where a discernible chromosome 3 status could 
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be obtained, and those as unsuccessful if chromosome 3 status was unclassifiable or 
showed AI. A comparison of the genetic results obtained from biopsies taken pre- and post- 
radiotherapy did not show any significant difference in the success rate for chromosome 3 
classification (Fisher’s Exact p=0.799). This was then compared to the time lapsed from 
administration of radiotherapy to date of biopsy. Of the 109 post-RXT samples, 12 (11%) 
were considered unclassifiable and 97 (89%) yielded a chromosome 3 classification. The 
time to biopsy had a median of 52 days (range, 1 -102 days) and wasn’t significantly 
associated with unsuccessful genotyping by MSA (Mann-Whitney U p=0.307). Successful 
samples had a median biopsy sampling at 52 days (range, 1 – 102 days) and unsuccessful 47 
days (range, 11 – 82 days) (Table 3.5). Any samples >270 post radiation were excluded from 
analysis as they were more likely associated with tumour regression or regrowth. 
 
Table 3.4 A comparison of chromosome 3 status in samples taken pre- and post-
radiotherapy 
 





Loss 39 26 0.799§ 
Normal 79 68  
Partial Loss 3 3  
Allelic Imbalance 7 8  
Unclassifiable 3 4  
 




















Median 33 days;  
Range 0 – 66 days 
109 
Median 52 days;  





Median 16 days;  
Range 0 – 35 days 
12 
Median 47 days;  




Median 33;  
Range 0 – 66 days 
97 
Median 52 days;  
Range 1 – 102* 
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*Post-radiotherapy tumour samples retrieved >270 days post-radiation were removed from 
statistical analysis to exclude regrowth or tumour regression. 
 
3.3.3   Survival 
Kaplan–Meier survival curves and tables were examined for all primary UM stratified 
according to chromosome 3 status as determined by MSA. Both M3 UM (Log rank, 
p=<0.001) and loss of 3q (Log rank, p=<0.001) were significantly associated with a reduced 
metastasis-free survival time (Figure 3.3 and Figure 3.4). UM classified as having AI of 
chromosome 3 were the most similar to patients with D3 in terms of metastasis-free 
survival (Log rank, p=0.480) (Figure 3.5). Survival was also compared for patients who had 
samples taken either before or after administration of radiotherapy and was found to be 





Figure 3.1 Kaplan Meier plots of patient survival where the chromosome 3 status was 
determined by MSA n=285; disomy 3 n=174, monosomy 3 n=78, partial loss of 3 (loss of 3q) 
n=8 and allelic imbalance n=17 (log rank p=<0.001). 
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3.4   Discussion 
The efficacy of MSA in chromosome 3 classifications in UM has been explored in other 
studies, however, this study was the first to examine this technique in samples taken pre- 
and post PBR and ruthenium plaque radiotherapy (212) (70) (190). The incidence of 
chromosome 3 loss in this study was not consistent with some of the previously reported 
MSA studies in the literature, which is possibly a reflection of the varying classification 
systems used to categorise the tumours as M3 or D3. Although the percentage of M3 cases 
differed between MSA studies (e.g. between 28 - 56%) (see Table 3.6), it was consistently 
associated with a poor outcome. In an audit of 500 cases of UM tested using MSA, Shields 
et al. reported M3 in 25% of cases, a figure consistent with 28% of cases identified as M3 in 
this study (70). However, in the same study, a large percentage of UM were classified as 
partial loss of chromosome 3 (27%), which is much greater than that reported in the 
present study (3%). Partial loss of chromosome 3 was found in 8/286 cases in this study, 
and was exclusively loss of 3q. This alteration was found to be significantly associated with 
a poor prognosis (p=0.001) (figure 3.3). The classification system used by Shields et al. 
(2011) required 9/10 markers to be LOH to be considered complete M3, and 8/10 for 
partial loss (70). The system adopted in the current study classified cases as partial loss if 2 
or more markers were LOH on one chromosome arm. This made Shields et al partial loss 
cases more similar to our M3. In contrast, Thomas et al. assigned cases as partial loss if at 
least one chromosome 3 marker showed LOH in a tumour with others showing retention of 
heterozygosity; these cases were more like the present studies’ D3 UM (190). Despite this, 
the amount of partial loss identified in the Thomas cohort was similar to that seen in this 
study with a detection rate of 3% and 4%, respectively. The incidence of partial loss of 
chromosome 3 differs significantly in the literature with some studies reporting between 
0% and others as much as 48% (219). This is most likely due to the different ways each 
individual research group classifies their cases. Some studies suggest that partial loss is 
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likely caused by tumour heterogeneity (219). Cytomorphological heterogeneity is well 
documented in posterior melanomas and has fuelled fears that extracting a biopsy from a 
single site may reflect in the accuracy of chromosome 3 genotyping (220). Previous studies 
examining this have shown heterogeneity of gene loci dosage quotients in studies utilising 
MLPA, but it did not alter the overall chromosome 3 statuses observed (187). Similarly 
Coupland et al. showed that Chromosome 3 data showed prognostic concordance for 
patient-matched samples in 28 cases that were initially biopsied and subsequently resected 
(221). 
AI were first reported by Tschentscher et al. who consistently observed allele ratios that fell 
just below the cut-off thresholds for gain or loss (211). They reasoned that this may be the 
result of clonal heterogeneity or more focal dosage changes. Zeschnigk and Lohmann 
described MSA as largely successful in evaluating allelic ratios in UM, but named AI as an 
issue that only affects chromosome 8 (189). Thomas et al. found 19/374 UM had AI of 
chromosome 3, suggesting heterogeneity of cells consisting of both M3 and D3 as a 
conceivable explanation for the phenomenon (190). They believe that AI UM defined by 
MSA should be given a poor prognosis. In contrast, all cases in this study defined as ‘AI’ 
were associated with good survival showing no significant correlation with a poor outcome 
(p=0.754) (figure 3.4) Another reason for the marked difference in survival could be the 
type of sample analysed by Thomas et al.; their study comprised mainly enucleation 
samples, whilst the vast majority of the cases analysed in the present study were 
intraocular biopsies (190). Enucleations tend to contain larger tumours, which are 
associated with a poor prognosis (139). In the study by Thomas et al, the AI cohort had a 
mean LBD 16.9mm and mean UH 11.3mm whereas in the present study AI tumours have a 




Table 3.6 A comparison of chromosome 3 status between studies that analysed UM 
samples by MSA  




Tschentscher et al. 
2000 
15/30 (50%) 13/30 (43%) - - 
Shields et al. 2007 44/140 (32%) 76/140 (54%) - - 
Shields et al. 2011 241/500 
(48%) 
126/500 (25%) 133/500 
(27%) 
- 
Thomas et al. 2012 128/374 
(34%) 
211/374 (56%) 16/374 (4%) 19/374 (5%) 
Present study 2017 175/286 
(62%) 
79/286 (28%) 8/286 (3%) 17/286 (6%) 
 
This present study examined the largest cohort to date of biopsies taken before and after 
radiotherapy; 131 pre and 109 post. There was no significant difference in the ability to 
determine chromosome 3 status in samples taken after radiotherapy (Fisher’s exact 
p=0.799) (Table 3.5). Other studies have reported similar results: Hussain et al (2016) 
analysed 102 cases of UM that had been treated by PBR wherein all patients had a biopsy 
by 20 days post treatment (222). Genetic analysis by MLPA and MSA was able to 
successfully differentiate between M3 and D3 tumours, and therefore predict metastasis-
free survival. Coupland et al. (2015) examined 28 UMs where an initial biopsy specimen was 
tested and a subsequent resection sample was available and the genetic results compared 
(221): for 4 cases in this cohort pre-radiotherapy and post-radiotherapy samples were 
assessed and were found to have concordant genetic results. Another study by 
Wackernagel et al. utilised array CGH to test samples pre- and post-radiotherapy; 5 patients 
had genetic analysis performed before and after radiotherapy and their results were also 
completely concordant (223). In contrast, Dogrusöz et al (2015) examined 36 eyes that had 
previously received radiotherapy prior to enucleation by karyotyping and FISH (224). The 
studies were performed on samples that were taken in some instances many months after 
administration of radiotherapy (range, 5-146 months). Analysis of these samples was 
largely unsuccessful by karyotyping, mainly due to tumour shrinkage and necrosis 
60 
 
associated with irradiation. This study contradicts the finding of the present study and 
other studies of its kind, and may be due to the lack of robustness of the genetic techniques 
employed in radiotherapy treated UM. In this study I also examined whether taking a 
biopsy before treatment with radiotherapy disseminates tumour cells, triggering 
metastases. An ex vivo study performed by Glasgow et al demonstrated iatrogenic 
dissemination of tumour cells following transvitreal biopsy (218). There have also been 
other case reports and series of suspected dissemination, which contribute to the 
reluctance of some ophthalmologists to take diagnostic and prognostic biopsies (225) (225) 
(217) (216). When metastasis-free survival between the two sampling groups was 
compared, no significance difference in survival was demonstrated. This is consistent with 
the findings of a recent study by Bagger et al. where a retrospective nationwide audit 
conducted demonstrated no association between tumour biopsy and increased mortality 
(226). 
 
In summary, this study has shown that MSA is a molecular technique that can accurately 
determine chromosome 3 status in small UM biopsy samples with low DNA concentrations. 
Moreover, it has shown that MSA can be used to reliably establish chromosome 3 status in 
post radiotherapy samples including both proton beam and ruthenium plaque. Unlike other 
studies this study has identified partial loss of chromosome 3 as an indicator of poor 
prognosis, making these cases more like M3 cases. Similarly this study has shown that AI 
cases are most similar to D3 in terms of patient survival. Our findings indicate that there is 




































4.1   Introduction 
As mentioned previously in Chapter 1.5.5.4, BAP1 is a prognostically important gene 
located at 3p21.1 consisting of 17 exons that produces 4Kb transcript and encodes a 759 
amino acid protein. BAP1 is a 90kDa member of the deubiquitylating enzyme family, which 
functions as an ubiquitin C-terminal hydrolase. Ubiquitylation is an important biological 
process whereby the small protein, ubiquitin, attaches to another targeted protein via 
isopeptide bonding to lysine residues. Ubiquitin is a highly conserved 76-amino acid 
regulatory protein found in most tissues in eukaryotic organisms. Ubiquitylation regulates 
several processes including: protein degradation, protein-protein interactions, protein 
localisation, differentiation, cell cycle progress, DNA repair and apoptosis. This post-
translational modification is an ATP-dependent process carried out by 3 classes of enzymes: 
E1, E2 and E3. The E1 enzymes are classed as activating enzymes; they initiate the 
ubiquitylation process by forming thioester bonds with ubiquitin. The active ubiquitin is 
then transferred to active cysteine sites on the E2 enzymes; also known as ‘ubiquitin 
conjugating enzymes’. E3 molecules or ‘ubiquitin ligases’ bind the target protein substrates 
by forming an isopeptide body between the carboxy-terminus of ubiquitin and the lysine 
residue on the protein substrate. The ubiquitylation process results in protein 
monoubiquitylation, multi- monoubiquitylation or polyubiquitylation of which there are 
numerous topologies: homogeneous, mixed, branched and unanchored ubiquitin chains 
(227). Monoubiquitin is mostly involved in the following processes: DNA damage response 
and repair, gene transcription and protein trafficking. Whereas polyubiquitylation is most 
associated with protein degradation, mainly due to the 7 lysine residues (K6, K11, K27, K29, 
K33, K48 and K63) allowing 7 linkages of ubiquitin to occur in a heterogeneous or 
homogenous manner, marking the protein for degradation. The ubiquitylation process is a 
reversible process mediated by de-ubiquitylating enzymes (DUBs) such as BAP1.  DUBs 
serve three major roles: removing ubiquitin chains that can result in either the safeguarding 
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of proteins from degradation or the reversal of ubiquitin signalling; trimming ubiquitin 
chains changing the form of ubiquitin modification; and  generating free ubiquitin 
molecules (228). BAP1 is part of the ubiquitin carboxy-terminal hydrolase (UCH) family of 
DUBs, which are classified as cysteine proteases. BAP1 contains the following: an N-
terminal conserved catalytic domain (UCH), an additional C-terminal domain (CTD) region 
consisting of ~500 amino acids, which contains a coiled-coil motif responsible for 
interacting with Putative Polycomb group proteins ASXL1/2; a nuclear localisation signal 
(NLS) in the C terminal; and various other binding sites (229) (Figure 4.1). Due to its 
involvement in controlling various cellular processes - such as cell cycle, differentiation, 
transcription and DNA damage response through deubiquitylating activity -, BAP1 is 
considered an important tumour suppressor. BAP1 complexes with host cell factor-1 (HCF1) 
by ubiquitylating lysine residues on the transcriptional regulator. HCF1 is involved in cell 
cycle progression as it is responsible for controlling transition from G1 to S phase (230). 
When BAP1 is lost either through gene deletion or loss of function mutations HCF1 is no 
longer ubiquitylated, resulting in an accumulation of HCF1 and promotion of S phase (231). 
Also BAP1 is essential for the formation of a ternary protein complex between HCF1 and 
forkhead transcription factors FoxK1/K2 which control cell cycle progression and cell 
proliferation. (230, 231). BAP1 is also an integral part of the polycomb repressive 
deubiquitinase complex (PR-DUB), which is fundamental in maintaining transcriptional 
balance. The complex is formed via an interaction between BAP1 and additional sex comb 
like 1/2 (ASXL1/2) genes. Within this group of proteins there are polycomb-repressive 
complexes (PRC), which function as histone ubiquitylators. Therefore, transcriptional 
balance is achieved by the ubiquitylation of histones by the PRCs and subsequent 
deubiquitylation by PR-DUB. Since polycomb proteins regulate cellular processes involved 
in differentiation, embryonic development and self-renewal, somatic mutations of BAP1 
can significantly alter these processes by inhibiting the DUB activity of BAP1, leading to 
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tumour development via increased ubiquitylation of histone 2A, which disrupts the cell 
cycle (126). BAP1 also interacts with the BRCA1/BARD1 heterodimer, a complex with dual 
E3 ubiquitin ligase activity that is involved in the regulation of DNA damage response (232). 
BAP1 binds to the RING finger domain of BARD1 and deubiquitylates ubiquitin chains. This 
coordinated activity of BAP1 and the BRCA1/BARD1 complex regulates ubiquitylation 
during DNA damage signalling and cell cycle progression (233). Due to BAP1’s involvement 
in numerous cellular processes, mutations or deletions of this gene have disastrous 
consequences that result in the formation of tumours. In addition to UM, inactivating 
germline and somatic mutations of BAP1 are also reported in other cancers including: 
breast, mesothelioma, clear cell renal carcinoma, cutaneous melanoma, and lung 
adenocarcinoma (5, 128, 234-238).  
 
Figure 4.1. The BAP1 gene and its functional domains; N-Terminal ubiquitin C-terminal 
hydrolase domain (blue amino acid (aa) 1-250), HCF1-binding domain (HBM) like motif (aa 
363-366), UCH37-like domain (ULD) (red; aa 634-693) and a nuclear localisation signal (NLS) 
(yellow; aa 656-661 and 717-722). Sites are also shown for interactions with BARD1 (aa 
182-365), HCF1 (aa 365-385), BRCA1 (aa 596-721) and YY1 (aa 642-686). Modified from 
Koopmans et al. 
 
BAP1 is located on chromosome 3p21.1, which is frequently lost in UM. There are two 
schools of thought on the events leading to mutations in BAP1. Robertson et al. suggest 
that BAP1 alterations occur after loss of one copy of chromosome 3. Others believe that the 
event occurs prior to the loss of chromosome 3, with the loss of chromosome 3 exposing a 
mutation on the remaining copy (239). BAP1 mutations in UM were first described by 
Harbour et al. where they identified a range of different mutations in 84% of metastasising 
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tumours (128). Since this study, numerous other reports have shown BAP1 to be mutated in 
25% to 100% of M3 UM (108, 117, 122). Mutations in BAP1 are strongly associated with 
loss of BAP1 protein expression (Koopmans et al. 2014). There are a number of studies that 
have examined BAP1 protein expression by immunohistochemistry (IHC); this chapter is an 
expansion of these studies, examining the largest cohort to date (240). 
 
The aim of chapter 4 was examine the relationship between nBAP1 protein expression and 
survival.  This was achieved by: 1) undertaking MLPA/MSA analysis of enucleation samples; 
2) analysing BAP1 protein expression by IHC; and 3) undertaking statistical analysis to look 
at the relationship between nBAP1 expression, chromosome 3 status and survival. 
66 
 
4.2   Materials and Methods 
4.2.1   BAP1 Immunohistochemistry 
165 patients treated by enucleation or local resection underwent IHC for BAP1 either as 
part of routine prognostication or undertaken by PhD student NF.  
 
4.2.2  IHC on Whole Tissue Sections 
Sections (4 µm thick) were cut from FFPE enucleated eyes, and mounted on X-traTM 
adhesive tissue slides (Leica, United Kingdom). Antigen retrieval was performed at 96°C for 
20 minutes using a PT Link (Dako, Carpinteria, CA; Ely, UK) pretreatment module and high-
pH (pH 9.0) retrieval solution. The following steps were performed at room temperature 
(RT) using a Dako FLEX Envision kit and Autostainer Plus: 5 mins endogenous peroxidase 
blocking, 30 mins incubation with primary antibody, 15 min incubation with mouse linker, 
20 min incubation with horseradish peroxidase, and positive staining was visualized by use 
of 3,3'-Diaminobenzidine (DAB) (DAKO, UK). Slides were washed with FLEX wash buffer 
between each step. Primary mouse anti human BAP1 antibody (Santa Cruz) was used at a 
concentration of 0.5µg/ml (1:400 dilution). An IgG1 isotype control was run at the same 
concentration as the primary antibody (1:200 dilution). Human pancreas tissue served as a 
positive control for the antibody. The slides were counterstained with Mayer’s 
haematoxylin (VWR, Leicestershire, UK) dehydrated and cover-slipped using a solvent 
based mountant (DPX™, Sigma). 
4.2.3   Scoring 
The stained slides were scored by four independent investigators within the Liverpool 
Ocular Oncology Research Group using a light microscope (Nikon Eclipse E600). A binary 
score was used for nBAP1 expression, with cases being defined as positive when staining 
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was present in the nucleus of the tumour cell, and negative in its absence. There was 100% 
concordance between all scorers. 
4.2.4   Chromosomal copy number analysis 
DNA was extracted from FFPE and frozen UM samples and quantified using methods 
described previously in chapter 2.  
The MLPA and MSA procedures for the assessment of chromosome 3 copy number 
alterations were performed using methods described in chapter 2. MLPA was performed in 
all cases yielding >100ng DNA whilst MSA was undertaken for samples with lower DNA 
yield.  
4.2.5   Statistical Analysis 
Multivariate analysis of risk factors associated with development of metastatic UM was 
undertaken using the Cox proportional hazards model for all covariates with p≤0.10 by 
univariate analysis. Survival time (months) was calculated from the date of first diagnosis 
until death, or study closure on 28th February 2018. All analyses were carried out using SPSS 











4.3   Results 
4.3.1   Clinical and histological features of examined UM 
BAP1 protein expression was examined in 165 patients treated by surgical excision at the 
LOOC between January 2013 and December 2015. For 29/165 (17.5%) cases surgical 
excision was performed subsequent to tumour recurrence or treatment complications. The 
median time from initial presentation to surgical excision for these cases was 33.5 months 
(range 1 – 570). The study consisted of 96 males and 69 females with a median age of 63 
years at primary management (range, 20 – 88 years) with a median follow-up of 31.3 
months (range, 5.7 – 348.5 months). At the time of the study closure on 28/02/2018, 
133/165 (81%) patients were alive, 25/165 (15%) patients had died from metastatic 
disease, and 8/169 (5%) patients died from other causes. The UM had a median LBD of 
14.4mm (range, 3.3 – 23.6mm) and a median ultrasound height of 8.3mm (range, 0.1 – 
18.5mm). 104/165 (63%) of UMs contained epithelioid cells; 61/165 (37%) of tumours 
involved the ciliary body and 20/165 (12%) of tumours had extraocular extension. 99/165 
(60%) tumours contained PAS+ loops and 31/165 (19%) tumours had necrosis. The samples 
had a median mitotic count of 3 mitoses per 40 high powered fields (range, 0 – 72).   
 
4.3.2   Genetics 
Genetic analysis was performed by either MLPA (153 cases) or MSA (12 cases). 103/165 
(62%) UM were M3, 48/165 (29%) cases were D3, and one case was isodisomy 3 (1%). 
13/165 (8%) were unclassifiable for chromosome 3 status due to the poor quality of the 
DNA.  For the remaining chromosomes classified by MLPA, the following numbers of cases 
were unclassifiable for each chromosome arm and thus excluded from analyses: 1p, n=7; 
6p, n=15; 6q, n=8; 8p, n=17; 8q, n=7. 
Chromosome 8p was lost in 25/136 (19%) of cases, normal in 98/136 (72%) of cases, gained 
in 13/136 (9%).  Chromosome 8q was lost in 2/146 (1%) of cases, normal in 54/146 (37%) of 
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cases and gained in 90/146 (62%). 8q gain was seen in 71/106 (67%) of monosomy 3 cases, 
17/51 disomy cases (33%), and 2/12 (17%) unclassifiable. Chromosome 6p was lost in 7/138 
(5%), normal in 77/138 (56%) cases and gained in 54/138 (39%) of cases. Chromosome 6q 
was lost in 20/145 (14%) of cases, normal in 105/145 (72%) of cases, and gained in 20/145 
(14%) of cases. Chromosome 1p was lost in 43/146 (30%) of cases, normal in 101/146 (69%) 
of cases and gained in 2/146 (1%) of cases. 
 
4.3.3   Immunohistochemistry 
Nuclear BAP1 protein expression was observed in 77/166 (45.5%) of cases and was absent 
in 88/165 (54.5%) cases. Of the M3 UM, 84/104 (81%) were nBAP1 negative, and 
interestingly 20/104 (19%) were nBAP1 positive (these are discussed in more detail below).  
Of the 48 D3 UM, 46/48 (96%) were nBAP1 positive, and 2/48 (4%) were nBAP1 negative. 
Of the 91 UM with gains on chromosome 8q, 63 (68%) were also nBAP1 negative. Of the 25 
UM patients who died from metastatic disease during the study, 22/25 (83%) had nBAP1 
negative UM, and 3/25 (17%) had nBAP1 positive UM.   
 
With regard to the M3/nBAP1+ve group there were 12 males and 8 females with a mean 
age of 59.4 with a median age of 61.5 (22 – 80 years) and only one patient died by at the 
close of this study. The median follow up for these cases was 2.1 months with a mean 
follow up period of 8.2 months (0.10 – 39.40 months). The UM had a mean LBD of 
13.69mm with a median of 12.2mm (7.10 – 22.7mm), and a mean UH of 7.07mm, median 








Figure 4.2. Immunohistochemistry of BAP1 using the Santa Cruz BAP1 Antibody at a dilution 
of 1:400. A) A nuclear BAP1 positive UM section showing clear brown staining in the cell 
nucleus. B) A nuclear BAP1 negative UM section showing a distinct lack of protein 
expression, no brown pigment is seen in the cell nucleus. C) Positive BAP1 staining on the 
positive control pancreas control section. D) Negative BAP1 staining of the negative control 























Age at PM (years) 
Median 63 ( 20 – 88) 59 (20 – 83) 65 (33 – 88) 0.003* 
Gender 
Female 69 (42%) 28 (36%) 41 (47%) 0.184† 
Male 96 (58%) 49 (64%) 47 (53%)  
Survival 
Alive 133 (81%) 72 (94%) 61 (69%) <0.001† 
Death from MUM 25 (15%) 3 (4%)  22 (25%)  
Death other 
causes 
7 (4%) 2 (2%) 5 (6%)  
Median  (months) 31.3 (5.7 – 
348.5) 
35.0 (5.7 – 
348.5) 
28.6 (7.9 – 249.7) 0.023* 
Largest Basal Diameter (mm) 
Median 14.4 (3.3 – 23.6) 13.5 (4.98 – 
22.7) 
16.1 (3.3 – 23.6) 0.001* 
Ultrasound Height (mm) 
Median 8.3 (0.1 – 18.5) 7.8 (0.1 – 14.6) 9.2 (1.4 – 18.5) 0.005* 
Ciliary Body Involvement 
Yes 61 (37%) 14 (18%) 47 (53%) <0.001† 
No 104 (63%) 63 (82%) 41 (47%)  
Extraocular Extension 
Yes 20 (12%) 6 (8%) 14 (16%) 0.111† 
No 145 (88%) 71 (92%) 74 (84%)  
Epithelioid Cells 
Yes 104 (63%) 35 (45%) 69 (78%) <0.001† 
No 61 (37%) 42 (55%) 19 (22%)  
Closed connective tissue Loops Present 
Yes 99 (60%) 38 (49%) 61 (70%) 0.007† 
No 66 (40%) 39 (51%) 26 (30%)  
Necrosis 
Yes 31 (19%) 11 (14%) 20 (23%) 0.166† 
No 134 (81%) 66 (86%) 68 (77%)  
Mitotic Count per 40 High Power Field 
Median 3 (0 – 72) 3 (0 - 72) 3 (0 – 21) 0.197* 
 
PM = Primary management; MUM = metastatic melanoma. 
Boldface values indicate statistical significance (p ≤ 0.05). 
 
*= Mann–Whitney U test. 







Table 4.2: Association between nBAP1 status and genetic factors  
 
 
Variable Total nBAP1 Present  nBAP1 Absent  p-value 
Chromosome 3                     (n=152)                      (n=66)                        (n=86) 
Loss 104 (68%) 20 (30%) 84 (98%) <0.001§ 
Normal  48 (32%) 46 (70%) 2 (2%)  
Chromosome 8p                   (n=136)                      (n=58)                        (n=78)  
Normal 98 (72%) 54 (93%) 44 (56%) <0.001§ 
Loss 25 (19%) 1 (2%) 24 (31%)  
Gain 13 (9%) 3 (5%) 10 (13%)  
Chromosome 8q                  (n=146)                       (n=64)                        (n=82) 
Normal 54 (37%) 34 (53%) 20 (24%) 0.001§ 
Loss 2 (1%) 1 (2%) 1 (1%)  
Gain 90 (62%) 29 (45%) 61 (75%)  
Chromosome 6p                  (n=138)                       (n=61)                        (n=77) 
Normal 77 (56%) 26 (43%) 51 (66%) 0.001§ 
Loss 7 (5%) 1 (1%) 6 (8%)  
Gain 54 (39%) 34 (56%) 20 (26%)  
Chromosome 6q                  (n=145)                       (n=66)                        (n=79) 
Normal 105 (72%) 45 (68%) 60 (76%) 0.424† 
Loss 20 (14%) 9 (14%) 11 (14%)  
Gain 20 (14%) 12 (18%) 8 (10%)  
Chromosome 1p                  (n=146)                       (n=66)                        (n=80) 
Normal 101 (69%) 51 (77%) 50 (63%) 0.083§ 
Loss 43 (30%) 15 (23%) 28 (35%)  
Gain 2 (1%) 0 (0%) 2 (2%)  
 
Boldface values indicate statistical significance (p ≤ 0.05). 
 
§ = Fisher exact test. 













4.3.4   Survival 
Kaplan–Meier survival curves and tables were examined for all primary UM stratified 
according to chromosome 3 status and nBAP1 protein expression. Both M3 UM (Log rank, 
p=0.001) and UM negative for nBAP1 (Log Rank, p<0.001) were significantly associated with 
a reduced survival time (Figure 4.3). The cases were further subdivided according to their 
chromosome 3 status. M3/nBAP1 positive UM had a significantly better prognosis than 
M3/nBAP1 negative tumours (Log rank, p=0.014) and were most similar to the patients 









Figure 4.3 Kaplan–Meier survival curves and tables for all primary UM stratified according 
to: A) nBAP1 protein expression (p=<0.001) in 165 patients (nBAP1 protein expression was 
scored as positive or negative); and B) chromosome 3 status (p=0.001) in 152 patients. 
Only cases with a discernible normal or loss of chromosome 3 were included. No. of events 
indicates the number of deaths. Log-rank tests utilised to compare survival across groups 














Figure 4.4. Kaplan–Meier survival curves estimate disease free survival in UM patients 
with: A) nBAP1+ve/-ve in monosomy 3 UM, n=104 (p=0.014); and B) nBAP1+ve/-ve in 
disomy 3 UM, n=48 (p=0.676), no survival statistics because all cases are censored. No. of 
events indicates the number of deaths. Log-rank tests utilised to compare survival across 







4.3.5   Univariate and Multivariate Analysis 
 
Univariate analysis using the Cox proportional hazards model identified the following 
factors as significantly associated with survival time (Table 4.3): nBAP1 protein expression, 
p=<0.001 (HR 0.173; 95% CI 0.067 – 0.450); age at primary management p=0.005 (HR 1.046; 
95% CI 1.014 – 1.080); presence of closed connective loops p=0.003 (HR 3.596; 95% CI 
1.541 – 8.389); mitotic count per 40 hpf, p=0.016 (HR 1.029; 95% CI 1.005 – 1.054); 
epithelioid cell morphology p=0.014 (HR 3.059; 95% CI 1.257 – 7.443); tumour height 
p=0.002 (HR 1.169; 95% CI 1.058 – 1.292); LBD p=0.006 (HR 1.142; 95% CI 1.039 – 1.255); 
and chromosome 3 loss, p=0.036 (HR 0.482; 95% CI 0.243 – 0.955). Multivariate analysis 
using the Cox proportional hazards model, demonstrated only nBAP1 protein expression as 
an independent factor significantly associated with survival, p=0.002 (HR 0.211; 95% CI 
0.079 – 0.562) in this cohort (Table 4.4). 
Table 4.3 Univariate Analysis of risk factors associated with metastatic disease 
Variable Sig. Hazard Ratio 
(HR) 
95.0% CI for HR 
Lower Upper 
nBAP1 0.000 0.173 0.067 0.450 
AgePM 0.005 1.046 1.014 1.080 
Loops 0.003 3.596 1.541 8.389 
Mitotic 0.016 1.029 1.005 1.054 
Epithelioid 0.014 3.059 1.257 7.443 
UH 0.002 1.169 1.058 1.292 
LBD 0.006 1.142 1.039 1.255 
CBI 0.078 1.872 0.933 3.756 
EOE 0.287 1.622 0.666 3.948 
Chr3 0.036 0.482 0.243 0.955 
Gender 0.740 0.886 0.433 1.813 
Necrosis 0.138 1.794 0.829 3.880 
 
UH = Ultrasound height 
LBD = Largest basal diameter 
CBI = Ciliary body involvement 
EOE = Extraocular extension 





Table 4.4. Multivariate Analysis of risk factors associated with metastasis in UM 
Variable Sig. Hazard Ratio 
(HR) 
95.0% CI for HR 
Lower Upper 
nBAP1 0.006 0.212 0.070 0.645 
AgePM 0.071 1.030 0.997 1.064 
Chr3 0.974 1.011 0.540 1.892 
 
4.4   Discussion 
To date, this is the largest study of BAP1 protein expression by IHC of primary UM. The 
incidence of nBAP1 negativity was consistent with other reports in the literature. BAP1 
protein expression in UM by IHC was first analysed by Shah et al (2013) who found lack of 
nBAP1 expression in 58% of primary UM (239). Kalirai et al (2014) found nBAP1 negativity in 
51% of primary UM and 77% of metastatic UM (131). Koopmans et al. (2014) reported a 
lack of BAP1 protein expression in 43% and Van de nes et al. (2016) in 54% of primary UM; 
both studies showing a strong correlation between the presence of BAP1 mutations as 
examined by Sanger sequencing and an absence of nBAP1 protein expression by IHC (130, 
241).  
The current study found nBAP1 protein expression to be absent in 54%, similar to our 
previous data on a different cohort of primary UM. Furthermore, our study showed 
similarities to other BAP1 studies where there was a correlation between loss of nBAP1 
protein expression and factors associated with high metastatic risk such as chromosome 3 
status, epithelioid cytomorphology, PAS+ loops, and ciliary body involvement. There was no 
correlation between nBAP1 expression and necrosis or extraocular growth.  
Other studies of primary UM where the BAP1 mutational rate were examined show a 
variety of results. Harbour et al. identified BAP1 mutations in 84% of the ‘class 2’ or high 
risk UM, consistent with the 81% of M3 cases in this study that were nBAP1 negative (129). 
Whereas Dono et al found a BAP1 mutation rate of 100% in their M3 cohort, with no BAP1 
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mutations in their D3 cases, with an overall study mutation rate of 31.5%. Interestingly, we 
observed that 4 D3 UM were nBAP1 negative. In contrast only 33% of M3 UM examined by 
Martin et al. had mutations in BAP1 and 1 D3 case that later metastasised, with an overall 
study BAP1 mutation rate of 11% (119). Interestingly, Koopmans et al. identified 3/74 (4%) 
cases of UM without BAP1 mutations but also had loss of nBAP1 protein (130). 
 
In a small number of cases in our series, loss of nBAP1 protein expression did not appear to 
be the metastatic driver. That is, 3/26 (11.5%) patients that developed metastatic disease 
were found to have nBAP1 positive tumours. Two of these patients had unfavourable 
clinical and histological characteristics, which would have placed them at high risk of 
developing metastases irrespective of nBAP1 status. 
 
The first case was a 39 year-old male who was initially treated by local resection who later 
underwent enucleation after recurrence disease. Clinically, the tumour had an LBD 15.5mm 
and an UH of 7.8mm with involvement of the ciliary body and extraocular growth. 
Histologically, the pUM contained epithelioid cells, PAS+ loops and had an extremely high 
mitotic count of 72/40 high power field. Interestingly, the patient was categorised as 
unclassifiable for chromosome 3, despite having a loss of 1p which is significantly 
associated with chromosome 3 loss (McNemar p=0.000) and gain of 8q (McNemar 
p=0.000). However his tumour had other poor prognostic characteristics, which would have 
placed him in the ‘high risk’ category for developing metastatic disease, irrespective of the 
Chr3 and nBAP1 status.  
Case 2 was a 70 year-old male whose primary treatment was enucleation. Clinically, the 
tumour was large, with an LBD 19.1mm and UH 2.8mm, in addition to having an epithelioid 
cell cytomorphology, a mitotic count of 5/40HPF and PAS+ loops. Moreover, the patient’s 
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tumour also showed M3 with a gain of 8q: both features associated with a poorer survival 
outcome.  
The third case was that of a 71 year-old male whose primary treatment was enucleation. 
The tumour had an LBD of 13.9mm and a UH of 1.8mm, with no ciliary body involvement or 
evidence of extraocular growth. The tumour consisted predominantly of spindle cells, no 
PAS+ loops with a low mitotic count of 1/40 hpf, and was cytogenetically normal for 
chromosome’s 1, 3, 6 and 8. However, previous studies have shown that disomy 3 UM do 
infrequently metastasise, due to mutations in SF3B1 and this could be why the patient 
developed metastatic disease.  
 
In this study chromosome 3 loss has been shown to be significantly associated with nBAP1 
negativity (Fisher’s Exact p=<0.001); however, interestingly, there were 3 disomy cases in 
the examined cohort that were nBAP1 negative. Chromosome 3 status for all of these cases 
was retested using MSA to rule out the possibility of isodisomy or ‘acquired homozygosity’, 
which cannot be detected by MLPA. Only one of these 3 cases showed isodisomy by MSA. 
The isodisomy case was that of a 75 year-old female who was initially treated by plaque 
radiotherapy but later underwent enucleation; she unfortunately subsequently died of 
metastatic UM. The tumour had an LBD of 5.8mm, an UH of 4.9mm with no involvement of 
the ciliary body or evidence of extraocular extension. The UM had an epithelioid 
cytomorphology, a mitotic count of 3/40hpf and did not contain any PAS+ loops. MLPA 
results showed a normal chromosome 3 with polysomy 8q and gain of 6p; MSA testing 
subsequently confirmed loss of heterozygosity of chromosome 3.  
The remaining two cases were tested for BAP1 mutations but were found to be wild type, 
indicative of an alternative non-genetic mechanism of nBAP1 loss.  
A particularly interesting finding of this study was the identification of a subset of 20 cases 
(19%) of M3 UM where nBAP1 protein expression was counterintuitively positive. 
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Histologically, the samples shared several characteristics that would place them in a lower 
risk group with respect to metastasis but the vast majority of samples contained epithelioid 
cells, a risk factor associated with increased metastatic potential. This indicates there two 
distinct subgroups are present with monosomy 3 tumours: M3 UM with a loss of BAP1 
function and M3 UM with a retained functional copy of BAP1. This was evident in the 
multivariate analysis whereby nBAP1 was found to be the only independent variable 
significantly associated with an increased risk of developing metastatic disease. This 
suggests that bi-allelic inactivation of BAP1 is required to influence metastases and 
therefore prognosis. This was consistent with the findings of Robertson et al. who found 
BAP1 mutations in 83.3% of M3 UM, identifying 16.7% M3 UM that were BAP1 wild-type, 
although they didn’t explore this in terms of survival.. 
 
In summary, I have demonstrated the importance of nBAP1 protein expression as an 
independent marker of prognosis in patients with UM that identifies a subpopulation of M3 
primary tumours with favourable survival times compared to their nBAP1-negative 
counterparts. Moreover, assessment of nBAP1 protein expression using IHC is an efficient 
and cost-effective way of stratifying UM patients, in order to ensure they are followed up 
with the appropriate surveillance program. In the meantime, BAP IHC is part of the routine 
work-up of all UM histological specimens sent to the Pathology Dept. in Liverpool, and in 
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5.1   Introduction 
Whole exome studies of UM have vastly improved our understanding of the molecular 
drivers of metastatic progression, which has laid the groundwork for improving the 
detection, prevention and treatment of the disease. The first study to examine UM by 
exome sequencing was Harbour et al. (2010) where they discovered recurrent mutations of 
BAP1 in two tumour samples. After re-sequencing by Sanger sequencing, they found this 
was a common molecular characteristic of high metastatic risk or ‘class 2’ uveal melanoma 
(129). Later a larger exome sequencing study of 22 UM undertaken by Martin et al. (2013) 
revealed recurrent somatic mutations in EIF1AX and SF3B1. This was the first study to 
associate mutations in SF3B1 to unusual D3 tumours where patients developed metastasis 
after a long period of time (119). These findings were confirmed by Yavuzyigitoglu et al. 
(2016) who examined SF3B1 and EIF1AX mutations in 151 UM patients and demonstrated 
that D3 SF3B1 mutants had an increased metastatic risk in comparison to D3 SF3B1 wild-
type tumours (242). In 2016, Royer-Bertrand et al. examined 33 UM by deep-coverage 
whole-genome sequencing where four major subgroups associated with mutational and 
metastatic status were identified as a result of unsupervised hierarchical clustering of copy 
number variation (134). These findings were echoed by the TCGA study of 80 UM where 
four molecular subsets of UM were identified based on copy number, mutation, 
methylation and mRNA profiles (135). Based on these findings there have been several 
efforts to design targeted NGS panels specifically for UM. In 2017, Reiman et al. designed a 
custom panel used to examine mutations in cutaneous and uveal melanoma 
simultaneously; however, this only examined mutations in GNAQ and GNA11, which are not 
associated with patient prognosis (243). More recently, Smit et al. developed a panel, which 
combines copy number and mutation analysis, the first of its kind (198). Using the Ion 
Torrent (Thermofisher Scientific) sequencing platform they developed a custom design 
integrating chromosomal aberrations in chromosomes 1, 3 and 8 and mutations in GNAQ, 
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GNA11, BAP1, SF3B1 and EIF1AX and successfully validated this on a cohort of 70 samples 
(198). 
 
However this panel did not include CYSLTR2, a cysteinyl leukotriene receptor that functions 
as a G-coupled protein receptor on 13q14.2 that activates the Gα subunits and has been 
shown to be mutated in some UM that lack mutations in GNAQ or GNA11 (132). 
Chromosome 6 was also not included on this panel despite loss of 6q being identified by 
Royer-Bertrand et al. as a somatic event defining tumour classes (134). Moreover, although 
previous studies have suggested that gains in 6p contribute to a better prognosis, this was 
also not included. Additionally, the panel does not detect mutations in PLCB4, which has 
been shown previously to be a downstream target of GNAQ/GNA11, suggesting that this is 
an alternative way of activating this signalling pathway (133). 
 
 In Chapter 3, I established that mutations in BAP1 that result in loss of protein expression 
drastically impact disease-free survival in UM with monosomy of chromosome 3 creating 
two subsets in terms of metastatic progression. This, in addition to recent studies 
implicating SF3B1 as a driver of late onset of metastases, highlights the need for a test that 
encompasses all of the major alterations. In an era of personalised medicine or 
‘theranostics’ NGS is an emerging and exciting technology that can allow the examination 
of both copy number changes and mutations simultaneously, eliminating the need for two 
separate, time-consuming molecular tests. Clinicians and scientists alike now recognise that 
a one size fits all approach is no longer appropriate for the effective management and 
treatment of patients with chronic diseases such as cancer. Technologies like NGS allow for 
a tailored approach in terms of patient surveillance in addition to arming the patient with 
knowledge of the mutational makeup of their tumours, allowing targeted therapies to be 
administered where available.  
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No two tumours are alike; they come in all shapes and sizes which affects the yield and 
quality of the DNA from commonplace extractions. As UM is a relatively rare cancer, 
centres such as the Liverpool Ocular Oncology centre receive a large number of referrals 
from other sites in the U.K. but also worldwide, most of which are FFPE. It is widely known 
that formalin fixation of tissues at room temperature results in poor preservation of high 
molecular weight DNA. In addition, low DNA yield is not just a problem affecting FFPE 
tissues. As established in chapter 3 prognostic and diagnostic biopsies often result in tiny 
amounts of tumour material being utilised for DNA extraction, which then results in a very 
low DNA yield. Therefore the development of a test that will allow testing of all sample 
types with a low DNA input is of paramount importance.  
 
In this chapter I examined the feasibility of designing and developing targeted NGS panels 
for UM utilising different sequencing chemistries that allow copy number changes in 
chromosomes 1, 3, 6 and 8 and mutations in GNAQ, GNA11, CYSLTR2, BAP1, SF3B1 and 
EIF1AX to be examined in tandem. I first validated the accuracy of these panels by testing 
samples that had already been fully profiled by the TCGA and others that had copy number 
information available from MLPA testing. When this was been achieved I took a cohort of 
samples with previous NGS data available and retested DNA extracted from matched FFPE 
material to ensure there was concordance and ergo was suitable for this sample type. Once 
a final design and sequencing chemistry was determined I tested a cohort of 80 samples. 
These samples had known copy number data but unknown mutational status. I then utilised 
these results to examine survival, which will help inform the way patients are managed 





5.2   Materials and Methods 
5.2.1   SureSelect QXT 
5.2.1.1   Panel Design 
The panel was designed to cover mutations in SF3B1 exons 12 & 14, GNAQ exons 4 & 5, 
GNA11 exons 4 & 5, EIF1AX exons 1 & 2 and all exons of: BAP1, FBXW7, DLK2, BRAF (as a 
negative control), CSMD1, CYSLTR2, KTN1, TP53BP1, SRSF2, PLCB4, TTC28. Additional 
probes were included to examine copy number changes in chromosome 1: 1541 probes; 
chromosome 3: 1287 probes; chromosome 6: 1094 probes; chromosome 8: 933.  
5.2.1.2   Fragment and Adaptor-Tag  
14 fresh UM samples plus an additional two reference samples (Genome In A Bottle HDx) 
were diluted and measured to 25ng/µl using 2 serial fluorometric assays (Qubit, Invitrogen). 
All reagents and enzymes were prepared as per manufacturer’s instructions (Agilent). The 
gDNA was fragmented enzymatically and adaptors were adhered to ends of DNA fragments 
following the manufacturer’s instructions (Agilent). In brief, 17µl SureSelect QXT buffer 
added to strip tubes with 2µl DNA samples and 2µl SureSelect QXT Enzyme Mix. Samples 
were vortexed and centrifuged briefly and placed on a thermal cycler (SureCycler 8800, 
Agilent) for DNA fragmentation; 45°C 10 minutes, 4°C 1 minute and 4°C Hold. Upon 
completion of the fragmentation samples were placed on ice and 32µl 1X SureSelect QXT 
Stop Solution was added (containing 25% ethanol) to each reaction. These were then 
vortexed, centrifuged and allowed to incubate at room temperature for 1 minute. 
5.2.1.3   Purifying the adaptor tagged library using AMPure XP beads 
Using pre-incubated and homogenous AMPure XP beads (Agencourt AMPure XP Kit, 
Beckman Coulter Genomics) 52µl of bead suspension was added to each reaction, vortexed 
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and spun briefly. Reactions were then incubated at room temperature for 5 mins before 
placing on a magnetic stand (Thermo Fisher Scientific) until solution was cleared. The 
cleared solution was removed and discarded and subjected to 2 washes with 200µl of fresh 
70% ethanol, waiting for 1 min before removing 70% ethanol. Samples were dried on a 
thermal cycler at 37°C for between 1 – 3 mins or until dry. Once dry, samples were re-
suspended in 11µl nuclease free water (Ambion), mixed well and centrifuged. Reactions 
were incubated at room temperature for 2 mins and cleared on magnetic stand. The 
cleared supernatant was removed and placed in fresh strip tubes. 
5.2.1.4   Amplify the adaptor-tagged DNA library 
All reagents and enzymes were prepared as per manufacturer’s instructions (Agilent). 40µl 
of Precapture PCR mix (nuclease free water, Herculase II 5x Reaction buffer, 100mM dNTP 
Mix (25nM), DMSO, SureSelect QXT Primer Mix, Herculase II Fusion DNA Polymerase) was 
added to 10µl purified DNA library samples. The strip tubes were placed in the thermal 
cycler and the pre-capture PCR was performed: 68°C 2 mins, 98°C mins and 8 cycles of; 
98°C 30 seconds, 57°C 30 seconds and 72°C for 1 min followed by 72°C 5 mins, 4°C hold. 
5.2.1.5   Purifying the amplified library with AMPure XP beads 
The amplified library was purified by adding 50µl of AMPure XP bead suspension to 
amplified DNA samples, vortexing and briefly spinning the library. Samples were incubated 
for 5 mins at room temperature and the reactions cleared on a magnetic stand for between 
3-5 mins. The supernatant was removed and discarded and subjected to 2 washes with 
200µl of fresh 70% ethanol, waiting for 1 min before removing 70% ethanol. Samples were 
dried on a thermal cycler at 37°C for between 1 – 3 mins or until dry. Once dry, samples 
were re-suspended in 13µl nuclease free water (Ambion) mixed well and centrifuged. 
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Reactions were incubated at room temperature for 2 mins and cleared on magnetic stand. 
The cleared supernatant was removed and placed in fresh strip tubes. 
5.2.1.6   Assessing library DNA quantity and quality 
Library quality and quantity assessed using Agilent DNA 1000 kit (Agilent) using the 
manufacturer’s instructions. In brief, 9µl of gel was pipetted into the corresponding well 
and the remaining 9µl loaded into remaining wells marked ‘G’. 5µl of marker was loaded 
into all 12 samples wells and ladder well. 1µl of ladder loaded into ladder well and 1µl of 
sample added to corresponding wells. The chip was vortexed for 1min and loaded onto the 
Agilent 2100 Bioanalyzer (Agilent). Samples were deemed successful if the peak of the DNA 
fragment size was between 245-325bp. 
5.2.1.7   Hybridising DNA samples to the capture library 
The DNA libraries were diluted to 750ng in 12µl and 5µl of SureSelect QXT Fast Blocker Mix 
was added, pipette mixing between 8 – 10 times. Reactions were transferred to a thermal 
cycler for the hybridisation PCR program; 95°C 5 mins, 65°C 10 mins, 65°C 1 min and 60 
cycles of; 65°C 1 min, 37°C seconds, 65° hold. The cycler was paused on the 3rd step and 
13µl room temperature capture library hybridisation mix was added to each sample well, 
pipette mixing 8-10 times before continuing the PCR program. 
5.2.1.8   Capture hybridised DNA using streptavidin-coated beads 
Dynabeads MyOne Streptavidin T1 magnetic beads (Thermo Fisher Scientific) were 
prepared as per manufacturer’s instructions. Samples were transferred to room 
temperature and 50µl re-suspended beads were added to fresh strips tubes. The beads 
were washed 3 times by adding 200µl SureSelect Binding Buffer and pipette mixing up and 
down 10 times, then transferring to the magnetic stand for 5 mins until cleared and 
discarding supernatant. The beads were then re-suspended in 200µl SureSelect Binding 
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Buffer. The hybridisation mixture was then transferred to wells containing 200ul washed 
streptavidin beads and incubated on a 96-well plate mixer (Eppendorf) at 1800RPM for 
30mins at room temperature. During this time 200µl aliquots of Wash Buffer 2 were 
prewarmed at 65°C in fresh strips, aliquoting 3 wells of buffer for each reaction. The 
hybridisation and bead mixture was then centrifuged briefly and placed on a magnetic 
stand to clear before removing and discarding the supernatant. The beads were then re-
suspended in 200ul SureSelect Wash Buffer 1, pipette mixing up and down 8-10 times. The 
mixture was then placed on a magnetic stand to clear for 1 min before removing and 
discarding the supernatant. The beads were then washed 3 times in 200µl prewarmed 
Wash Buffer 2 incubated at 65°C on a thermal cycler then placed on a magnetic stand 
waiting 1 min until cleared then removing and discarding the supernatant. Samples were 
centrifuged briefly after the last wash step to remove any remaining droplets. 23µl of 
nuclease free water (Ambion) was then added to each sample well. 
5.2.1.9   Amplify the captured libraries to add index tags 
The post-capture PCR reaction mix was prepared as per manufacturer’s instructions; 
nuclease fee water 13.5µl, Herculase II 5x Reaction Buffer 10µl, 100mM dNTP mix (25mM 
each dNTP) 0.5µl and Herculase II Fusion DNA Polymerase 1µl. 25µl of PCR reaction mix was 
added to the bead bound DNA samples in addition to 1ul of both P7 and P5 dual indexing 
primers (Table 6.1). The samples were mixed well, ensuring beads were fully re-suspended 
and transferred to thermal cycler to complete Post-capture PCR cycling; 98°C 2 mins, 10 
cycles of: 98°C 30s, 58°C 30s, 72°C 1 min. 72°C 5 mins and 4°C hold. Once completed, the 
strip tubes were centrifuged briefly and place on magnetic stand to clear at room 
temperature for 2 mins. Once cleared the supernatant was removed and aliquoted into 




5.2.1.10   Purify the amplified captured libraries using AMPure XP beads 
60µl of homogeneous AMPure XP bead suspension were added to each 50ul amplified DNA 
sample, vortexed and incubated at room temperature for 5 mins. The solution was then 
cleared on a magnetic stand for between 3-5mns, once cleared the supernatant was 
removed and discarded. 2 washes were carried on the magnetic stand by dispensing 200µl 
fresh 70% ethanol each sample well, waiting for 1 minute before removing the ethanol. 
Samples were then dried on a thermal cycler at °37C for 1-3 mins. Once dried, 25µl of 
nuclease free water (Ambion) was added to each sample well and incubated at room 
temperature for 2 mins. The reactions were then cleared on a magnetic stand for 2 mins 
and the cleared supernatant transferred into fresh 1.5ml DNA LoBind tubes (Eppendorf). 
Table 5.1 Index assignments for Agilent validation cohort. 
Sample ID Index 1 Index 2 
S154.11 P7i1 P5i4 
S191.11 P7i2 P5i4 
S173.13 P7i3 P5i4 
S162.12 P7i4 P5i4 
S183.13 P7i5 P5i4 
S031.13 P7i6 P5i4 
S107.12 P7i7 P5i4 
S032.13 P7i8 P5i4 
S080.09 P7i1 P5i3 
S095.08 P7i2 P5i3 
S001.09 P7i3 P5i3 
S102.09 P7i4 P5i3 
S129.09 P7i5 P5i3 
S083.08 P7i6 P5i3 
GIAB P7i7 P5i3 
GIAB P7i8 P5i3 
 
5.2.1.11   Assess indexed library DNA quantity and quality 
Quantity and quality of the indexed library DNA was assessed using the High Sensitivity 
DNA Assay (Agilent) as per manufacturer’s instructions. In brief, 9µl of gel was pipetted into 
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the corresponding well of the High Sensitivity Chip (Agilent) and the remaining 9µl loaded 
into remaining wells marked ‘G’. 5µl of marker was loaded into all 12 samples wells and 
ladder well. 1µl of ladder loaded into ladder well and 1µl of sample added to corresponding 
wells. The chip was vortexed for 1min and loaded onto the Agilent 2100 Bioanalyzer 
(Agilent). DNA quantity and quality was deemed successful if the electropheragram showed 
the peak of DNA fragment size positioned between 325 and 450bp. 
5.2.1.12   Pooling 
Libraries (16 in total) were then pooled in equimolar amounts based on the 
aforementioned Qubit and Bioanalyser data. The pool was further purified using Agencourt 
AMPure XP beads (Beckman Coulter). The size of the final pool was assessed on a 
Bioanalyser high sensitivity DNA chip and the DNA concentration was determined initially 
by Qubit double-stranded DNA high sensitivity assay, and then by qPCR, using an Illumina 
library quantification kit (KAPA) on a Roche LightCycler 480 II system. The pool of 16 target 
enriched libraries was sequenced on one MiSeq run, using custom sequencing primers (as 
per the Agilent protocol) and version 3 chemistry, generating 2 x 250bp paired end reads. 
 
5.2.2   TruSeq Customer Amplicon Low Input Kit 
5.2.2.1   Panel Design 
The panel was designed to cover mutations in SF3B1 exons 12 & 14, GNAQ exons 4 & 5, 
GNA11 exons 4 & 5, EIF1AX exons 1 & 2 and all exons of: BAP1, FBXW7, DLK2, BRAF, 
CSMD1, CYSLTR2, KTN1, TP53BP1, SRSF2, PLCB4, and TTC28. Additional probes were 
included to examine copy number changes in chromosome 3: 83 amplicons consisting of 39 
on 3p and 44 on 3q; chromosome 6: 76 amplicons consisting of 34 on 6p and 42 on 6q; 
chromosome 8: 67 amplicons consisting of 23 on 8p and 44 on 8q.  
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5.2.2.2   Quantify and Dilute DNA 
14 fresh UM samples plus an additional two reference samples were quantified using 
fluorometric assay (Qubit, Thermo Fisher). gDNA was diluted to 25ng/µl in Resuspension 
Solution 1 (RS1) (Illumina) and re-quantified to check final amount. gDNA was then further 
diluted to 2.5ng/µl in RS1 in a LoBind tube (Eppendorf) and 1µl of Sample Stablization 
Solution (SS1) (Illumina) was added. 
5.2.2.3   Hybridise Oligo Pool 
All reagents and enzymes prepared as per manufacturer’s instructions. The following 
reagents were added to the HYB plate; 5µl of diluted 2800M, 5µl of diluted ACP3 was added 
to well containing diluted 2800M as a control, 5µl of RS1 added to one well as a no 
template control, 5µl of gDNA added to remaining wells, 5µl of CAT added to each well 
containing gDNA and no template control and 15µl of OHS2 added to each well, pipetting 
slowly to mix. The samples placed on a Veriti thermal cycler (Applied Biosystems) and the 
HYB program was run (Table 5.2) 
Table 5.2 HYB PCR program for Applied Biosystems 96-Well Thermal Cycler 
Step Ramp Speed Increment (°C) Temperature 
(°C) 
Hold 
1   95 3 minutes 
2 2.1% -0.5 90 30 seconds 
3   Step 2 for 59x  
4 2% -0.5 60 1 minute 
5   Step 4 for 19x  
6 2.1% -1.0 50 2 minutes 
7   Step 6 for 9x  
8 2%  40 10 minutes 
  
5.2.2.4   Remove Unbound Oligos 
All reagents and enzymes prepared as per manufacturer’s instructions.25µl of Sample 
Purification Beads (SPB) (Illumina) were added to each well of the HYB plate, pipetting 
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slowly to mix. The plate was incubated at room temperature for 5 mins and the plate was 
placed on magnetic stand (DynaMag-96 Side Skirted Magnet) to clear for 2 mins. The 
supernatant was removed and discarded and the beads were washed three times as 
follows; 80µl of Stringent Wash 1 (SW1) (Illumina) was added to each well and incubated at 
room temperature for 30 secs before removing and discarding the supernatant. Any 
residual SW1 was removed from each well and 80µl of 60% ethanol was added to each well, 
incubated at room temperature for 30 secs and then removed and discarded. Any residual 
ethanol was removed before air drying for 5 mins. 
 
5.2.2.5   Extend-Ligate Bound Oligos 
The plate was removed from the magnetic stand and 22µl of ELB/ELE mix was added to 
each well and mixed using a pipette. The plate was then placed on the thermocycler and 
the EXT_LIG program was run; 37°C 45 mins, 70°C 20 mins and 4°C hold.  
5.2.2.6   Amplify Libraries 
The HYP plate containing beads was placed on a TruSeq Index Plate Fixture (Illumina) and 
4µl of each Index 1 and Index 2 adapter was added. Index 1 and Index 2 adapters were 
arranged as follows (Table 6.3). The plate was then placed on ice and 20µl of EDP/EMM 
mixture was added to each well, pipetting well to mix. The plate was then centrifuged at 
280 x g for 1 minute then placed on ice. The custom design included 751 amplicons; 
therefore, 27 PCR cycles were used for the library amplification step. The plate was placed 
on the thermal cycler and the library amplification PCR was run; 95°C for 3 minutes, 27 





Table 5.3 Index assignments for Illumina validation cohort. 
 1 2 3 4 5 6 7 8 
A    501-701 501-709 501-705   
B    502-702 502-710    
C    503-703 503-711    
D    504-704 504-712    
E    505-705 505-701    
F    506-706 506-702    
G    507-707 507-703    
H    508-708 508-704    
 
5.2.2.7   Clean-Up Libraries 
All reagents prepared as per manufacturer’s instructions. The HYP plate was centrifuged at 
280 x g for 1 min and 45µl of supernatant from each well of the HYP plate was transferred 
to the corresponding wells of the CLP plate. 36µl of SPB was added to each well of the CLP 
plate and the plate was shaken at 1800RPM for 2 mins. The plate was then incubated at 
room temperature for 5 mins before centrifuging at 280 x g for 1 minute. The plate was 
then transferred to a magnetic stand for 2 mins until the samples were cleared before 
removing and discarding the supernatant. Two washes were carried out by adding 200µl 
freshly prepared 80% ethanol to each sample well, incubating on the stand for 30 secs and 
removing and discarding all supernatant from each well. The plate was then removed from 
the magnetic stand and air dried for 5 mins. Once dry 25µl RSB was added to each well and 
the plate was placed on the shaker at 1800 RPM for 2 minutes. The plate was then 
incubated at room temperature for 2 mins before centrifuging at 280 x g for 1 minute. The 
plate was transferred to the magnetic stand for 2 mins until the liquid was cleared and 20µl 
of purified library was transferred into a new LNP plate. The remaining liquid in the CLP 
plate was used to assess quality and quantity of DNA libraries. The final purified libraries 




5.2.2.8   Troubleshooting 
The Bioanalyser DNA 1000 chip results (Agilent) showed primer dimer in some of the 
libraries and lower than expected amplicon concentrations, suggesting the possible 
presence of a contaminant which interfered with the Qubit assay. Therefore, each of the 
libraries was further purified using 0.8× Agencourt AMPure XP beads (Beckman Coulter). 
After this, the libraries were again quantified by Qubit ds DNA HS assay and the size 
distribution assessed on a Fragment Analyser (Advanced Analytical Technologies) using a HS 
NGS kit. The concentration of library 14 (sample S083.08) was similar to some of the other 
libraries; however, the amount of amplicon visible on the Fragment Analyser 
electropheragram was negligible.  Also, some of the libraries still contained primer dimer: in 
order to remove these, firstly the libraries (including sample 14) were pooled in equimolar 
amounts based on the Qubit and Fragment Analyser data, then the pool was size-selected 
on a 1.5% agarose Pippin gel cassette (Sage Science). For this, 1.5% DF Marker K settings 
were used, with collection of fragments between 240 and 500bp.  The size-selected pool 
was purified using 1.8× Agencourt AMPure XP beads and then ran on a Bioanalyser HS DNA 
chip, which showed that primer dimer had been removed. The DNA concentration of the 
pool was determined initially by Qubit ds DNA HS assay, and then by qPCR, using an 
Illumina library quantification kit (KAPA) on a Roche LightCycler 480 II system. 
5.2.2.9   Pooling 
The pool of 15 TruSeq custom amplicons was sequenced on one MiSeq run, using version 3 






5.2.3   SureSelect XT HS 
5.2.3.1   Panel Design 
The original SureSelect XT design (see 5.2.2.1) was modified for the 96 cohort to include 
FFPE samples. The 14 validation cohort samples were aligned using SureCall (Agilent) and 
the average and median read depths were 200-300x. The percentage of target bases 
covered at 50x and 100x were very high with ~99% and ~97% respectively. Regions that 
were consistently lower than 50x across more than 6 samples were identified. These 
comprised of 13 regions corresponding to exons in the following genes KTN1 (6 exons), 
TP53BP1, PLBC4, TTC28, FBXW7 and CSMD1 (3 exons). These had a tendency to at the 
edges of the regions, so we duplicated the probes in these regions to boost the coverage. 
5.2.3.2   Sample Preparation 
Fresh samples were quantified using the Qubit BR dsDNA Assay Kit (Qubit, Invitrogen) and 
75ng of gDNA was diluted with 1X Low TE Buffer to a final volume of 50µl. DNA integrity of 
FFPE samples DNA integrity was qualified performing a qPCR using the Agilent NGS FFPE QC 
Kit (Agilent) resulting in an Cq DNA integrity score and the precise quantity of amplifiable 
DNA in the sample. Samples with Cq DNA integrity score 1, were deemed as good 
quality amplifiable gDNA and the Qubit- based gDNA concentration was used to determine 
input. Samples with Cq DNA integrity score 1, the qPCR- based concentration of 
amplifiable gDNA, was utilised to determine amounts of input DNA. 
5.2.3.3   DNA Shearing 
High quality gDNA was sheared using the Covaris S-series instrument (SonoLab software) 
using a two-round shearing protocol: shearing for 2 minutes, centrifuging for 10s, vortexing 
for 5 seconds and centrifuging for 10 seconds then repeating this process. FFPE samples 
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were sheared for 6 minutes and centrifuged briefly. The settings for both sample types had: 
a 10% duty factor, 175 Peak Incident Power (PIP) and 200 cycles per burst. 
5.2.3.4   Repairing and dA-Tailing the DNA ends 
All reagents were prepared as per the manufacturer’s instructions. The ligation master mix 
was prepared by adding the 23µl ligase buffer and 2µl T4 DNA Ligase per reaction into a 
1.5ml Eppendorf tube. This was kept at room temperature for 30–45 minutes before use to 
allow equilibration to room temperature. The End Repair/dA-Tailing master mix was 
prepared by combining 16µl End Repair-A Tailing Buffer and 4µl End Repair-A Tailing 
Enzyme Mix per reaction. 20 µl of the End Repair/dA- Tailing master mix was added to each 
sample well containing approximately 50 µl sheared DNA and placed on a thermal cycler for 
15mins at 20°C and 15 minutes at 72°C for End Repair/dA-Tailing. 
5.2.3.5   Ligating the molecular-barcoded adaptor 
Once the thermal cycler reached the 4°C hold step, samples were transferred to ice. 25 µl 
of the Ligation master mix that was prepared previously was added to each end- 
repaired/dA- tailed DNA sample (approximately 70 µl) and mixed by pipetting up and down 
at least 10 times using a pipette set to 85 µl, then briefly spun. 5 µl of Adaptor Oligo Mix 
was added to each sample and mixed by pipetting up and down 15–20 times using a pipette 
set to 85 µl. Samples were spun and transferred to a thermal cycler for 30 minutes at 20°C. 
A unique molecular barcode sequence is incorporated into each library DNA fragment at 
this step. 
5.2.3.6   Purify the sample using AMPure XP beads 
Performed as described in 6.2.2.3 with 80µl AMPure XP beads (Agencourt AMPure XP Kit, 
Beckman Coulter Genomics) eluted in 35µl nuclease free water (Ambion). 
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5.2.3.7   Amplify the adaptor-ligated library 
Pre- capture PCR reaction mix was prepared by adding 10µl 5× Herculase II Reaction Buffer, 
0.5µl 100 mM dNTP Mix, 2µl Forward Primer and 1µl Herculase II Fusion DNA Polymerase 
per reaction. 13.5 µl of the PCR reaction mixture was added to each purified DNA library 
sample in the PCR strip tubes. 2 µl of the corresponding SureSelect XT HS Index Primer was 
added to each reaction. Samples were transferred to a thermal cycler for: 2 minutes at 
98°C, 9 cycles for intact fresh DNA or 12 cycles for FFPE DNA of 30 s at 98°C, 30 s 60°C 1min 
at 72°C and 5 minutes at 72°C.  
 
5.2.3.8   Purifying the sample using AMPure XP beads 
Performed as described in 6.2.2.3 with 50µl AMPure XP beads (Agencourt AMPure XP Kit, 
Beckman Coulter Genomics) eluted in 15µl nuclease free water (Ambion). 
5.2.3.9   Assessing Precapture library DNA quantity and quality 
Performed as described in 6.2.2.6. DNA quantity and quality was deemed successful if the 
electropheragram showed the peak of DNA fragment size positioned between 300 to 400bp 
for high- quality DNA and approximately 200 to 400bp for FFPE DNA. 
 
5.2.3.10   Hybridising DNA samples to the Capture Library 
The hybridization reaction required 500–1000 ng of prepared DNA in a volume of 12 µl. The 
maximum amount of prepared DNA available within this range was used. 5 µl of SureSelect 
XT HS and XT Low Input Blocker Mix was added to each DNA library sample well, vortexed 
at high speed for 5s and spun briefly. Sealed sample strips were transferred to the thermal 
cycler for 5mins at 95°C and 10 mins at 65°C. The thermal cycler was paused at 65°C. Whilst 
the cycler was running the hyb solution was prepared by combining: 0.5µl SureSelect RNase 
Block, 4.5µl Nuclease-free water, 2 µl Capture Library, 6µl SureSelect Fast Hybridization 
Buffer per reaction. Keeping the DNA and Blocker samples in the cycler, 13 µl of the room- 
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temperature Capture Library Hybridization Mix was added to each sample well and mixed 
by pipetting up and down slowly 8 to 10 times. The thermal cycler was then resumed for 60 
cycles of: 1 min at 65°C and 3 seconds at 37°C with a final hold at 65°C. 
 
5.2.3.11   Preparing streptavidin-coated magnetic beads 
Dynabeads MyOne Streptavidin T1 magnetic beads (Invitogen) were vigorously re-
suspended on a vortex mixer. 50µl per hybridisation sample of the re-suspended beads 
were added to wells of a fresh strip tube. The beads underwent three washes by: adding 
200µl of SureSelect Binding Buffer, mixing by pipetting up and down 20 times, clearing the 
strip tube on a magnetic separator device and waiting at least 5 minutes until the solution 
was clear and removing and discard the supernatant. The beads were re-suspended in 200 
µl of SureSelect Binding Buffer. 
 
5.2.3.12   Capturing the hybridized DNA using streptavidin-coated beads 
After the hybridization step was completed and the thermal cycler reached the 65°C hold 
step), the samples were transferred to room temperature. The entire volume 
(approximately 30 µl) of each hybridization mixture was transferred to wells containing 200 
µl of washed streptavidin beads using a multichannel pipette. These were mixed by 
pipetting up and down 5–8 times to mix then sealed with fresh caps. The samples were 
incubated on a 96-well plate mixer, mixing vigorously at 1500rpm, for 30 minutes at room 
temperature.  During the 30 minute incubation for capture, SureSelect Wash Buffer 2 was 
prewarmed at 70°C. 200µl aliquots of Wash Buffer 2 were transferred to in wells of a fresh 
96- well plate, aliquoting 6 wells of buffer for each DNA sample in the run. The wells were 
capped and incubated in the thermal cycler, with heated lid on, held at 70°C until used 
later. When the 30 minute incubation period initiated was completed, the sampled were 
spun briefly to collect the liquid. The strip tubes were then placed on a magnetic separator 
to collect the beads, when the solution was cleared the supernatant was removes and 
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discarded. The beads were re-suspended in 200 µl of SureSelect Wash Buffer 1 and mixed 
by pipetting up and down 15–20 times, until beads were fully re-suspended. The strip tubes 
were then placed in a magnetic separator for 1 minute until the solution was cleared. The 
supernatant was then removed and discarded. The strip tubes were removed from the 
magnetic separator and transferred to a rack at room temperature. The beads were then 
with the prewarmed Wash Buffer 2 a total of 6 times using the following steps. The beads 
were re-suspended in 200 µl of 70°C Wash Buffer 2, and pipetted up and down 15–20 
times, until the beads were fully re-suspended. The wells were sealed with fresh caps and 
vortexed at high speed for 8 seconds. The strip tubes were spun briefly to collect the liquid 
without pelleting the beads. The samples were incubated for 5 minutes at 70°C on the 
thermal cycler with the heated lid on. The strip tubes were placed on the magnetic 
separator at room temperature for 1 minute until the solution was clear, then the 
supernatant was removed and discarded. After the last wash and after verifying that all 
wash buffer had been removed, 25 µl of nuclease-free water was added to each sample 
well, and pipetted up and down 8 times to re-suspend the beads.  
 
5.2.3.13 Amplifying the captured libraries 
The PCR reaction mix was prepared by combining 12.5µl Nuclease-free water, 10µl 5× 
Herculase II Reaction Buffer, 1µl Herculase II Fusion DNA Polymerase, 0.5µl 100 mM dNTP 
Mix and 1µl SureSelect Post-Capture Primer Mix per reaction. 25 µl of the PCR reaction mix 
was added to each sample well containing 25 µl of bead- bound target- enriched DNA. PCR 
reactions were mixed well by pipetting up and down until the bead suspension was 
homogeneous. The samples were transferred to a thermal cycler 98°C for 2 minutes then 
12 cycles of 98°C 30s, 60°C 30s and 72°C 1 minute with a final elongation 72°C for 5 mins. 
When the PCR amplification program was complete, the strip tubes were briefly spun. The 
streptavidin-coated beads were removed by placing the plate or strip tube on the magnetic 
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stand at room temperature for 2 minutes until the solution was clear. The supernatant was 
removed and transferred (approximately 50 µl) into wells of fresh strip tubes.  
 
5.2.3.14   Purifying the amplified captured libraries using AMPure XP beads 
Performed as described in 5.2.2.3 with 50µl AMPure XP beads (Agencourt AMPure XP Kit, 
Beckman Coulter Genomics) eluted in 25µl nuclease free water (Ambion). 
5.2.3.15   Assessing sequencing library DNA quantity and quality 
AS performed in 5.2.2.11. DNA quantity and quality was deemed successful if the 
electropheragram showed the peak of DNA fragment size positioned between 200 and 400 
bp. 
5.2.3.16   Sample Pooling 
Libraries (96 in total) were pooled in equimolar amounts based on the aforementioned 
Qubit and Bioanalyser data. Two pools were created; one pool of 14 FFPE samples and one 
pool of 82 fresh samples. The pool was further purified using Agencourt AMPure XP beads 
(Beckman Coulter). The size of the final pool was assessed on a Bioanalyser high sensitivity 
DNA chip and the DNA concentration was determined initially by Qubit double-stranded 
DNA high sensitivity assay, then by qPCR, using an Illumina library quantification kit (KAPA) 
on a Roche LightCycler 480 II system. The pool of 96 target enriched libraries was 
sequenced on two MiSeq runs, using custom sequencing primers (as per Agilent protocol) 











5.2.4   Bioinformatics Analysis 
Samples were sequenced on the Illumina MiSeq platform (2x 250 bp paired-end) (Illumina, 
Inc., San Diego, CA) by the Center for Genomic Research (www.cgr.liv.ac.uk), University of 
Liverpool, UK. Base-calling and de-multiplexing of indexed reads were performed by 
CASAVA version 1.8.2 (Illumina, Inc., San Diego, CA) to produce the raw sequence data in 
FASTQ format. The raw FASTQ reads were trimmed to remove Illumina adapter sequences 
using Cutadapt version 1.2, and low quality bases using Sickle version 1.200. 
 
Trimmed reads were aligned to the human GRCh37 reference genome (ftp://ftp-
trace.ncbi.nih.gov/1000genomes/ftp/technical/reference/phase2_reference_assembly_seq
uence/hs37d5.fa.gz) with the short read alignment tool, BWA-MEM (version 0.7.5a-r405). 
Following alignment, PCR and optical duplicate reads were identified and removed with 
UMI-tools (https://github.com/CGATOxford/UMI-tools). Subsequently, the Genome 
Analysis Toolkit (GATK) (version 3.7) Indel Re-aligner module was used to locally re-align 
reads around putative insertion and deletion sites. GATK BaseRecalibrator module was used 
for recalibrating the base calls. The aligned data was then analysed using tCoNut 
(https://github.com/tgen/tCoNuT) to detect CNVs. The variants were called by GATK and 


















5.2.5   Statistical Analysis 
Survival time (months) was calculated from the date of first diagnosis until death, or study 
closure on 28th February 2018. Analyses were carried out using SPSS Statistics v.24 (IBM), 
Microsoft R 3.5.1 and the packages rms, cmprsk and mstate. A Cox model was used to 
estimate the hazard rates of the two causes of death. Each of the causes of death is 
accounted for in the model by a stratum, so that the baseline hazards are different as it’s 






















5.3   Results 
5.3.1   Comparison of validation panels 
5.3.1.1   Copy-Number Variation 
Of the 14 samples analysed, 1/14 (7%) and 3/14 (21%) failed to produce discernible copy 
number variation data with the SureSelect and TSCA panels respectively (Table 5.5).  13/14 
(93%) samples had available copy number data from previous MLPA analysis for 
chromosomes 1, 3, 6 and 8; the remaining sample was tested via MSA and only examined 
chromosome 3. Chromosome 1p was not included on the TSCA NGS panel due to tiling 
limitations. 12/13 (92%) samples analysed using SureSelect were concordant with previous 
MLPA data; the non-concordant sample was reported as unclassifiable by MLPA and loss by 
SureSelect. Chromosome 3 data for MLPA, SureSelect and TSCA were concordant across all 
analysable samples; 13/13 and 11/11 respectively. Chromosome 6p showed less 
concordance with only 4/13 (31%) SureSelect and 5/11 (45%) TSCA in agreement with the 
previous MLPA results, however there was 100% concordance between SureSelect and 
TSCA results. Similarly, there was 100% concordance for chromosome 6q copy number 
between SureSelect and TSCA but only 8/13 (62%) SureSelect and 6/11 (55%) TSCA data 
matched the MLPA classification. Chromosome 8p was concordant with previous MLPA 
data in 8/13 (62%) SureSelect and 7/11 (64%) TSCA; SureSelect and TSCA were in 
agreement in 8/10 (80%) of samples. Chromosome 8q was 100% concordant between 
previous MLPA data and the SureSelect and TSCA samples. The SureSelect and TSCA were 
able to produce a clear result for 2 cases where 8q was unclassifiable by MLPA. 






Table 5.4 Concordance data from 14 sample validation run 
Enrichment Method Copy Number detection Copy Number Concordance 
with MLPA data 
PCR 11/14 (79%) 11/11 (100%) 




Table 5.5 A comparison of copy number variations as detected by MLPA, SureSelect and TSCA target enrichment 
 
- = Not included on NGS panel 





TEST MLPA SS TSCA MLPA SS TSCA MLPA SS TSCA MLPA SS TSCA MLPA SS TSCA MLPA SS TSCA 
CHR 
1p 3 6p 6q 8p 8q 
ID 
S154.11 N N - N N N U G G N L L G L L U G G 
S191.11 N N - L L L N N N N N N L L L G G G 
S177.13 - L - L L L - N N - N N - G G - G G 
S162.12 L L - L L L L N N U N N N N N U G G 
S183.13 L L - L L L L N N N N N N G N G G G 
S031.13 U N - L L L U G G U L L N N N G G G 
S107.12 N N - L L L N G G N L L L L L G G G 
S032.13 U L - L L * G N * N N * G N * G G * 
S080.09 N N - L L * N G * N N * N N * G G * 
S095.08 N N - N N N G G G N N N N N N N N N 
S001.09 N N - N N N N N N N N N N N N G G G 
S102.09 N N - L L L N N N N N N N L N G G G 
S129.09 N * - L * L G * G N * N N * N N * N 
S083.08 N N - N N * G N * N N * N L * G G * 
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5.3.1.2   Single Nucleotide Variation 
Of the 14 samples analysed, 8/14 (57%) had previous mutation data from TCGA analyses 
and 6/14 (43%) had an unknown mutation status (Table 2.6). TCGA analysis yielded: 1 
GNAQ, 5 GNA11, 1 SF3B1 and 1 CYSLTR2 mutation, which were also detected by both the 
SureSelect and TSCA. The BAP1 mutations were detected by both SureSelect and TSCA were 
100% concordant in the TCGA cohort of samples; however, they weren’t completely in 
agreement with those detected by the TCGA. The TCGA did not detect the W196* mutation 
in sample S107.12 and both SureSelect and TSCA panels did not find the homozygous 
deletion in sample S177.13, which was visible on the SNP array data (Figure 5.1). For the 
samples for which TCGA mutation data were not available, there was 100% (6/6) 
concordance between mutations detected in GNAQ, GNA11, BAP1, SF3B1 and EIF1AX by 
both the SureSelect and TSCA panels. The discovery genes on each panel produced varying 
results. A novel missense mutation of unknown significance was detected on TTC28 I1296V 
on both SureSelect and TSCA panels (Table 5.7).  
 
 
Figure 5.1 A homozygous deletion of the BAP1 loci. 
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Table 5.6 A comparison of single nucleotide variations in GNAQ, GNA11, BAP1, SF3B1 and EIF1AX as detected by MLPA, SureSelect and TSCA target 
enrichment 
TEST TCGA SS TSCA TCGA SS TSCA TCGA SS TSCA TCGA SS TSCA TCGA SS TSCA 
CHR 
GNAQ GNA11 BAP1 SF3B1 EIF1AX 
ID 
S154.11 N/A N/A N/A N/A N/A N/A NA N/A N/A N/A N/A N/A N/A N/A N/A 











N/A N/A N/A N/A N/A N/A 
S177.13 N/A N/A N/A N/A N/A N/A 
Homozygous 
deletion 
N/A N/A N/A N/A N/A N/A N/A N/A 
S162.12 N/A N/A N/A Q209L Q209L Q209L N/A N/A N/A R625H R625H R625H N/A N/A N/A 
S183.13 N/A N/A N/A Q209L Q209L Q209L 
Splicing 
variant 
V27fs V27fs N/A N/A N/A N/A N/A N/A 
S031.13 Q209P Q209P Q209P N/A N/A N/A 
Frameshift 
 
P124fs P124fs N/A N/A N/A N/A N/A N/A 
S107.12 N/A N/A N/A Q209L Q209L Q209L N/A W196* W196* N/A N/A N/A N/A N/A N/A 
S032.13 N/A N/A N/A Q209L Q209L Q209L 
Frameshift 
 
R213fs R213fs N/A N/A N/A N/A N/A N/A 
S080.09 - N/A N/A - R183C R183C - N/A N/A - R625C R625C - N/A N/A 
S095.08 - Q209L Q209L - N/A N/A - N/A N/A - N/A N/A - P2R P2R 
S001.09 - Q209P Q209P - N/A N/A - N/A N/A - N626I N626I - N/A N/A 
S102.09 - Q209P Q209P - N/A N/A - T69fs T69fs - N/A N/A - N/A N/A 
S129.09 - * NA - * N/A - * 
Q642 
A648del 
- * N/A - * N/A 
S083.08 - N/A * - Q209L * - S58fs * - N/A * - N/A * 
 
- = Not included in TCGA analyses 
* = Sample fail
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Table 5.7  A comparison of single nucleotide variations CYSLTR2, TP53BP1, CSMD1, TTC28, DLK2 and KTN1 as detected by MLPA, SureSelect and 
TSCA target enrichment 
TEST TCGA SS TSCA TCGA SS TSCA TCGA SS TSCA TCGA SS TSCA TCGA SS TSCA TCGA SS TSCA 
CHR 
CYSLTR2 TP53BP1 CSMD1 TTC28 DLK2 KTN1 
ID 
S154.11 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A I1296V I1296V N/A N/A N/A N/A N/A N/A 
S191.11 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
S177.13 L129Q L129Q L129Q N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
S162.12 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
S183.13 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
S031.13 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
S107.12 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
S032.13 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
S080.09 - N/A N/A - N/A N/A - N/A N/A - N/A N/A - N/A N/A - N/A N/A 
S095.08 - N/A N/A - N/A N/A - N/A N/A - N/A N/A - N/A N/A - N/A N/A 
S001.09 - N/A NA - N/A N/A - N/A N/A - N/A N/A - N/A N/A - N/A N/A 
S102.09 - N/A NA - N/A N/A - N/A N/A - N/A N/A - N/A N/A - N/A N/A 
S129.09 - * NA - * N/A - * N/A - * N/A - * N/A - * N/A 







5.3.1.3   Quality of Sequencing 











than 0 (%) 
Mean Depth of 
Coverage for 
the bases with 
coverage more 
than 0 
PCR 92.06 16.33 92.99 302x 
Hybrid Capture 97.68 74.37 99.99 497.25x 
 
Table 5.9 Sequencing quality in 94 sample cohort. 
Reads mapped % Reads mapped % 
after UMI 
removed 
Number of bases 
with coverage 
more than 0 (%) 
Mean Depth of 






















5.3.2   94 sample cohort 
 
5.3.2.1   Clinical and Histopathological features of the examined UM 
The study consisted of 54 males and 40 females with a mean age of 63 years at primary 
management (median age 64; range 16 – 87 years). The mean follow-up period was 129 
months (median follow-up 142 months; range 0 – 287 months). Primary management was 
enucleation 69/94 (73%), local resection 11/94 (12%), endoresection 1/94 (1%), fine-needle 
aspirate biopsy 3/94 (3%), PBR 3/94 (3%) and ruthenium plaque RXT 7/94 (7%). Secondary 
treatment was necessary for 4/94 (4%) patients; one local resection patient required a 
subsequent enucleation 32 months after treatment, one patient treated by PBR required an 
endoresection 36 months after administration of RXT, another patient treated by PBR 
required enucleation 29 months after treatment and one patient treated by plaque RXT 
required an enucleation 24 months after treatment. At study closure (28/02/2018), 50/94 
(53%) patients were alive, 30/94 (32%) patients had died from metastatic disease, 10/94 
(11%) patients died from other causes and 4/94 (4%) patients were lost to follow-up. 
Epithelioid cells were present in 54/94 (57%) of cases with the remaining 40/94 (43%) 
having a spindle cell morphology. Closed PAS+ loops were identified in 40/94 (44%) cases, 
absent in 41/94 (43%) cases and not assessed in 13/94 cases (14%). Necrosis was seen in 
19/94 (65%) cases, absent in 19/94 (20%) cases and not assessed in 14/94 (15%) cases.  
There was ciliary body involvement in 29/94 (31%) cases and extraocular extension was 
present in 6/94 (6%) of cases. The mean LBD was 14.8mm (median LBD 15.3; range 4 – 
21mm) with a mean UH of 7.89mm (median UH 8.2; range 1 – 16mm). The tumours had a 
mean mitotic count of 7/40hpf (median 5; range 1 – 72/hpf). 
5.3.2.2   Mutation Frequency 
The following frequencies of mutations were detected; GNAQ 51/94 (54%), GNA11 36/94 
(38%), BAP1 39/94 (41%), SF3B1 19/94 (20%), EIF1AX 20/94 (21%), CYSLTR2 2/94 (2%), 
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PLCB4 1/94 (1%), KTN1 1/94 (1%), TTC28 3/94 (3%), CSMD1 2/94 (2%), TP53BP1 2/94 (2%) 
(Table 5.10). No mutations were detected in BRAF, DLK2, FBXW7 or SRSF2.   





 All Tumours 
(n=94) 
M3 (n=44) D3 (n=46) L3p (n=1) ID (n=2) 
GNAQ 51/94 (54%) 19/44 (43%) 29/46 (63%) 1/1 (100%) 2/2 (100%) 
GNA11 36/94 (38%) 21/44 (48%) 14/46 (30%) - - 
BAP1 39/94 (41%) 35/44 (80%) 1/46 (4%) - 2/2 (100%) 
SF3B1 19/94 (20%) 4/44 (9%) 14/46 (30%) 1/1 (100%) - 
EIF1AX 20/94 (21%) 2/44 (5%) 17/46 (37%) - - 
CYSLTR2 2/94 (2%) 1/44 (2%) 1/46 (2%) - - 
PLCB4 1/94 (1%) 1/44 (2%) - - - 
SRSF2 - - - - - 
KTN1 1/94 (1%) - 1/46 (2%) - - 
TTC28 3/94 (3%) 5/44 (2%) 1/46 (2%) - - 
CSMD1 2/94 (2%) 1/44 (2%) 1/46 (2%) - - 
TP53BP1 2/94 (2%) 1/44 (2%) - - - 
BRAF - - - - - 
DLK2 - - - - - 




Figure 5.2 IGV Ver 2.3.94 images of novel mutations in PLCB4, KTN1 and TTC28. From left to 
right: a disruptive in-frame deletion p.M549_G556delinsI in PLCB4, a missense mutation in 












Figure 5.3 IGV Ver 2.3.94 images of novel mutations in CSMD1 and TP53BP1. From left to 
right: missense mutations in p.P1097H and p.P108L in CSMD1 and a disruptive in-frame 




5.3.2.3   Copy Number Variation 
The cut off values set for the log2 ratio to classify losses and gains were set at 0.65 and 1.35 
respectively based on the dosage quotients set for the current MLPA testing performed at 
Liverpool (186). One case failed to produce a clear genotype. Chromosome 1p was lost in 
26/94 (28%), normal in 66/94 (70%) and gained in 1/94 (1%) of cases. The q arm of 
chromosome 1 was normal in 80/94 (85%), gained in 12/94 (13%) and showed regions of 
loss and gains in 1/94 (1%) of cases. Monosomy 3 was seen in 44/94 (47%), normal in 46/94 
(49%), isodisomy in 2/94 (2%), gained in 1/94 (1%) and loss of 3p in 1/94 cases (1%). 
Chromosome 6p was normal in 58/94 (62%) and gained 35/94 (37%); 6q was normal in 
71/94 (71%), lost in 19/94 (20%) and gained in 3/94 (3%) of cases. The p arm of 
chromosome 8 was lost in 17/94 (18%), normal in 67/94 (71%) and gained in 9/94 (10%) of 
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cases. Chromosome 8q was normal in 41/94 (44%) and gained in 52/94 (55%) of cases. One 
1/94 (1%) case displayed polyploidy (Figure 5.4). 
 
Figure 5.4 Copy number analysis of sample 56 (S027.08) displaying polyploidy 
5.3.2.4   Concordance 
When compared with previous genotypes conducted by MLPA, concordance was observed 
in: 80/93 (86%) chromosome 1p, 90/93 (97%) chromosome 3, 75/93 (81%), chromosome 
6p 75/93 (81%) chromosome 6q, 70/93 (75%) chromosome 8p and 75/93 chromosome 8q 






Table 5.11 Concordance between chromosome copy number detected by NGS vs. MLPA 




























5.3.2.5   FFPE concordance 
When compared with mutation and genotype data obtained from previous MLPA testing, 
NGS conducted at Rotterdam and NGS conducted during part of the panel validation the 
following levels of concordance were found: GNAQ (100%); GNA11 (100%); BAP1 (86%), 
SF3B1 (86%), EIF1AX (86%) and CYSLTR2 (100%) (Table 5.12). An additional missense 
mutation in p.P108L was also detected in CSMD1 in sample 3. Copy number was found to 
be concordant with previous MLPA analyses: chromosome 1p, 10/13 (77%); chromosome 3, 
12/13 (92%); chromosome 6p, 7/12 (58%); chromosome 6q, 10/12 (83%); chromosome 8p, 




Table 5.12 Mutation concordance Fresh vs FFPE validation 
 Fresh FFPE Fresh FFPE Fresh FFPE Fresh FFPE Fresh FFPE Fresh FFPE 
Sample GNAQ GNA11 BAP1 SF3B1 EIF1AX CYSLTR2 
1 Q209R Gln209Leu Na Na V478fs Val460fs Na Na Na Na Na Na 
2 Na Na Q209L Gln209Leu L334fs Na Na Na Na Na Na Na 
3 N/A Na N/A Na N/A Na N/A Na N/A Na L129Q L129Q 
4 Q209L Gln209Leu Na Na Na Na E622D Glu622Asp Na Na Na Na 
5 Na Na Q209L Gln209Leu T111fs Thr111fs V634I Na Na Na Na Na 
6 Q209P Gln209Pro Na Na Na Na R625H Arg625His N4H Asn4His Na Na 
7 
Na Na Q209L Gln209Leu Na 
Arg213fs, 
Ile214_Gly220del Na Na Na Na Na Na 
8 Q209L Gln209Leu Na Na Na Na Na Na N4S Asn4Ser Na Na 
9 Q209L Gln209Leu Na Na S489fs Ser489fs Na Na Na Na Na Na 
10 Na Na Na Na L633fs Leu633fs Na Na Na Na Na Na 
11 Q209P Gln209Pro Na Na Q260* Gln260* Na Na Na Na Na Na 
12 Q209P Gln209Pro NA Na NA Na N626I Na NA Na Na Na 
13 Na Na Q209L Gln209Leu Q593* Gln593* Na Na Na Na Na Na 
14 Na Na Q209L Gln209Leu Na Na Na Na G6D Na Na Na 







Table 5.13 Copy number concordance Fresh vs FFPE validation 
 Fresh FFPE Fresh FFPE Fresh FFPE Fresh FFPE Fresh FFPE Fresh FFPE 
Sample Chr1p Chr3 Chr6p Chr6q Chr8p Chr8q 
1 Loss Normal Loss Loss Gain Normal Normal Normal Loss Gain Gain Gain 
2 Loss Loss Loss Loss Normal Normal Normal Normal Normal Normal Normal Gain 
3 Loss Normal Loss Loss Gain Normal Normal Normal Normal Normal Gain Normal 
4 Normal Loss Normal Normal Gain Gain Normal Normal Normal Normal Gain Gain 
5 Loss Normal Loss Loss Unclassifiable Normal Gain Normal Unclassifiable Normal Unclassifiable Gain 
6 Loss Normal Unclassifiable Normal Gain Normal Gain Normal Gain Normal Gain Normal 
7 Loss Loss Loss Loss Loss Normal Normal Normal Normal Gain Gain Gain 
8 * Normal Loss Normal * Normal * Normal * Normal * Normal 
9 Normal Normal Loss Loss Loss Gain Unclassifiable Loss Loss Loss Gain Gain 
10 Normal Normal Loss Loss Normal Normal Normal Normal Loss Loss Gain Gain 
11 Normal Normal Loss Loss Normal Normal Loss Loss Loss Loss Gain Gain 
12 Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal Gain Gain 
13 Normal Normal Loss Loss Normal Normal Normal Normal Normal Normal Gain Normal 
14 Normal Normal Normal Normal Normal Normal Normal Normal Gain Normal Normal Normal 







5.3.2.6   Survival 
5.3.2.6.1   Mutations 
Kaplan–Meier survival curves and tables were examined for all UM examined according to 
mutation status as determined by NGS. Mutations in BAP1 (Log rank, p=≤0.001) were 
significantly associated with a reduced survival time (figure 5.5). Mutations in EIF1AX (Log 
rank, p=0.040) were associated with improved survival overall but not within the disomy 3 
cohort alone (Log rank, p=0.254) (figure 5.6). Mutations in SF3B1 were not significantly 
associated with a worse clinical outcome in terms of survival (Log rank, p=0.378). This was 
also true when only disomy 3 cases were analysed for the effect of SF3B1 mutations on 
survival (Log rank, p=0.140) (figure 5.7). There was no difference in survival between GNAQ, 
GNA11, CYSLTR2 mutants and wild type UM (Log rank, p=0.533) (figure 5.8). When survival 
was compared based on the combined chromosome 3 and chromosome 8q status M3 P8q 
had the highest metastatic risk (Log rank, p=≤0.001), M3 D8 had an intermediate risk 
whereas D3 D8 and D3 P8q shared a similar low risk (figure 5.9).  
 
5.3.2.6.2   Copy Number 
Kaplan–Meier survival curves and tables were examined for all UM according to copy 
number status as determined by NGS. Gain of chromosome 1q was associated with a worse 
outcome (Log rank, p=0.027) whereas changes in chromosome 1p were not (Log rank, 
p=0.568) (Figure 5.10). Loss of chromosome 3 and isodisomy of chromosome 3 were 
significantly associated with reduced disease-free survival (Log rank, p= ≤0.001) (Figure 
5.11). Loss of 6p was associated with improved disease-free survival (Log rank, p=0.006) 
whereas changes in copy number of 6q was not (Log rank, p=0.462) (Figure 5.12). Loss of 8p 
was significantly associated with a poor survival outcome (Log rank, p=0.008), as was gain 
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of 8q (Log rank, p=0.006) (Figure 5.13).  Due to multiple testing, only BAP1 qualifies as a 











No. % % Lower Upper 
Mutant 39 22 17 43.6 130.418 106.752 154.084 
Wild-type 55 8 47 85.5 250.614 227.570 273.658 
Overall 94 30 64 68.1 206.549 183.333 229.764 
 
 
Figure 5.5 Kaplan Meier curves and tables where patient survival was stratified according to 

















EIF1AX Total No. No. of 
Events 




No. % % Lower Upper 
Mutant 20 3 17 85.0 239.070 209.084 269.057 
Wild-type 74 27 47 63.5 190.357 161.831 218.882 




Disomy 3 EIF1AX Total No. No. of 
Events 




No. % % Lower Upper 
Mutant 17 3 14 82.4 233.484 198.222 268.747 
Wild-type 29 3 26 89.7 260.543 232.871 288.216 
Overall 47 6 440 87.0 261.364 233.344 278.914 
 
Figure 5.6. Kaplan Meier curves and tables where patient survival was stratified according 
to EIF1AX mutation status determined by NGS; A) Overall EIF1AX wild-type (n=74) vs. 
EIF1AX mutants (n=20) (p=0.040) and B) Disomy 3 EIF1AX wild-type (n=29) vs. EIF1AX 







SF3B1 Total No. No. of 
Events 




No. % % Lower Upper 
Mutant 19 4 5 78.9 229.692 183.113 276.271 
Wild-type 75 26 49 65.3 201.298 175.579 227.016 




Disomy 3 SF3B1 Total No. No. of 
Events 




No. % % Lower Upper 
Mutant 14 3 11 78.6 232.092 180.768 283.417 
Wild-type 32 29 29 90.6 265.338 242.361 288.417 
Overall 47 40 40 87.0 261.364 233.344 278.914 
 
Figure 5.7 Kaplan Meier curves and tables where patient survival was stratified according to 
SF3B1 mutation status determined by NGS; A) Overall SF3B1 wild-type (n=75) vs. SF3B1 
mutants (n=19) (p=0.378) and B) Disomy 3 SF3B1 wild-type (n=32) vs. Disomy 3 SF3B1 













No. % % Lower Upper 
GNAQ 51 13 38 74.5 223.961 195.053 252.869 
GNA11 36 14 22 61.1 186.394 148.429 224.359 
CYSLTR2 2 1 1 50.0 115.000 30.458 199.542 
Wild-type 5 2 3 60.0 136.125 111.587 160.663 
Overall 94 30 64 68.1 206.549 183.333 229.764 
 
Figure 5.8 Kaplan Meier curves and tables where patient survival was stratified according to 
GNAQ, GNA11 and CYSTLTR2 mutation status determined by NGS; GNAQ mutants (n=51), 
GNA11 mutants (n=36), CYSLTR2 mutants (n=2) and GNAQ, GNA11, CYSLTR2 and PLCB4 























No. % % Lower Upper 
M3 P8q 32 20 12 37.5 112.693 87.845 137.542 
M3 D8 14 5 9 64.3 176.462 139.906 213.017 
D8 P8q 19 2 17 89.5 261.595 228.823 294.367 
D8 D8 27 3 24 88.9 260.364 234.939 285.789 
Overall 92 30 62 67.4 205.290 181.856 228.724 
 
Figure 5.9 Kaplan Meier curves and tables where patient survival was stratified according to 
chromosome 3 and chromosome 8q status determined by NGS; M3 P8q (n=32), M3 D8 
(n=14), D3 P8q(n=19) and D3 D8 (n=27) (p=≤0.001). Cases of isodisomy and partial loss 






















Chromosome 1q Total No. No. of 
Events 




No. % % Lower Upper 
Normal 80 23 57 71.3 215.228 190.959 239.497 
Gain 12 7 5 41.7 124.429 73.037 175.820 




Chromosome1p Total No. No. of 
Events 




No. % % Lower Upper 
Loss 26 10 16 61.5 - - - 
Normal 66 20 46 69.7 - - - 
Gain 1 0 1 100.0 - - - 
Overall 93 30 63 67.7 - - - 
 
Figure 5.10 Kaplan Meier curves and tables where patient survival was stratified according 
copy number of A) chromosome 1q normal (n=80) and gain (n=12) (p=0.027) and B) 
chromosome 1p gain (n=1), normal (n=66) and loss (n=26) (p=0.568). *No survival statistics 








Chromosome 3 Total No. No. of 
Events 




No. % % Lower Upper 
Isodisomy 2 2 0 0.0 - - - 
Monosomy  44 22 20 50.0 - - - 
Disomy  46 6 40 87.0 - - - 
Loss of 3p 1 0 1 100.0 - - - 
Overall 93 30 63 67.7 - - - 
 
Figure 5.11. Kaplan Meier curves and tables where patient survival was stratified according 
copy number of chromosome 3; isodisomy (n=2), monosomy 3 (n=44), disomy 3 (n=46) and 
















Chromosome 6p Total No. No. of 
Events 




No. % % Lower Upper 
Normal 58 25 33 56.9 179.978 150.912 209.044 
Gain 35 5 30 85.7 249.303 219.254 279.352 




Chromosome 6q Total No. No. of 
Events 




No. % % Lower Upper 
Loss 19 7 12 63.2 - - - 
Normal 71 23 48 67.6 - - - 
Gain 3 0 3 100.0 - - - 
Overall 93 30 63 67.7 - - - 
 
Figure 5.12. Kaplan Meier curves and tables where patient survival was stratified according 
copy number of A) chromosome 6p normal (n=58) and gain (n=35) (p=0.006) and B) 
chromosome 6q gain (n=3), normal (n=71) and loss (n=19) (p=0.462). *No survival statistics 







Chromosome 8p Total No. No. of 
Events 




No. % % Lower Upper 
Loss 17 11 6 35.3 127.928 96.537 159.319 
Normal 67 16 51 76.1 221.768 195.740 247.797 
Gain 9 3 6 66.7 203.317 125.685 280.949 




Chromosome 8q Total No. No. of 
Events 




No. % % Lower Upper 
Normal 41 8 33 80.5 235.368 206.375 264.362 
Gain 52 22 30 57.7 180.303 148.043 212.562 
Overall 93 30 63 67.7 205.493 182.103 228.883 
 
Figure 5.13. Kaplan Meier curves and tables where patient survival was stratified according 
copy number of A) chromosome 8p loss (n=17), normal (n=67) and gain (n=9) (p=0.008) and 






















5.3.2.7   Cox Regression 
Multivariate analysis of: age; gender; BAP1, SF3B1, EIF1AX and chromosome 1q was carried 
using the cox proportional hazards model (table 5.14). BAP1 was selected as I have 
previously shown it can be used as a surrogate marker for chromosome 3. Chromosome 1q 
was selected as it was shown to be significant by Kaplan-Meier. SF3B1 and EIF1AX were 
chosen due to the suggested influence on survival in the literature. Age and gender were 
included to adjust for the impact on survival. The model identified the following factors as 
significantly associated with survival: BAP1 mutation status p=0.00058 (HR 5.88: 95% CI 
2.14 – 16.11) and copy number of chromosome 1q p=0.015 (HR 3.22 CI 1.25 – 8.26). The 
hazard ratios are shown in Table 5.13 for each prognostic factor with 95% confidence 
intervals, z test p-values and Schoenfeld’s χ2 test of proportionality of hazards (PH) p-
values. The model’s likelihood ratio statistic is 35.64 on 6 degrees of freedom (p-value 
0.000003). The global Schoenfeld’s χ2 test of proportionality of hazards is 2.71 (p-value 
0.85.). No strong deviation from the hypothesis of proportionality of hazards was observed.  
Table 5.14 Hazard ratios for prognostic factors in UM 
Factor Hazard ratio [95% CI] z test  
p-value 
PH χ2 test  
p-value 
Cause of  
Death 
Age 1.12 [1.03,1.21] 0.0047 0.24 Other 
Gender 0.51 [0.12, 2.09] 0.35 0.99 Other 
BAP1 5.88 [2.14, 16.11] 0.00058 0.83 Metastasis 
SF3B1 0.63 [0.20, 1.98] 0.43 0.59 Metastasis 
EIF1AX 1.13 [0.25, 5.02] 0.87 0.63 Metastasis 











5.4.1   14 sample cohort 
This is the first study of its kind to compare hybrid capture and PCR-based enrichment 
methods in UM. Both methods vary in exactly how the targeted regions are amplified and 
hybridised. Hybrid capture methodologies involve shearing gDNA into smaller fragments 
and hybridising the sample with targeted biotinylated RNA baits. Using magnetic 
streptavidin beads these baits can be separated and amplified. Whereas PCR-based 
methods hybridise a custom oligo pool flanking targeted regions on unfragmented gDNA. 
These are then extended and ligated and PCR is performed to integrate indexes and 
sequencing primers. There are advantages to using a PCR-based method such as reduced 
DNA input and a relatively short sample preparation time. However, in this study, I have 
demonstrated that hybrid capture outperformed the PCR-based enrichment as it provided 
a deeper coverage, had a larger percentage of reads mapped before and after unique 
molecular barcode removal, and had a greater mean depth of coverage (Table 5.8). 
Although there were no differences in the ability to call variants, the failure rate for copy 
number variant analysis for the PCR-based method was higher than the hybrid capture 
method. This echoes the finding of several comparison studies examining the differences 
between each methodology. In a similar study Hung et al. compared the enrichment 
chemistries used in the present study to personalise the management of lymphoma and 
found limited sensitivity of PCR-based sequencing, with several variants being missed due 
to regions of high GC content and suboptimal PCR conditions yielding a minimal coverage, 
limitations that were not seen using hybrid capture (244). Similarly, Samorodnitsky et al. 
demonstrated an increased incidence of false positives and missed variants in PCR-based 
enrichment when evaluating hybrid capture versus PCR-based methods for whole-exome 
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sequencing (245). Though neither study found differences between the success rates of 
copy number analysis unlike the present study. A reason for this could be common trouble 
shooting issues typically experienced during PCR ranging from suboptimal PCR conditions 
such as: presence of inhibitors such as melanin; a high GC content or insufficient coverage 
(246) (247). Due to the higher failure rate of PCR-based amplification I chose to move 
forward with the larger subset of samples using the hybrid capture methodology.    
There was a high degree of copy number concordance between SureSelect and TSCA 
classifications for chromosomes 6 and 8.  The concordance for these chromosomes was 
however lower when the NGS data from each panel was compared with MLPA 
classifications. This was, however not the case for chromosome 3, where there was 100% 
agreement between all genetic tests. This is likely due to the low probe coverage on 
chromosomes 6 and 8 in the MLPA panel; 6q and 8p 2 probes and 6p and 8q 4 probes 
respectively. The increased coverage of these on the NGS panel will increase accuracy of 
copy number variant detection moving forward.  
Both hybrid capture and PCR-based enrichment panels were effective in detecting 
mutations in both samples molecularly profiled by TCGA analyses and in those samples with 
unknown mutation status. There was 100% concordance for GNAQ, GNA11, SF3B1 and 
EIF1AX between all samples. There was some discordance between the detection of BAP1. 
Sample 3 (S177.13), a sample submitted to the TCGA by the Liverpool Ocular Oncology 
Research Group, contained a homozygous deletion not detected by the NGS panel. 
Homozygous deletions are a rare in phenomenon occurring in cancers and often target 
tumour suppressor genes such as BAP1. However, after carefully analysing the copy 
number data it is apparent there is a homozygous deletion (Figure 5.1). 
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An additional W196* nonsense mutation was detected in BAP1 for sample 12 (S107.12), 
detected by both enrichment methods but was not described in the recent TCGA analyses. 
However, a recent study by Field et al. analysed the same TCGA sample (A8KF) and 
surmised that it had been missed due to low exome coverage by the mutation could be 
detected when compared with matched RNA-Seq (136). This is an obvious advantage to 
adopting a targeted approach to NGS as it enables for an increase in gene coverage. This 
was also true of sample 1 (S154.11) where a p.I1296V missense mutation in TTC28 was 
detected by both enrichment methods but not by the TCGA analyses.  
5.4.2   94 sample cohort 
Three samples were not concordant with the original MLPA analyses results for 
chromosome 3. Sample 54 (S245.13) was shown to have region of deletion in chromosome 
3p not identified in previous analyses. This is potentially due to an increased number of 
probes covering chromosome 3p not included in the MLPA assay. The other two samples 
both had a M3 genotype in the original analyses but were shown to have a D3 profile by 
NGS. Neither sample contained a mutation in BAP1, which is strongly associated with loss 
of chromosome 3 (Chi-squared p=≤0.001), and one sample contained a mutation in SF3B1, 
which has also been associated with a D3 profile (Chi-squared p=0.015). Two cases of 
isodisomy of chromosome 3 were also detected that had been classified as disomy by MLPA 
due to the limitations of the assay in detecting acquired homozygosity. 
There was discordance between the original MLPA analyses and the NGS copy number for 
chromosomes 1, 6 and 8 in several of the cases, however, this is likely due to the low probe 
coverage of these genes on the MLPA panel as mentioned previously. 
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In the larger 94 sample cohort, sample 46 (S151.11) failed to produce a clear genotype, 
however this was expected as the sample had a low yield post-capture. This was reflected 
in the quality results whereby the sample only had 3.36x depth of coverage. 
Some of the samples used in the FFPE validation cohort were the FFPE counterpart to fresh 
tissue sequenced in Rotterdam for a different study. Although there was complete 
concordance between GNAQ and GNA11 there was a disparity between mutations 
identified in BAP1, SF3B1, and EIF1AX. Sample 2 (S056.14) did not harbour a p.L334fs 
mutation in BAP1 that was called by the Ion Torrent analysis. When the coordinates were 
checked using IGV to authenticate its presence, the mutation could not be found in the 
sequencing reads. In contrast, two BAP1 mutations (p.R213fs and p.I214_G220del) were 
observed in the present study in sample 7 (S183.13) that were not called by the initial 
analysis in Rotterdam. Additionally, two SF3B1 mutations were called in the initial analyses 
in samples 5 (S106.13) and 12 (S001.09) in p.V634I and N626I respectively that were not 
identified in the present study. Similarly, a mutation in EIF1AX p.G6D not detected in this 
study, was observed in the Ion Torrent data. When the sequencing reads were checked 
using IGV no mutation could be detected even at low levels. The most logical explanation 
for these differences is the variance in chemistry used in both the enrichment and 
sequencing during the initial analyses. The group that sequenced the samples initially utilise 
a PCR-based enrichment (AmpliSeq) and the sequencing is run on the Ion Torrent Personal 
Genome Machine (PGM) (Thermofisher). Several studies have demonstrated that false-
positives can arise from multiplex PCR-based enrichment methodologies such as AmpliSeq 
(248) (245). Similarly, the Ion torrent PGM is well known for sequencing errors caused by 
homopolymers; repeats of the same nucleotide present on the template strand. The semi-
conductor detects nucleotides based on the hydrogen ions released during polymerisation 
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of DNA, measuring the pH change. Homopolymers cause more hydrogen ions to be 
released in a single cycle due to the repeats of the same nucleotide, resulting in a greater 
pH change and a proportionally greater electronic signal. 
Mutations in GNAQ and GNA11 occurred in a mutually exclusive fashion in 92% of cases 
(54% and 38%, respectively). This is consistent with the reported cases in the literature 
(134) (135) (198). Mutations predominantly occurred in exon 5, although interestingly 
sample 46 (S151.11) contained two unusual mutations in exon 4 p.R214K and p.R214S. 
These regions do not lie within any of the known functional domains of GNA11 and have 
not been characterised in the scientific literature and therefore, their effect on GNA11 
protein function are unknown. Only one mutation occurred in exon 4 in GNAQ and GNA11, 
p.R183Q and p.R183C respectively. Mutations in CYSLTR2 were found in 2 cases in the hot 
spot region p.L129Q in exon 1, previously reported by other studies and occurred in a 
mutually exclusive manner to mutations in GNAQ and GNA11 (132). Consistent with our 
general understanding of the function of these mutations, there were no differences in 
survival outcome based on the mutational status of the driver mutations GNAQ, GNA11 and 
CYSLTR2 (p=0.533) (Figure 5.8). This is in agreement with the study by Koopmans et al. 
where univariate analysis showed no correlation between disease-free survival and 
mutation status in GNAQ or GNA11 (249). Similarly, Staby et al. demonstrated no significant 
differences in the prevalence of mutations in UM patients with or without metastatic 
disease (250). Mutations in GNAQ or GNA11 have been shown to consistently activate the 
protein kinase C (PKC) pathway and the map kinase pathway (MAPK) (115). However, a 
recent review of the efficacy and safety of MEK inhibitors in metastatic or unresectable UM 
low radiologic response rates in UM (251). Though there is no prognostic significance of 
these mutations, the therapeutic potential of them remains hopeful. 
135 
 
The mutation rate for BAP1 in the literature ranges from 18% to 60% in all UM (129) (133) 
(134, 135) (198). The frequency of BAP1 mutations in the present study was 41%, a figure 
consistent with the findings of Robertson et al, Royer-Bertrand et al and Smit et al (134, 
135, 198). Mutations in BAP1 occurred in 80% of monosomy 3 cases in this study, 
concordant with the findings of Harbour et al. (129). Only one missense BAP1 p.A142P 
mutation was detected in a D3 tumour similar with the rate reported by Koopmans et al. 
(252). The majority of mutations observed were frameshift mutations (54%) although some 
nonsense (15%), missense (10%), INDELS (10%) and splice site mutations (15%) were also 
identified. In chapter 4, I demonstrated the prognostic impact of loss of nuclear BAP1 
(nBAP1) protein expression on patient survival, with multivariate analysis identifying this as 
a worse prognostic factor than loss of chromosome 3 (240). Loss of nBAP1 has been 
strongly associated with loss of function mutations in other studies (130). In the present 
study, I was unable to correlate mutations and protein expression due to the unavailability 
of some of the pathology samples and the lack of time. In the present study BAP1 mutation 
was also the strongest predictor of metastatic death during cox analysis, despite a wide 
confidence interval (Table 5.14). Unlike the previous study, M3 BAP1 wild-type UM samples 
did not have a significantly better survival (p=0.062). However, this may be due to the small 
numbers. In the present study, mutation in BAP1 was strongly associated with a reduced 
disease-free survival (p=≤0.001) (Figure 5.5). Of the patients with UM that harboured a 
mutation in BAP1, 22/39 (56%) died from metastatic disease. Mutations in BAP1 were 
significantly associated with loss of one copy of chromosome 3 and isodisomy of 
chromosome 3 (Fisher’s Exact p=≤0.001).  
The frequency of EIF1AX mutations detected in the present NGS UM study is consistent 
with the mutation rates of Smit et al. and Royer-Bertrand et al. (134). The frequency of 
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EIF1AX mutations in studies conducted by others was higher and lower than the present 
study at 34% and 14% respectively (119) (133) (135). Interestingly, two samples contained 
mutations in both EIF1AX and SF3B1 despite previously reports that these occur in a 
mutually exclusive fashion (134) (198). One sample that contained a p.N4H mutation in 
EIF1AX also contained a mutation in p.R625H of SF3B1 and the other contained a mutation 
in p.G9D in EIF1AX and p.K666N in SF3B1. Both samples had a normal chromosome 3, 6 and 
8, with one sample containing a loss of 1p. Also of interest, both patients died from 
metastatic disease 34 months and 148 months, respectively, after primary treatment. There 
is only one other reported case of this phenomenon in the literature by Robertson et al. 
(135), however, in contrast to the present study, this patient was still alive and well at study 
closure with a follow up of 62 months. EIF1AX mutations are typically associated with D3 
tumours; however in the present study we identified two cases of M3 tumours that 
harboured mutations. Both cases lacked mutations in BAP1 and one patient had died from 
other causes leaving the other patient alive and well at the end of the study.  Only one 
other case of an EIF1AX mutation has been reported in the literature in a M3 tumour, 
however this also harboured a splicing mutation in BAP1 whereas the M3 EIF1AX mutants 
in the present study were BAP1 wild type (134). In our cohort mutations in EIF1AX were 
associated with an overall improved survival (p=0.040), however within the D3 subset of 
samples there was no discernible difference (p=0.254 (Figure 5.6). This was most likely 
because 3/5 (60%) of the patients with D3 who died from metastatic disease harboured 
mutations in EIF1AX. When examined In the Cox proportional hazards model, EIF1AX was 
associated with an increase of the hazard; however, the confidence interval included the 
value 1, so no conclusions can be drawn from this. However, mutations in EIF1AX were 
significantly associated with D3 tumours (Fisher’s exact p=≤0.001). 
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The incidence of SF3B1 mutations in the literature ranges from 11% - 34%. In this study 
SF3B1 mutations occurred in 20% of UM, which was consistent with the findings of Smit et 
al and Royer-Bertrand et al (134) (198). SF3B1 mutations were identified in 5% of M3 cases 
and 34% of D3 cases. SF3B1 mutations are thought to occur primarily in D3 tumours, 
however, in this study, two were found in M3 UM and one in a UM case with loss of 3p. 
Four cases of M3 UM with SF3B1 mutations were identified by Robertson et al; two of 
which did not have mutations in BAP1, neither of which died from metastatic disease and 
two with BAP1 mutations, one of which died from metastatic disease (135). In this study 
three SF3B1 mutations were found to occur alongside BAP1 mutations. Two cases 
contained the p.R625H mutations in SF3B1 alongside p.L14fs and p.A142P. The third case 
has a missense mutation in p.N626H with a p.F118fs in BAP1. One patient died from 
metastatic disease 31 months following a local resection. The other two patients are alive 
and well with no evidence of metastatic disease with a follow up of 190 and 197 months 
respectively. This has been described in the literature once before by Robertson et al. who 
identified two cases with mutations in both SF3B1 and BAP1 (135). In their study, only one 
of the patients had died from metastatic disease also. Unlike other studies, the present 
study did not find mutations in SF3B1 to be associated with an increased metastatic risk in 
comparison to those without when all UM cases were considered (p=0.378) (Figure 5.7). 
Similarly, when only D3 cases were analysed there was no difference in survival between 
those with or without SF3B1 mutations (p=0.140) (Figure 5.7). This is in contrast to the 
study by Yavuzyigitoglu et al. who found an association between SF3B1 and late onset 
metastases for D3 UM (242). This could be due to the relatively short-follow up (5 years 
minimum) in comparison to other studies, which may have contributed to the lack of 
deaths in this cohort of samples, despite a similar rate of mutations detected. However, my 
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data are consistent with that of TGCA, whereby an association between SF3B1 and an 
increased late onset risk of metastasis could not be made (135). Longer follow-up of this 
patient cohort may shed further light on the role of SF3B1 mutations and metastatic risk. 
Disruptive in-frame deletions in p.M549_G556delinsI and M561_G568delinsI mutations 
were observed in PLCB4 in a single sample of the 94 sample cohort (Figure 5.2). 
Interestingly, this sample also contained a p.R183Q mutation in GNAQ. Previous studies 
identified recurrent mutations in PLCB4 in a hotspot region p.D630Y and p.D630N on exon 
20 (133). The mutation identified in the present study occurred in exon 18 and is the first 
mutation in this region to be described in UM. Though it was initially thought that PLCB4 
mutations occurred in a mutually exclusive manner to GNAQ, GNA11 and CYSLTR2, this 
study and Robertson et al. have demonstrated the occurrence of PLCB4 mutations 
alongside GNAQ and GNA11 mutations (135).  The mutation observed in this is located in 
highly conserved catalytic domain of PLCB4, the Y-Box, which has been shown to control 
signal transduction in the retina. (133). As a downstream target of the GNAQ and GNA11 
alpha subunits of G-protein coupled receptors, PLCB4 interacts with the alpha subunit to 
catalyse the conversion of phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-
trisphosphate (IP3) and diacylglycerol (DAG) (253).  
Three mutations in TTC28 were identified in this study; two missense mutations in 
p.P1216H and A18G and one nonsense mutation in p.R21*, occurring in both M3 and D3 
tumours (Figure 5.2). Other studies have also detected mutations in TTC28 in UM at a 
similar low frequency (119) (134). TTC28 is a ubiquitous protein thought to have a role in 
regulating mitosis and cytokinesis during mammalian cell cycle processes (254). Dysfunction 
of TTC28 has been shown to contribute to tumour progression (255). Inactivating mutations 
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in TTC28 have been demonstrated to increase microtubule turnover and induce mitotic 
defects; cell cycle aberrations are a hallmark of cancer (256). 
Two mutations in CSMD1 were discovered in this study; two missense mutations in 
p.P1097H and p.P108L (Figure 5.3). Other studies have also detected mutations in CSMD1 
at similar low levels (134). CSMD1 is located on chromosome 8p23, a region that is 
commonly deleted in many cancers including UM. As a candidate tumour suppressor gene, 
loss of CSMD1 has been shown to be associated with a number of cancers including breast, 
head and neck, lung and skin tumours (257) (258), and is specifically associated with a poor 
prognosis in breast cancer.   
A single missense mutation in p.P195T of KTN1 was identified in sample 19 (S231.11) 
(Figure 5.2). KTN1 encodes Kinectin 1, a protein primarily localised to the endoplasmic 
reticulum (259). KTN1 has various functions including kinesin binding which plays a role is 
mitosis, particularly in microtubule movement and spindle formation (260).  This protein 
also binds with translation elongation factor-1 delta by acting as membrane anchor for 
kinesin on intracellular organelles (261). In cancer, KTN1 has been observed to form a 
fusion with RET, creating a novel rearranged form of a proto-oncogene observed in 
radiation-induced childhood papillary thyroid carcinoma (262) (263). The functional impact 
of the mutation observed in the present study is unknown; however missense mutations 
can render the affected protein non-functional, which in this case could result in 
dysregulation of mitosis or unregulated cytoskeletal activities (264). 
 
Two mutations in TP53BP1 were observed in the present study; one nonsense mutation in 
Glu1529* and a disruptive in-frame deletion in p.I455_P456del (Figure 5.3). The only other 
study to identify mutations in TP53BP1 in UM found a splice site mutation and a missense 
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in p.V1496D, suggesting mutations in this gene do not occur in hotspots (134). TP53BP1 
interacts with the tumour suppressor protein p53, a critical protein for cells in multicellular 
organisms to suppress cancer formation. TP53BP1 is heavily involved in the DNA double-
strand break repair pathway, promoting non-homologous end joining pathways. TP53BP1 
promotes checkpoint signalling following DNA damage and acts as a molecular scaffold, 
recruiting proteins that assist in the repair of damaged chromatin (265). Mutations in 
TP53BP1 have been observed in aggressive inflammatory breast cancer and have been 
shown to increase cell proliferation in colon cancer (266) (267). 
 
This panel was custom designed to have full coverage of the TTC28, CSMD1, KTN1 and 
TP53BP1 genes and due to its targeted nature had fuller coverage in comparison to whole-
exome sequencing methodologies. This could be a possible explanation to the low 
frequency of mutations in the literature. However, due to the low frequency of mutations 
identified in TTC28, CSMD1, KTN1 or TP53BP1 in this study no association could be made 
with a particular genotype or survival group. More functional work needs to be undertaken 
in the future to understand the implications of these. 
This is the largest NGS study to date; however, previously described mutations in SRSF2, 
DLK2 or FBXW7, which have been detected in low frequency in other studies, were not 







Table 5.15 Frequency of mutations in original whole-exome and targeted NGS UM studies 
 Mutation Frequency 

















GNAQ 9/22 (41%) 8/28 (29%) 31/70 (44%) 19/33 (58%) 40/80 (50%) 51/94 (54%) 
GNA11 9/22 (41%) 14/28 (50%) 30/70 (42%) 14/33 (42%) 36/80 (45%) 36/94 (38%) 
BAP1 4/22 (18%) 11/28 (39%) 29/70 (41%) 16/33 (48%) 35/80 (44%) 39/94 (41%) 
SF3B1 3/22 (14%) 3/28 (11%) 11/70 (16%) 6/33 (18%) 27/80 (34%) 19/94 (20%) 
EIF1AX 3/22 (14%) 4/28 (14%) 14/70 (20%) 7/33 (21%) 27/80 (34%) 20/94 (21%) 
CYSLTR2 1/22 (5%) - - - 3/80 (4%) 2/94 (2%) 
PLCB4 - 2/28 (7%) - - 2/80 (3%) 1/94 (1%) 
TTC28 1/22 (5%) - - 2/33 (6%) - 3/94 (3%) 
CSMD1 1/22 (5%) - - 2/33 (6%) - 2/94 (2%) 
TP53BP1 - - - 2/33 (6%) - 2/94 (2%) 
SRSF2 - - - - 3/80 (4%) - 
KTN1 - - - 2/33 (6%) - 1/94 (1%) 
DLK2 - - - 2/33 (6%) - - 
FBXW7 2/22 (10%) - - - - - 
 
As expected, both M3 and isodisomy of chromosome 3 were associated with a poor survival 
(p=≤0.001) consistent with numerous published studies (Figure 5.11) (268) (91) (95). Both 
cases of isodisomy of chromosome 3 harboured nonsense BAP1 mutations, the tumour 
would therefore have two non-functional alleles of the tumour suppressor gene. This is 
evident in the median survival of the isodisomy group, which was 61 months (range, 54 – 
64 months) in comparison to the M3 cohort who had a median survival of 126 months 
(range, 15 – 236).  
In the present study loss of 6q did not appear to be associated with overall poor survival 
(p=0.462) or impact the survival of those with M3 (p=0.157) in this study, contradicting the 
findings of other studies that demonstrated loss of 6q to be predictive of poor prognosis 
(Figure 5.12) (269) (270) (102). In contrast, gain of 6p was significantly associated with an 
improved disease-free survival (p=0.006), consistent with the findings of a plethora of 
studies (93) (271). There are suggestions in the literature that the presence of oncogenes 
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and tumour suppressor genes on 6p and 6q respectively are involved in the development of 
UM though the importance is not yet fully understood (99).  
In agreement with previous studies, both loss of chromosome 8p and gain of 8q were 
associated with a poor overall survival outcome (p=0.008 and p=0.006, respectively) (Figure 
5.13) (268) (270) (76). Concomitant loss of 8p and gain of 8q were observed in 16/52 (31%), 
of these 14/16 (88%) were M3 or isodisomy of chromosome 3 and 10/16 (63%) of patients 
died from metastatic disease. In the D3 cohort, loss of 8p was associated with a worse 
survival (p=0.004). Gain of 8q in the same cohort had a neglible effect on survival in disomy 
3 tumours (p=0.654) or SF3B1 or EIF1AX mutant tumours (p=0.986) in contrast to the 
findings of other studies (134) (135).   
In a study of interest, Caines et al. performed cluster analysis on 602 cases of UM 
genotyped by MLPA and found four distinct subgroups in terms of survival based on a 
combination of chromosome 3 and 8q data, whereby D3 with polysomy 8q (P8q) was 
associated with an intermediate metastatic risk (185).  This was consistent with the study 
by Cassoux et al. who also found D3 with P8q to be associated with an intermediate 
metastatic risk (272). When grouped in a similar fashion, the data in the present study 
found three distinct subgroups in terms of survival, however there was no difference in 
survival for samples with disomy 3 plus or minus polysomy 8q (Figure 5.5). Increased copy 
number burden of 8q has been described in the literature and is associated with a worse 
survival outcome, with an association between a ploidy of five copies or more and 
metastatic potential (135) (134). In the present study, I did not assess ploidy of 8q, which 
could have potentially aided our analysis. Moving forward with the panel, this will be 
something that would be useful to develop. 
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Loss of 1p has been well documented in the literature in UM. It is said to be one of the few 
abnormalities that provide prognostic information regarding disease-free survival, 
independent of chromosome 3 copy number status (94). It has been demonstrated that a 
concurrent loss of 1p and monosomy 3 contribute to poor survival in UM patients (108). 
Other studies have pinpointed specific loci that are believed to harbour genes directly 
involved with the progression of UM specifically with M3 (273). The p-arm of chromosome 
1 contains p73, a homolog of P53 and loss of the p73 locus was associated with the 
upregulation of p73Deltaex2 and TAp73 transcripts, suggesting a potential function of p73 
deletion transcripts in UM progression (274). In the present study 1p loss was not 
associated with a reduced disease-free survival overall (p=0.568) or in M3 tumours 
(p=0.505). An interesting observation of this study was the significance of 1q gain and its 
association with a worse outcome in terms of patient survival (p=0.027) (Figure 5.10). In the 
cox model, 1q gains were associated with an increase in the hazard of metastatic death, 
although not as strongly as BAP1 (Table 5.13). Early studies suggest there is an association 
between M3 and an isochromosome formation of 1q (102). The frequency of 1q 
amplifications have been described to occur in as many as 24% of UM (1). However, little 
has been published regarding the prognostic significance of these gains. In the present 
study, 62% of 1q amplifications were accompanied with loss of 1p (figure 5.14). Field et al., 
found gains of 1q were associated with Class 1 PRAME positive UM who in GEP profiling 
studies, identifying an increased metastatic risk for patients with ‘Class 1’ or disomy 3 UM 
(194). This juxtaposes the findings of the current study where 1q loss was observed in both 
M3 (46%) and D3 (54%) tumours with the vast majority having P8q (92%). 
In summary, I have demonstrated it is possible to analyse both copy number and single 
nucleotide variants using an NGS assay in both fresh and formalin-fixed tissues. A 
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comparison of hybrid capture and PCR-based library preparation identified hybrid capture 
as the superior methodology in terms of quality. Mutations in GNAQ, GNA11 and CYSLTR2 
occurred in a mutually exclusive fashion and were not associated with increased metastatic 
risk, supporting the evidence in the literature these are initiating mutations. A previously 
undescribed mutation in PLCB4 was identified in this study that did not fall within the 
hotspot on exon 20. Mutations in BAP1 were the biggest indicator of metastatic risk in both 
Kaplan-Meier and cox analysis, consistent with the findings of Chapter 4. In contrast to 
suggestions in the literature, SF3B1 was associated with a reduction of metastatic risk and 
EIF1AX with an increase in metastatic risk. However, mutations in EIF1AX were still 
associated with improved disease-free survival. No mutations in SRSF2, DLK2 or FBXW7 
were detected in this study; however novel mutations in TTC28, CSMD1, KTN1 and TP53BP1 
were detected at a low frequency. The prognostic significance of these genes remains 
unknown. Copy number analysis showed monosomy 3, 6p gain, loss of 8p and 8q gains to 
be associated with a worse outcome. Novel concomitant losses of 1p and gains of 1q were 
observed in this study, with gain of 1q being identified as a significant hazard in the 
increased incidence of metastatic death. A larger cohort of samples with a longer follow-up 




































6.1   Introduction 
 
As mentioned in chapter 1, UM possess inactivating mutations in GNAQ and GNA11, which 
have been shown to inhibit the GTPase function of the gene. The inability to hydrolyse GTP 
to GDP leaves the alpha subunit in a constitutively active state leading to prolonged 
signalling. Ras guanyl-releasing protein 3 or RasGRP3 is a guanine nucleotide exchange 
factor that activates small GTPases. RasGRP3 acts as a RAS activator by maintaining an 
active GTP bound state and promoting acquisition of GTP. This conversion of Ras-GDP to 
Ras-GTP stimulates the activation of numerous downstream pathways, such as the Raf-
Mek-Erk kinase cascade (275). Activation of the RAS pathway is abundant in many human 
cancers and several of the RasGRP family members are involved in cancer development. 
RasGRP molecules contain C1 domains that bind to diacylglycerol (DAG) and diacylglycerol 
analogs such as phorbol esters, which are tumour-promoting molecules through the 
activation of protein kinase C (PKC). RasGRP3 in particular has a high affinity for binding 
phorbol esters. Therefore, RasGRP3 serves as a PKC-independent pathway due to its affinity 
for phorbol ester binding (276). RasGRP3 has been shown in the literature to be expressed 
in B-cells (277), in addition to regulating B cell proliferation by facilitating B cell receptor-
Ras signaling (275). High expression of RasGRP3 has been linked to Burkitt's lymphoma, 
precursor–B-cell leukaemia and natural killer (NK)/T-cell leukaemia (278). Additionally, 
RasGRP3 transcripts were found to be elevated in a subset of prostate carcinomas, which 
contributed to increased proliferation, anchorage independent growth, and tumour growth 
(279). Moreover, increased expression of RasGRP3 has been shown play a role in the 
malignant progression and increased prostate specific antigen (PSA) levels in recurrent 
prostate cancer (226). RasGRP3 overexpression has also been linked to increased cell 
proliferation in cutaneous melanoma cells, with suppression inhibiting cell proliferation in 
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numerous melanoma cell lines (280). A recent study has shown a link between RasGRP3 
expression and oncogenic signalling downstream of GNAQ/11 mutant UMs to the 
Ras/Raf/MEK/ERK pathway through a number of mechanisms; DAG binding, 
phosphorylation by PKC and consequential upregulation at the protein level by PKC 
activation (281). This, therefore, makes RasGRP3 a molecule of interest as it has the 
potential to be used as a promising therapeutic target. 
 
Figure 6.1 Involvement of RasGRP3 in the GNAQ/11 pathway; phospholipase C beta (PLCβ) 
cleaves phosphatidylinositol (4,5)-bisphosphate (PIP2) to yield diacylglycerol (DAG) and 
inositol triphosphate (IP3) promoting stimulation of protein kinase C (PKC), which leads to 
activation of the mitogen-activated protein kinase (MAPK or MEK) pathway and cell 
proliferation. Original image. 
 
The aim of Chapter 6 was to further understand the role of RasGRP3 protein in UM by: (1) 
examining its expression by IHC in a tissue microarray (TMA) consisting of primary UM 
samples with known GNAQ/11 mutation status; and (2) using Western blotting to 
determine RasGrp3 protein expression in well-characterised UM cell lines.  
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6.2   Materials and Methods 
6.2.1   Preparation of cell lysates and protein determination 
Cell lysates were prepared from the GNAQ/11 mutant UM cell lines, 92.1, MEL270, OMM1 
and the conjunctival melanoma cell lines CRMM1 and CRMM2 (BRAF V600E positive and 
GNAQ/GNA11 wild-type). The 92.1, Omm1 and Mel270 UM cell lines were grown in RPMI 
(Life Technologies, Paisley, UK) supplemented with 10% fetal calf serum (FCS) (Biosera, 
France) 2mM L-glutamine (Sigma-Aldrich Ltd, United Kingdom), 200µg/ml Penicillin–
Streptomycin (Sigma-Aldrich Ltd, United Kingdom). All cell lines used in the study were 
kindly provided by Professor Martine Jager (Leiden University Medical Centre, Leiden). The 
CRMM1 and CRMM2 conjunctival melanoma cell lines (used as additional controls) were 
grown in Ham's F-12K (Kaighn's) Medium (Life Technologies) plus 10% FCS (Biosera, France) 
2mM L-glutamine (Sigma-Aldrich Ltd, United Kingdom), at 37°C in a humidified atmosphere 
containing 5% CO2. The cell lines had previously been shown to be mycoplasma free and 
had concordant short tandem repeat (STR) profiles with those published in the 
literature/ATCC website (Table 6.2) (282) (283) (284) (285). At ~70% confluency, media was 
removed from the 75cm2 tissue culture flasks and a wash was performed using cold 
phosphate buffered saline (PBS). 500µl of lysis buffer (1% SDS, 5mM EDTA, 50mM Tris-HCl 
(pH.6.8) and 1% Glycerol) and 5µl of protease cocktail inhibitor at 1:100 (EMD Biosciences, 
San Diego, USA) were added to the flask. Cells were scraped off and transferred to an 
Eppendorf tube and incubated on ice for 30mins. Cells were sonicated using a water bath 
sonicator (look for make and model) for 10 mins; 30secs at high level sonication and 30secs 
rest. The Eppendorf tube was then placed on a Thermomixer (Eppendorf) and heated at 
90°C for 10mins. The cells were then spun at 14,000 RPM in a cold centrifuge (4°C) for 
10mins. The supernatant was then carefully transferred into a fresh Eppendorf tube.  A 
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protein determination assay was performed using the colourimetric Bio-Rad DC protein 
assay (Bio-Rad, Hemel Hempstead, UK). Bovine Serum Antigen (BSA) standards were 
prepared at the following decreasing concentrations; 1000µg/ml, 500µg/ml, 250µg/ml, 
125µg/ml, 62.5µg/ml, 31.25µg/ml, 15.625µg/ml and 0µg/ml. 5µl of standard and 5µl of 
sample lysate were added to the corresponding wells and were run in triplicate. A working mix 
of Protein Assay Reagent A + S was prepared at a dilution of 1:50 (1ml of reagent A and 20µl 
Reagent S) and 25µl of Reagent A + S was added into each well. 200µl of Reagent B was added 
into each well and the plate was incubated in the dark for 15 mins. The absorbance was 
subsequently read using a plate reader at 750nm.  
Table 6.1 STR profiles of cell lines cultured for RasGRP3 experiments. All cell lines 
correspond to the profiles as published by De Waard-Siebinga et al., White et al., Chen et al. 
and Nareyeck et al. 
 
 Cell Lines 






AMEL X X, Y X X X, Y 
vWA 16 17, 18 19 15 16, 17 
TPOX 8,9 10 8, 9 8, 11  8 
TH01 9, 9.3 6, 9 7 7 7, 9.3 
D21S11 30 28, 29 30, 30.2 29, 32.2 28, 31.2 
D5S818 9, 11 12 11 12, 13 11 
D13S317 11, 12 12 12 12 8, 11 
D7S820 10, 11 8, 9 13 8, 11 8, 11 
D16S539 12 12 9 5, 11 9, 13 
CSF1PO 10, 11 11 10, 12 10, 13 12 
 
6.2.2   Western Blotting 
The 12.5% running gel was prepared using 5.95mL water, 4.25mL, ProtoGel resolving buffer 
(Geneflow, Staffordshire, UK) and 6.8mL ProtoGel 30% 37.5:1 acrylamide (Geneflow, 
Staffordshire, UK). The 5% stacking gel was prepared using 4.36mL water, 1.9mL ProtoGel 
stacking buffer (Geneflow, Staffordshire, UK) and 1.24mL 30% 37.5:1 acrylamide (Geneflow, 
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Staffordshire, UK). Ammonium persulphate (APS) (0.2g in 2mls water) and TEMED were 
added to the resolving gel mixture, poured between the glass plates and overlaid with 
water until set. This step was repeated with the stacking gel mix, which was then pipetted 
on top of the resolving gel and a 10-well comb was inserted prior to allowing the gel to set. 
Samples were loaded onto the gel with a molecular weight ladder and the gel was run at 
30mA for an hour using 1x running buffer (3.03g Tris base, 14.4g Glycine and 1.0g SDS). The 
gels were removed from the cassettes and the stacking gel discarded. Sponges soaked in 
cold 1x transfer buffer (3.03g Tris base and 14.4g Glycine) were placed on the back of the 
cassette followed by blotting paper dipped in transfer buffer and the gel. The (PVDF) poly 
vinyl difluoride, 0.2µm membrane was submerged in methanol and placed directly onto the 
gel. A final sponge soaked in transfer buffer was placed on top. The cassette was then 
closed and placed inside the electrode assembly and the proteins were allowed to transfer 
at 400mA for 1 hour. The membrane was removed from cassette and a small cut made in 
the top left hand corner to mark the orientation. The membrane was blocked in 5% non-fat 
milk (NFM) for 1 hour at RT on a shaker. The RasGRP3 antibody at a dilution of 1:1000 
(ProteinTech, Manchester, UK) was prepared in 5% NFM and incubated overnight at 4°C on 
a shaker. The membrane underwent the following wash steps: 2 x 30 seconds, 2 x 5 min 
and 1 x 15 min with wash buffer (1X TBS, 0.1% Tween 20). The secondary antibody, 
horseradish peroxidase conjugated (HRP) goat anti-rabbit (DAKO) was prepared at a 
dilution of 1:5000 in 2.5% milk and incubated for 1 hour at RT. The previous wash steps 
were then repeated. The blot was developed via chemiluminescence using the Immobilon 
Western Chemiluminescent HRP Substrate kit (Merck-Millipore, United Kingdom). A 
working HRP substrate mixture was prepared by mixing 1mL Luminol Reagent and 1mL 
Peroxide Solution. The mixture was allowed to reach room temperature for 10 minutes. 
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The membrane was blotted dry and the HRP substrate mixture was pipetted on ensuring 
even coverage and left for 1 minute. Excess mixture was removed by blotting the edge of 
the membrane. The membrane was then sealed in plastic wrap and imaged on the 
GeneGnome XRQ Image Capture machine (Syngene).  
 
6.2.3   DNA extraction from fresh UM tissue 
Seventeen frozen UM samples collected between 2014 and 2015 were sampled in 
microfuge tubes, snap frozen in liquid nitrogen and stored at -80°C. Samples were thawed 
at RT and the tissue minced using a sterile scalpel blade in a petri dish. DNA extraction was 
carried out using methods previously described in Chapter 2.2.1    
6.2.4   DNA quantity assessment 
DNA quantitation was carried out using the methods previously described in Chapter 2.2.4    
6.2.5   Sanger Sequencing for GNAQ and GNA11 mutations 
Exons 4 and 5 of GNAQ and GNA11 were amplified using end-point PCR in a G-Storm GS1 
Thermal Cycler (GRI – Genetic Research Instrumentation Ltd, Essex) using; 0.5% BSA (Sigma, 
St. Louis) Thermo-Start Taq DNA Polymerase, 10x HP Buffer, 25mM MgCl2, 10mM dNTPs 
(Thermofisher, Massachusetts) and PCR Primers (Table 6.2). DNA was initially denatured for 
15 min at 95°C followed by 35 cycles of 15 sec 95°C, 30 sec 60°C and 1 min 72°C. The 
reaction was then completed by 10 min elongation at 72°C.  25ng DNA was used in each 
reaction. PCR products were purified using the Qiagen QIAquick PCR purification kit (Qiagen 
GmbH, Hilden). The purified PCR products were then quality assessed on a 2% agarose gel 
run at 100V for 30 mins. PCR products were sent to GATC Biotech, (Konstanz, Germany) for 
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chain termination reaction and subsequent analysis of electropherograms was performed 
using Chromas Lite (Technelysium Pty Ltd, Australia).  
Table 6.2 Primer Sequences for Exons 4 & 5 of GNAQ and GNA11 
Gene Primer Sequence 
GNAQ Q209 Forward TTTTCCCTAAGTTTGTAAGTAGTGC 
GNAQ Q209 Reverse CCCACACCCTACTTTCTATCATTTAC 
GNAQ R183 Forward TGGTGTGATGGTGTCACTGACATTCTCAT 
GNAQ R183 Reverse AGCTGGGAAATAGGTTTCATGGACTCAGT 
GNA11 Q209 Forward CGCTGTGTCCTTTCAGGATG 
GNA11 Q209 Reverse CCACCTCGTTGTCCGACT 
GNA11 R183 Forward GTGCTGTGTCCCTGTCCTG 
GNA11 R183 Reverse GGCAAATGAGCCTCTCAGTG 
 
6.2.6   Preparation of FFPE cell pellets of UM and conjunctival melanoma cell lines 
At ~75% confluence the cells were removed from the bottom of 75cm2 tissue culture flasks 
using a cell scraper. The cells were then pelleted at 1500rpm for 2 minutes and fixed in 10% 
neutral buffered formalin for 10 minutes. Following fixation, the cells were washed in PBS 
(Sigma-Aldrich Ltd, United Kingdom) before transferring the cell pellet to a microfuge tube 
for a final wash with PBS and centrifugation at 8000rpm for 1 minute. The supernatant was 
removed and 100µl of 4% molten agar was added and mixed quickly into the cell pellet 
prior to centrifugation at 14,000rpm for 30 seconds. The agar cell pellet was then removed 
from the microfuge tube and placed into a tissue cassette for processing through a series of 
alcohols and xylenes. After dehydration, the pellet was paraffin wax embedded, such that 





6.2.7   Tissue Microarray (TMA) construction 
A TMA was constructed using a Beecher tissue microarrayer (Beecher Instruments, Sun 
Prairie, WI). Arrays contained triplicate 0.6-mm cores taken at random from the tumour 
areas of FFPE tissues for each of the UM samples.  
6.2.8   Immunohistochemistry 
6.2.8.1   Optimising the Antibody 
The Protein Tech RasGRP3 antibody (Protein Tech, Manchester, UK) was tested at 1:50-, 
1:100- and 1:200 dilutions using human pancreas and duodenum control tissue. A 1:200 
dilution was selected as the optimum concentration for IHC. Duodenum was selected as the 
positive control tissue for all subsequent experiments. 
6.2.8.2   IHC on whole tissue sections, TMA and cell pellets 
Sections (4 µm thick) were cut from the cell pellet blocks of UM and conjunctival melanoma 
specimens, TMA and whole tissue sections and mounted on X-traTM adhesive tissue slides 
(Leica, United Kingdom). Antigen retrieval was performed at 96°C for 20 minutes using a PT 
Link (Dako, Carpinteria, CA; Ely, UK) pretreatment module and high- pH (pH 9.0) retrieval 
solution. The following steps were performed at room temperature (RT) using a Dako FLEX 
Envision kit and Autostainer Plus: 5 mins endogenous peroxidase blocking, 30 mins 
incubation with primary antibody, 15 min incubation with mouse or rabbit linker, 20 min 
incubation with horseradish peroxidase, and positive staining was visualized by use of 3-
amino-9-ethylcarbazole (AEC, Vector Laboratories Ltd., Peterborough, UK, 30 min). Slides 
were washed with FLEX wash buffer between each step. The following RasGRP3 primary 
antibodies were used: rabbit polyclonal, 13162-1-AP (ProteinTech, Manchester, UK) at 
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1:200, and mouse monoclonal, ab156937 (Abcam, Cambridge, UK) at 1:200. An IgG1 
isotype control was run at the same concentration as the mouse monoclonal, and omission 
of the primary antibody served as the negative control for the rabbit polyclonal. Human 
duodenal tissue served as a positive control for both antibodies. The slides were 
counterstained with Mayer’s haematoxylin (VWR, Leicestershire, UK) and cover-slipped 






















6.3   Results 
6.3.1   Patient Demographics 
DNA was extracted from 17 frozen UM from eyes enucleated between 2014 and 2015. The 
cases included 12 males and 5 females with a median age of 62 years (range, 22 – 78 years). 
The median LBD was 17.35mm (range, 8.9 – 22.7mm) and the median UH was 9.9mm 
(range, 2.8 – 16.3mm). 11/17 (65%) of the examined UM contained epithelioid cells and 
3/17 (35%) cases had extraocular extension. 5/17 (29%) UM contained necrotic cells. At the 
time of the study 14 patients were alive, 1 patient was alive with liver metastases and 2 
patients had died from metastatic disease. The mean DNA concentration was 334.94ng/µl 
with a median of 183ng/µl (range, 40.2 – 1600ng/µl), DNA extracted from 17 (100%) of the 
primary UM samples yielded a concentration >25ng/µl. 
 
6.3.2   Sanger Sequencing for GNAQ and GNA11 
2% agarose gels run to assess the quality of the PCR and subsequent PCR purification 
confirmed the tests had yielded good quality products (Figure 6.2 and Figure 6.3). Of the 20 
sequenced cases, there were 8 GNA11 Q209 mutant UM, 8 GNAQ Q209 mutant UM, and 2 
samples were wild type (Figure 6.4). One of the GNAQ/11 wild type samples was a BRAF 
V600E positive conjunctival melanoma. No mutations were detected in exon 4 at codon 
R186 for either GNAQ or GNA11, but this was expected as the literature has shown these 




Figure 6.2 Electropherograms from quality assessment of GNAQ and GNA11 PCR products 










Figure 6.4 Mutation spectra of GNAQ and GNA11 at codon Q209. A) The only mutation 
observed in GNA11 was an adenosine to thymine transition resulting in a substitution to 
leucine (GNA11 c.626 A>T Q209L) B) An adenosine to guanine transition resulting in a 
substitution to arginine (GNAQ c.626 A>G Q209R) C) An adenosine to cytosine transition 
resulting in a substitution to proline (GNAQ c.626 A>C Q209P) and D) An adenosine to 










Figure 6.5 A standard curve showing the absorbance of BSA standards at 750nm. A) 
Absorbance of BSA standards at 750nm; B) Absorbance of 92.1, MEL270, OMM1, CRMM1 




6.3.4   Western Blot 
Western blot examination of RasGRP3 protein expression was carried out in 5 UM cell lines 
and the 2 conjunctival melanoma cell lines (Figure 6.6). Of these, all UM cell lines 
demonstrated protein expression of RasGRP3 at the expected molecular weight 78kDa. No 
additional bands were present on the western blot demonstrating specificity of the 
antibody for RasGRP3. Neither conjunctival melanoma cell line, regardless of BRAF 
mutation status, expressed RasGRP3.  
 
 
Figure 6.6 Expression of RasGRP3 in GNAQ mutant (92.1, Mel270, OMM2.3 and OMM2.5) 
and GNA11 mutant (OMM1) UM cell lines and BRAF V600E mutant (CRMM1) and BRAF wild 











6.3.5   Immunohistochemistry 
6.3.5.1   Tissue Microarray Immunohistochemistry 
18 samples were run in triplicate totalling 54 cores plus 8 normal tissue controls; 2 
pancreas, 2 testis, 2 gallbladder and 2 colon. Of the 54 cores; 17/54 (31%) scored weakly, 
23/54 (43%) moderate, 2/54 (4%) strong, 9/54 (17%) couldn’t be scored and 3/54 (5%) 
cores were missing. Both nuclear and cytoplasmic protein expression was observed for 
RasGRP3 in the primary UM tissue microarray.  The pattern of cytoplasmic and nuclear 
staining showed no significant association with GNAQ/GNA11 mutation status, as no 
difference between the mutant and wild type primary UMs was noted (Figure 6.7 A, B and 
D). However, the GNAQ/11 wild type BRAF V600E mutant conjunctival melanoma sample 









Figure 6.7 RasGRP3 Immunohistochemistry of primary UM samples using Protein Tech 
antibody at 1:200 A) GNAQ mutant primary UM samples, B) GNA11 mutant primary UM 
samples, C) BRAF V600E mutant primary conjunctival melanoma sample (used as control), 
D) GNAQ and GNA11 wild type primary UM sample and E) Tissue microarray consisting of 8 








6.3.5.2   Cell Pellet Immunohistochemistry 
 
Positive cytoplasmic staining was observed in the majority of the UM cell lines, Mel270, 
92.1 and OMM1. Staining was not present in either of the two conjunctival cell lines 
CRMM1 and CRMM2. Speckled cytoplasmic staining was observed in the duodenum 






Figure 6.8 Immunohistochemistry of cell pellets using the Protein Tech RasGRP3 antibody at 





Figure 6.9 Immunohistochemistry of cell pellets using the Protein Tech RasGRP3 antibody at 









6.4   Discussion 
Examination of RasGRP3 in both primary UM tumour samples and well-characterised UM 
cell lines by IHC and western blotting revealed several key differences in protein expression.  
In the primary UM samples, there was no clear association between GNAQ and GNA11 
mutation status and the pattern of RasGRP3 protein expression. However, there was a 
distinct absence of RasGRP3 protein expression for the GNAQ/11 wild type conjunctival 
melanoma cell lines and strong protein expression in the UM cell lines in both the IHC and 
western blotting experiments. An observation of this work was the lack of consistency 
between the protein expressions of RasGRP3 in UM cell lines and primary UM samples. A 
reason for this could be the less heterogeneous nature of cell lines in comparison to 
primary UM which are more likely to contain clonal populations of both GNAQ/11 mutant 
and wild-type cells. Intra-tumour heterogeneity is a well-documented phenomenon in UM 
and this is likely the reason the cell line strand of this study generated more consistent 
results (179, 229-231). Another limitation of the primary UM component of this study was 
the degree of pigmentation present in a proportion of the UM samples. This made scoring 
some of the TMA cores problematic and several of the cores had to be excluded from 
analysis. Despite these limitations, in this study RasGRP3 has been shown to be markedly 
upregulated in GNAQ/11 mutant UM cells and is an essential effector linking oncogenic 
GNAQ/11 signalling. Activation of the MAPK pathway typically occurs through mutations or 
amplifications in genes such as BRAF or NRAS, in cancers such as cutaneous melanoma. As 
UM lacks mutations in these genes, it is thought that mutations in GNAQ/11 activate the 
MAPK pathway by stimulation of PKC. The work presented in this study was part of a larger 
study that was able to demonstrate that MAPK activation is dependent on activation of Ras 
by RasGRP3 (286). They were able to show that activation of RasGRP3 was PKC 
independent as well via PKC δ- and ε-dependent phosphorylation.  However, mutations in 
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GNAQ and GNA11 have also been shown activate other oncogenic pathways, such as the 
Yes-associated pathway (YAP)-Hippo pathway tumour suppressor pathway (287). YAP is 
translocation into the cell nucleus is triggered by mutations in GNAQ/11 that stimulate YAP-
dependent activation of the guanine exchange factor Trio, activating small GTPases RhoA 
and Rac1 (Figure 2.10) (288). This signalling cascade contributes to YAP-dependent growth 
of UM cells, which means YAP inhibitors such as verteporfin are potential therapies for UM 
patients with GNAQ/11 mutations (289). Therefore, activation of a different pathway such 
as the Hippo-YAP may also be another possible explanation for the inconsistent staining 
patterns observed in the primary UM samples, as it is likely not all GNAQ/11 mutants have 
the same activated pathways. 
 
 
Figure 6.10 The Hippo-YAP signalling pathway in UM. Constitutively active GTP stimulate 
YAP-dependent activation of the guanine exchange factor Trio, activating small GTPases 
RhoA and Rac1which leads to activation of the YAP pathway leading to tumour growth and 




In this chapter I have shown a lack of RasGRP3 protein expression in BRAF V600E mutant 
and wild-type conjunctival melanoma. In contrast, RasGRP3 is expressed in primary UM 
tumour tissues and GNAQ and GNA11 mutant UM cell lines. This demonstrates that 
activation of the MAP-kinase pathway occurs through a different mechanism to 
conjunctival melanoma. These findings change the way oncogenic signalling in UM is 






Summary and Future Directions 
 
The purpose of this thesis was to examine different aspects of the methodologies used to 
stratify UM patients into high or low-risk with respect to developing metastatic disease, in 
order to refine prognostication for UM patients. 
In Chapter 2, I examined the rarest subtype of UM, namely iris melanomas (IM). Little was 
known about the genetic characteristics of these tumours at the time of my examinations. 
By performing a retrospective database review and identifying 24 archival tissue specimens 
over a twenty year period, I was able to perform molecular analysis. Previous data 
suggested monosomy 3 (M3) leads to a poor outcome in posterior UM; therefore, I sought 
to establish whether this was the same for IM. This was the largest at the time that 
examined tumours that originated in the iris. Interestingly, I was able to demonstrate that 
the same chromosomal aberrations observed in posterior UM are also seen in IM, in both 
treatment naïve and irradiated IM, with a low-metastatic risk genotype most commonly 
observed in these tumours. During the course of this research there have been subsequent 
studies examining mutations in IM. Similar mutations in IM to those frequently observed in 
posterior UM have been identified in GNAQ, GNA11, BAP1, SF3B1 and EIF1AX in addition to 
less frequent mutations in NRAS, BRAF, PTEN, cKIT and TP53. More research needs to be 
undertaken in larger scale studies to establish the mutational signature of IM and whether 
they share a similar clinical outcome to posterior UM. 
In Chapter 3, I performed an audit of 285 UM that were genotyped by MSA. The majority of 
samples genotyped by this method are usually small DNA-yielding FNAB specimens, some 
of which have been irradiated prior to sampling. I was able to demonstrate that MSA is a 
molecular technique, which can accurately determine chromosome 3 status in small UM 
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biopsy samples with low DNA concentrations. When I compared the genotyping success 
rate of treatment naïve and irradiated UM samples, I found no demonstrable differences in 
the quality or clarity of the genotypes generated. Thus I showed that MSA can be used to 
reliably establish chromosome 3 status in post radiotherapy samples treated with either 
proton beam and ruthenium plaque. All cases followed the predicted clinical course 
irrespective of irradiation status. To establish the effects of surgical intervention and 
iatrogenic dissemination, I examined metastasis-free survival in samples taken before and 
after administration of RXT and found no significant difference in survival between the two 
cohorts. Our findings indicate that there is no increased metastatic risk when biopsies are 
taken before administration of radiotherapy. This study identified loss of 3q as an indicator 
of poor prognosis, which made this cohort of samples similar to M3 in terms of survival. In 
this study only a small group was identified. A study on the long-term significance of partial 
loss of chromosome 3, both 3p and 3q, on survival needs to be undertaken to fully 
understand the molecular behaviour of this UM subgroup and overall survival. Additionally, 
the cohort of UM with an AI genotype behaved the most similar to D3 in terms of survival. 
Similarly, longer follow-up is required to fully appreciate the clinical significance of this 
subgroup.  
Nuclear BAP1 protein expression is easily examined by IHC: in Chapter 4, I sought to 
examine the prognostic potential of BAP1 IHC in a cohort of 165 UM enucleation 
specimens; the largest study to date. By performing multivariate analysis of clinical, 
histopathological and genetic factors, I was able to demonstrate that nuclear BAP1 
negativity is a significant independent prognostic parameter associated with metastatic risk 
and thus reduced survival. In multivariate analysis loss of BAP1 protein expression was a 
more significant risk factor than loss of chromosome 3. I was also able to identify two 
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subgroups within M3 UM: either nBAP1 positive or negative, with distinct and independent 
survival profiles. Strikingly, nBAP1+ M3 UM were associated with prolonged survival 
compared to nBAP1- M3 UM. This subgroup of UM patients’ need to be followed up closely 
to examine continued disease-free survival, and to determine whether the patients will 
eventually follow the same clinical course as M3 nBAP1- UM. This research has highlighted 
the utility of using BAP1 IHC as a surrogate marker for prognostication, especially in 
hospitals where genetic testing is not embedded into clinical management of UM patients. 
As a result of this study, BAP1 IHC is now part of the routine workup of all UM histological 
specimens sent to the Pathology Dept. in Liverpool, and assists in determining the 
appropriate surveillance program for patients. As the BAP1 data accrue, a larger scale audit 
is necessary to assess the impact of incorporating this as an additional covariate in LUMPO 
III, the prognostication model currently used to estimate all-cause mortality for UM 
patients at LOOC and around the world. 
In Chapter 5, I assessed the feasibility of designing and implementing a targeted NGS panel 
examining mutations in GNAQ, GNA11, BAP1, SF3B1, EIF1AX, CYSTLR2, PLCB4, TTC28, KTN1, 
TP53BP1, and CSMD1 in addition to copy number changes in chromosomes 1, 3, 6 and 8. I 
designed, compared and evaluated two different library preparation methodologies and 
validated their efficacy using samples where mutation data and copy number data was 
available, demonstrating the superiority of hybrid capture. I also demonstrated that it is 
possible to analyse copy number and single nucleotide variants in both fresh and formalin 
fixed tissue. I was able to establish that mutations in GNAQ, GNA11 and CYSLTR2 occurred 
in the mutually exclusive fashion described in the literature and were not associated with 
increased metastatic risk, supporting the evidence in the literature that these are initiating 
mutations. Additionally, I identified a mutation in PLCB4 in this study that did not fall within 
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the hotspot on exon 20 in a sample with a GNAQ mutation; not previously described in UM. 
I also observed several other novel mutations in TTC28 (22q12.1), CSMD1 (8p23.2), KTN1 
(14q22.3) and TP53BP1 (15q15.3) at a low frequency. To fully understand their role in 
tumour progression more functional studies focussed on the significance of these need to 
be undertaken. Mutations in BAP1 were found to be the most important prognostic factor 
in terms of survival, consistent with the findings in Chapter 4. In contrast to the findings of 
others, in this study mutations in SF3B1 were not associated with an increase in metastatic 
risk. However, the follow-up period for these patients was relatively short; therefore, the 
risk that SF3B1 mutations poses for these patients cannot be fully appreciated. This cohort 
of patients’ needs to be followed-up regularly to comprehend the long-term risk that 
mutations in SF3B1 pose. Mutations in EIF1AX were associated with improved disease-free 
survival despite regression analysis associating EIF1AX with an increase in metastatic risk; 
however this was due to a relatively small follow-up. Consistent with other studies, copy 
number analysis showed monosomy 3, 6p gain, loss of 8p and 8q gains to be associated 
with a worse outcome. However, loss of 6q was not found to be associated with a poor 
survival contradicting the results of others. This study identified novel concomitant losses 
of 1p and gains of 1q, with gain of 1q being identified by cox-regression as a significant 
hazard contributing to the increased incidence of metastatic death. A larger cohort of UM 
samples with a longer follow up is now needed to further validate the panel for clinical use.  
Constitutive activation of Gαq signaling by mutations in G-coupled protein receptors GNAQ 
or GNA11 occur in over 80% of UM and activate MAPK signalling. In Chapter 6, in 
collaboration with the University of California San Francisco, I worked with Dr. Boris Bastian 
and Dr. Xu Chen to investigate a potential target RasGRP3, which was identified as 
significantly and selectively overexpressed in response to GNAQ/11 mutations. Conjunctival 
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melanoma (ConM) and UM cell lines were used to create cell lysates for the examination of 
RasGRP3 protein expression by western blotting. I found that BRAF V600E mutant and wild-
type ConM did not express RasGRP3 whereas GNAQ/11 mutant UM cell lines did. I also 
performed a series of immunohistochemistry (IHC) experiments to examine the expression 
of RasGRP3 in UM and ConM cell lines in addition to a tissue microarray of primary UM 
tumour tissue, which also confirmed overexpression of this molecule in UM. This 
demonstrates that activation of the MAPK pathway occurs through a different mechanism 
to cutaneous melanoma. This opens up the potential of using RasGRP3 as a therapeutic 
target for UM patients requiring initial testing in in vitro and in vivo models of the disease. 
In conclusion, our understanding of the factors influencing metastatic risk in UM has been 
significantly expanded from analysing only copy number alterations in chromosomes 3 and 
8q.  I and others have clearly demonstrated the clinical need for integrating somatic copy 
number variations and gene mutation status when determining the prognosis for UM 
patients. Prediction of disease risk or treatment response is one of the pillars of 
personalised medicine. Prognostication is an important but often underused tool in clinical 
practice. It impacts highly medical decision-making in daily clinical practice. This is 
particularly important for patients with advanced terminal illness’ such as cancer, as 


















Reads mapped % 
after UMI removed 
Number of bases 
with coverage more 
than 0 (%) 
Mean Depth of 
Coverage for 
the bases with 
coverage more 
than 0 
1 2,478,326 2,248,499 90.73% 286,408 11.56% 124,149 (96.28%) 374.21x 
2 1,269,340 1,142,922 90.04% 218,890 17.24% 123,845 (96.05%) 292.49x 
3 924,312 849,156 91.87% 95,768 10.36% 123,033 (95.42%) 129.94x 
4 3,265,808 3,096,256 94.81% 246,311 7.54% 124,174 (96.30%) 331.42x 
5 1,286,042 1,183,523 92.03% 230,935 17.96% 124,023 (96.19%) 311.93x 
6 6,142,882 5,969,994 97.19% 227,976 3.71% 123,679 (95.92%) 309.14x 
7 2,163,454 1,925,847 89.02% 278,625 12.88% 124,101 (96.25%) 367.22x 
8 2,402,312 2,134,430 88.85% 807,969 33.63% 123,303 (95.63%) 319.14x 
9 2,533,624 2,374,497 93.72% 614,043 24.24% 124,264 (96.37%) 352.92x 
10 3,720,226 3,627,122 97.50% 274,837 7.39% 124,266 (96.37%) 375.93x 
11 6,791,340 6,664,085 98.13% 238,491 3.51% 123,663 (95.91%) 320.14x 
12 3,445,808 3,186,811 92.48% 210,132 6.10% 123,825 (96.03%) 277.22x 
13 2,962,808 2,843,195 95.96% 228,020 7.70% 124,090 (96.24%) 309.51x 
14 2,420 1,768 73.06% 1,718 70.99% 63,962 (49.61%) 4.70x 
15 3,222,334 3,077,388 95.50% 327,489 10.16% 124,139 (96.28%) 450.69x 

















Reads mapped % 
after duplicates 
removed 
Number of bases 
with coverage more 
than 0 (%) 
Mean Depth of 
Coverage for 
the bases with 
coverage more 
than 0 
1 2,376,700 2,335,881 98.28% 1,784,958 75.10% 471,242 (99.99%) 462.43x 
2 2,545,582 2,493,908 97.97% 1,912,437 75.13% 471,284 (100.00%) 479.19x 
3 2,308,124 2,246,406 97.33% 1,479,937 64.12% 471,284 (100.00%) 409.62x 
4 2,947,696 2,880,098 97.71% 2,149,398 72.92% 471,242 (99.99%) 547.34x 
5 2,508,522 2,458,067 97.99% 1,895,731 75.57% 471,284 (100.00%) 483.09x 
6 2,996,436 2,914,272 97.26% 2,402,807 80.19% 471,284 (100.00%) 453.31x 
7 2,420,862 2,367,918 97.81% 1,834,341 75.77% 471,284 (100.00%) 447.92x 
8 2,428,668 2,368,412 97.52% 1,879,672 77.40% 471,242 (99.99%) 437.77x 
9 2,588,586 2,528,706 97.69% 1,952,734 75.44% 471,284 (100.00%) 464.82x 
10 2,862,900 2,802,999 97.91% 2,061,664 72.01% 471,284 (100.00%) 540.84x 
11 2,840,288 2,772,997 97.63% 1,982,899 69.81% 471,284 (100.00%) 531.48x 
12 3,166,404 3,082,413 97.35% 2,389,347 75.46% 471,242 (99.99%) 491.03x 
13 3,889,588 3,804,658 97.82% 2,869,632 73.78% 471,284 (100.00%) 725.36x 
14 2,886,854 2,798,417 96.94% 2,217,223 76.80% 471,284 (100.00%) 426.24x 
15 2,828,828 2,771,046 97.96% 2,151,815 76.07% 471,284 (100.00%) 558.25x 
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